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Abstract 
Sodium benzoate (NaB) is a sodium salt that is widely used in the 
pharmaceutical, cosmetic and food industries. This widespread use results 
in almost everybody in the world being exposed daily to this compound. 
Currently very little is known about the effects of NaB can have on the 
immune response, even though it has been associated with the clinical 
course of chronic inflammatory diseases, such as orofacial granulomatosis 
and neurodegenerative disorders. Here, I show that THP-1 cells, a 
monocytic human cell line presents an altered immune response when 
exposed to NaB. Immunologically stimulated THP-1 cells in the presence 
of NaB secreted reduced levels of IL6 and IL1β and higher levels of TNF, 
while other cytokines such as IP10 and IL8 were unaffected. The inhibitory 
effect in IL6 and IL1β secretion was a consequence of a free radical 
scavenging characteristic of NaB, which neutralizes the reactive oxygen 
species (ROS) generated downstream of TLR activation. This resulted in 
the impairment of a secondary signalling event, which is required to fully 
activate the cells immune response. The use of microarray analysis in 
combination with q quantitative proteomic analysis revealed that NaB has 
a significant effect on the THP-1 cells beyond the alteration in cytokine 
secretion.  NaB also interferes with cellular amino acid metabolism and has 
a major attenuating effect on the immune response. Taken together, these 
results suggest that NaB is not inert and has a major effect on a cells ability 
to mount an immune response. These findings could have major 
implications in how NaB is used in the future and in particular if it can be 
beneficial as a treatment for chronic inflammatory diseases, such as 
diabetes, atherosclerosis, rheumatoid arthritis, neurodegenerative 
disorders, and so on. On the other hand, by disturbing the inflammatory 
response, NaB could have a negative impact on other conditions such as 
orofacial granulomatosis. Further work will be needed to determine the role 
NaB plays in human inflammatory diseases. 
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Impact statement 
Sodium benzoate (NaB) is widely used by pharmaceutical, cosmetic 
and food industries, resulting in a routinely daily exposure to most people 
worldwide. It is added to processed food as a preservative to control 
microbial growth and can be found in soft drinks, fruit juices, beers, salad 
dressings, but also occurs naturally in many fruits and vegetables: apples, 
tomatoes, strawberries, and dark green vegetables. An individual’s 
exposure to NaB has the potential to be very high and cumulative due to 
the diverse sources of ingestion. Even though our ingestion of this 
compound is so high we know very little about how NaB affects the immune 
response.  NaB has been associated with chronic inflammatory diseases, 
such as orofacial granulomatosis (OFG) and neurodegenerative disorders, 
such as Parkinson’s disease and Alzheimer’s disease. My findings will 
have the potential to have an impact on a whole spectrum of industries that 
routinely include NaB in their products.  
The Oral Medicine department in the Eastman Dental Hospital is a 
reference service in the country to treat patients with OFG, and even 
though using all the resources available, only 70% of the patients had a 
complete resolution of their problems in a 10-year period. The treatment is 
usually based on immunomodulatory drugs, which have many side effects. 
Studies have shown that changing the patient diet for a benzoate-free type 
without any medication, achieves a resolution in between 50-70% of the 
cases, which is not too different to that observed with current medications. 
My results provide a plausible mode of action for NaB and how it may 
influence disease state in OFG. Therefore, the implementation of benzoate 
free diets may be used more frequently for this group of patients.  
My results may have an impact on the regulatory bodies and 
governments that conduct routine toxicity tests on food additives and set 
national and international guidelines. The toxicity tests prior to approval to 
human consumption are usually made in a controlled environment under 
physiological conditions. However, in everyday life, people are exposed to 
many stimulatory substances and microbial agents that can stimulate the 
immune system and alter metabolic processes. Although the regulatory 
agencies require the companies to describe what is in their products 
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(benzoates in Europe are under the numbers E210-E219), the population 
should be aware of the negative effects associated with these substances.  
My work has also demonstrated that using techniques such as 
microarray and proteomics has the potential to improve our understanding 
of how a compound can influence the cellular response in a non-biased 
way. 
NaB (or any other substance capable of neutralizing ROS) which 
reduce the release of IL6 and IL1β can potentially work as a therapy for 
many chronic inflammatory diseases such as diabetes, atherosclerosis, 
rheumatoid arthritis, neurodegenerative disorders, and so on. It is therefore 
possible that my results will have an impact on a diverse array of clinical 
specialities and researchers who specialize in the treatment of these 
conditions.  
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dNTP deoxyribonucleotide triphosphate 
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DTT dithiothreitol 
EAE experimental allergic encephalomyelitis 
EDTA ethylene diamine tetraacetic acid 
EGTA ethylene glycol tetraacetic acid 
ELISA enzyme-linked immunosorbent assay  
ERK extracellular signal–regulated kinases  
FBS foetal bovine serum 
FDA Food and Drug Administration 
FLG  filaggrin 
GI gastrointestinal 
GPX glutathione peroxidases  
H2O2 hydrogen peroxide 
HC healthy control 
HCL hydrochloric acid  
HD Huntington’s disease  
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HkEc heat-killed E. coli 
HkPg heat-killed Porphyromonas gingivalis  
HLA human leukocyte antigen  
HMOX1 heme oxygenase 1 
IBD inflammatory bowel disease  
IFN interferon 
Ig immunoglobulin 
IKBa nuclear factor of kappa light polypeptide gene enhancer in B-cells 
inhibitor, alpha 
IKK inhibitor of nuclear factor kappa-B kinase 
IKKε the inhibitor of kappa light polypeptide gene enhancer in B-cells 
IL interleukin 
IL6r IL6 receptor 
iNOS inducible nitric oxide  
IP10 interferon gamma-induced protein 10 
IRAK interleukin-1 receptor-associated kinase 
IRF interferon regulatory factor 
IRGM immunity-related GTPase M 
JNK c-Jun N-terminal kinase 
KEAP1  kelch-like ECH-associated protein 1  
KEGG Kyoto Encyclopaedia of Genes and Genomes  
LB Luria-Bertani  
LC-MS/MS liquid chromatography-tandem mass spectrometry  
LPS lipopolysaccharide  
LRR leucine-rich repeat  
LTA lipoteichoic acids  
MAPK mitogen-activated protein kinase 
MAPKK MAP kinase kinases 
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MD2 lymphocyte antigen 96 
MDM monocyte-derived macrophages 
MEK MAPK/ERK kinase 
MHC major histocompatibility complex  
MIC minimum inhibitory concentration  
MIG monokine induced by gamma interferon  
MMP matrix metalloproteinase 
MOI multiplicity of infection 
MPTP 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
mRNA messenger RNA 
MRS Melkersson-Rosenthal syndrome  
MS multiple sclerosis  
mSP65 mycobacterium stress protein 65kd 
MTT 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide 
MYD88 myeloid differentiation primary response gene 88 
NaB sodium benzoate 
NAC N-acetyl-L-cysteine  
NADPH nicotinamide adenine dinucleotide phosphate  
NCTC National Collection of Type Culture 
NDD neurogenerative diseases  
NFkB nuclear factor kappa-light-chain-enhancer of activated B cells 
NK natural killer cells 
NLR NOD-like receptor 
NMDAR N-methyl-D-aspartate receptor  
NO nitric oxide  
NOD nucleotide oligomerisation binding domain 
NOX NADPH oxidase  
NRF2 nuclear factor (erythroid-derived 2)-like 2  
NT-3 neurotrophin-3  
O2− superoxide anion  
OFG orofacial granulomatosis  
OH· hydroxyl radicals  
OTC ornithine transcarbamylase  
Pam3CSK4 trihydrochloride 
PAMP pathogen-associated molecular pattern 
PBMC peripheral blood mononuclear cell 
PBM-DM peripheral blood monocyte-derived macrophages  
PBS phosphate-buffered saline 
PCA principal component analysis  
PCR polymerase chain reaction  
PD Parkinson’s disease 
pH potential of hydrogen 
PHGDH phosphoglycerate dehydrogenase 
PKA protein kinase A  
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PMA phorbol 12-myristate 13-acetate  
PPIA peptidylprolyl isomerase A  
PRR pathogen recognition receptor 
PRX peroxiredoxins 
PSAT1 phosphoserine aminotransferase 1 
PSPH  phosphoserine phosphatase 
qRT-PCR quantitative reverse transcription-PCR 
RIG-1 retinoic acid-inducible gene I 
rIL6 recombinant IL6 
RIN RNA integrity  
RIPA radioimmunoprecipitation assay  
rLPS rough LPS  
RLR RIG-I-like receptor 
RNA ribonucleic acid 
RNS reactive nitrogen species  
ROO peroxy radical  
ROS reactive oxygen species  
RPMI Roswell Park Memorial Institute 
rTNF recombinant TNF 
SASP senescence-associated secretory phenotype  
SCA spinocerebellar ataxia  
SD standard deviation 
SDS Sodium Dodecyl Sulfate 
SDS-PAGE SDS polyacrylamide gel electrophoresis  
SEM standard error of the mean 
sLPS smooth LPS  
SMA spinal muscular atrophy  
SNARF seminaphtharhodafluor 
SOD superoxide dismutases  
SOS superoxide dismutases  
STAT signal transducer and activator of transcription 
TAK1 transforming growth factor-beta-activated kinase 
TBK TANK-binding kinase 
TCR T-cell receptors  
TGF transforming growth factor 
TIR Toll-interleukin 1 receptor  
TIRAP TIR domain-containing adaptor protein  
TLR Toll-like receptor 
TMT Tandem mass tag 
TNF tumour necrosis factor α 
TNFR TNF receptor 
TRAF TNF receptor-associated factor  
TRAF6 TNF receptor-associated factor 6  
TRAM TRIF-related adaptor molecule 
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TRIF TIR domain-containing adaptor protein inducing interferon-β  
Trx thioredoxin  
UC ulcerative colitis 
UCD urea cycle disorders  
UCL University College London 
UCLH University College London Hospitals  
UCP mitochondrial uncoupling protein 
UK United Kingdom 
USA United States of America 
UV Ultra Violet 
WHO World Health Organization    
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
23 
 
Chapter 1 Introduction 
Sodium benzoate (NaB) is a sodium salt that has antifungal and 
antibacterial activity. It is widely used in the food and cosmetic industry as 
a preservative1,2 and is also an approved drug for the treatment of urea 
cycle disorders3. NaB and its derivates have been implicated in human 
diseases, showing an improvement in disease progress4, memory, 
cognition5 and overall symptoms of diverse neurodegenerative 
disorders6,7,8. On the other hand, and of special interest in this study, 
patients with orofacial granulomatosis are associated with the initiation of 
symptoms due to ingestion of benzoate-containing diets9,10,11. Although 
there is large scale usage of benzoates and its known potential effects on 
human health, little is known about its effects on the immune system and 
especially on the innate immune response of macrophages. 
 
1.1 Sodium benzoate (NaB) and benzoic acid 
NaB is a salt with the chemical formula C6H5COONa and a 
molecular mass of 144.1 g·mol−1 (Figure 1-1A)12. This salt does not occur 
naturally and requires artificial manufacturing by chemical neutralization of 
benzoic acid with sodium hydroxide, sodium bicarbonate, or sodium 
carbonate. Benzoic acid is an aromatic carboxylic organic acid (Figure 1-
1B) and the main source of NaB13. NaB and benzoic acid (C6H5COOH) 
differ only in a single atom, the hydrogen in the carboxyl group of benzoic 
acid is replaced by a sodium atom. 
 
Figure 1-1: Chemical structure of sodium benzoate (A) and benzoic acid 
(B). Oxygen: red; Carbon: black; Hydrogen: white; and Sodium: purple. 
Downloaded from Google website under public domain rights. 
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Industrial production of benzoic acid is undertaken by oxidizing 
toluene with a molecular oxygen-containing gas in the liquid phase. 
Manganese and nickel are added to catalyse the reaction and heated up 
above 135 °C14. Sodium benzoate is the preferred form for 
commercialization because it forms a solid salt at room temperature 
(Figure 1-2), and also has a higher solubility in water when compared to 
benzoic acid15. The global production of sodium benzoate in 2015 was 
72,750 tonnes16. 
 
Figure 1-2: Molecular arrangement of NaB crystals. Hexagonal tapes 
showing π–π interactions between the tapes are dashed in grey (A). Side 
view of a single tape (B). Single tape representing a worm-like micelle (C). 
Adapted from Butterhof et al., 201315. 
 
The antimicrobial activity of NaB is the main reason for its addition 
to foods. Furthermore, other important factors have contributed to its 
popularity, such as the ease of production and incorporation into products, 
low cost of production and low toxicity17. NaB has desirable properties for 
a food additive, such as it's colourless, odourless and a slight astringent 
taste, which is beneficial for minimal interference with the natural flavours 
and appearance of food12.  
NaB was the first chemical approved by the United States of 
America (USA) Food & Drug Administration (FDA) for using as a food 
preservative. The maximum level of NaB permitted in food is 1000 ppm 
(0.1% of total weight of approximately 7 mM) according to the FDA13. The 
amount of benzoates added to products in the United Kingdom (UK) is 
regulated by the European Union regulations and this amount is variable 
depending on the type of food. For instance, non-alcoholic drinks can 
contain a maximum of 150 mg/L, in liquid tea and fruits (600 mg/L), olives 
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and olive-based preparations (1 g/kg), in dietetic foods (1.5 g/kg), 
vegetables in vinegar, brine or oil (2 g/kg), semi-preserved fish products (2 
g/kg), and concentrations as high as 6 g/kg in Crangon crangon18. NaB 
dissociates in aqueous solution to form benzoic acid. Benzoic acid and its 
derivatives;  salts, esters and acids are generically known as benzoates 
and registered with E numbers E210-E2199. 
Benzoic acid occurs naturally in many fruits and vegetables: apples, 
prunes, cranberries, apricots, tomatoes, strawberries, peaches, avocado, 
dark green vegetables such as spinach, rocket and sage, and can be also 
found in spices such as cinnamon, and nutmeg1,9,11,13,19. Benzoic acid, or 
benzoates in general, is a food additive and used as preservatives in many 
processed foods such as fizzy drinks, fruit juices, beers, salad dressings, 
vinegar, sausages, dairy products, cocoa, hot chocolate, vinegar and 
pickles, prawns and some other shellfish1,9,11,13,19,20. Cosmetic and 
pharmaceuticals products are other important sources of benzoates that 
can contribute to the total intake dose of benzoates by humans (Figure 1-
3)21. 
 
Figure 1-3: Global sodium benzoate market by application 2016. Data 
source from Technavio, 201721. 
 
Benzoate consumption is rising worldwide. Food and beverages 
accounted for nearly 49% of world consumption of benzoic acid in the form 
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of sodium and potassium benzoate in 2013, increasing at an average 
annual rate of 10.7% compared to the 4 previous years.22 While the rise in 
concerns about the use of synthetic preservatives, especially in Europe 
and North America caused a market decline, the Asia Pacific, Middle East 
and Africa markets are compensating, in part, due to a rise in the search 
for convenient food in these regions16. The Asia Pacific and Europe 
accounted for 64% and 22.5% world consumption respectively. China is 
the leading producer and consumer in the world, consuming more than 
50% of the world production of benzoates16. 
 
1.1.1 Antimicrobial mechanisms of benzoates 
 The mechanisms of action of benzoates are pH-dependent. The 
antifungal and antibacterial activity of benzoic acid is carried out by its 
undissociated form, which varies from 93.5% at pH 3, 59.3% in pH 4, 
12.8% in pH 5 and only 1.44% in pH 6, with a pKa of 4.204 at 25 °C13. The 
required concentration of benzoic acid to inhibit yeast growth increases as 
the pH becomes less acidic. At pH 3, the majority of yeast growth is 
inhibited with a concentration of 250 mg/L, whereas at pH 5, the 
concentrations required to control yeast growth to the same extent is  
between 500-750 mg/L, and at pH 7, all yeasts that tolerated this pH can 
grow even with a dose of 1200 mg/L of benzoic acid23. 
 Several mechanisms are involved in benzoates microbial inhibitory 
growth effects. Benzoic acid, as a weak organic acid, has its maximum 
inhibitory activity at low pH. In low pH, the uncharged and undissociated 
benzoic acid is sufficiently lipophilic to traffic across the microbial cell 
membrane and enter the cell24 (Table 1).  
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Table 1: Effect of benzoate concentration inside and outside the cell 
according to change in external pH. The concentration of benzoic acid was 
0.01mM at pH below than 6.96 and 2mM in pH equal or higher than 6.96. 
pH of external 
medium 
Ratio 
[benzoate] in pH in intracellular 
water [benzoate] out 
2.5 39.5 5.8 
3.54 63.2 6.08 
4.43 37.1 6.2 
5.91 2.98 6.39 
6.78 0.71 6.62 
6.96 0.34 6.5 
7.16 0.22 6.51 
7.47 0.12 6.53 
Data source: Krebs et al., 198324. 
 
As an immediate effect, when the benzoic acid reaches a higher pH 
within the cell cytoplasm, the molecules dissociate and accumulate protons 
and anions inside the cell, changing the intracellular pH and other key 
metabolic reactions (Figure 1-4)25. 
 
Figure 1-4: Schematic balance of benzoic acid in the intra and extracellular 
compartments. Undissociated benzoic acid is found in a higher percentage 
in acid conditions (see scale bar). In this medium, these lipophilic 
molecules can easily pass across the plasma membrane by simple 
diffusion, but when they reach a more neutral and stable intracellular pH, 
they dissociate and can interfere with cell metabolism. Adapted from 
Blausen.com staff. 
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The effects of intracellular pH-change after sodium benzoate 
administration was evaluated in Bacillus subtilis, results showed that after 
the administration of NaB, there was a reduction of intracellular pH and 
only mild and transient changes in the extracellular pH. A transcriptome 
analysis was carried out and showed that the main changes observed in 
gene expression profile were related to pH homeostasis and similar to 
those observed in external pH reduction induced by acid. The pH stress 
genes included important acid reversal mechanisms, such as formate 
dehydrogenases and amino acid transporters26. Furthermore, resistance 
against weak organic acids is associated with genes known to regulate 
cytosolic pH. Resistance to organic acid preservatives has been reported 
for the following species of yeasts: Saccharomyces cerevisiae, 
Zygosaccharomyces bailii, and Zygosaccharomyces rouxii. These species 
upregulate the expression of H+ ATPases to control the cytosolic pH27. 
It is believed that weak acid preservatives will diffuse into the cell 
until anions and cations reach an equilibrium with the pH gradient across 
the membrane25. The metabolic changes induced by benzoates include 
inhibition of fermentation due to ATP depletion; interference with the 
permeability of the microbial cell membrane causing reduced transport of 
amino acid and cell starvation; and inhibition of specific enzyme systems 
within cells13,25. The changes in intracellular pH cause an energetic 
expensive stress response to the cell attempts to restore the homeostasis 
resulting in limited energy availability for cell division and other metabolic 
functions25.  
Krebs et al. 198324 investigated the effects of benzoates in a strain 
of baker’s yeast (Saccharomyces cerevisiae) to elucidate their antifungal 
mechanism. The authors found that there was a relationship between 
intracellular pH, phosphofructokinase inhibition and CO2 production. They 
concluded that benzoates accumulate inside the cell at low pH affecting 
the function of phosphofructokinase and causing glycolysis inhibition and 
ATP depletion and subsequently growth restriction (Figure 1-5). 
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Figure 1-5: Effects of benzoate in intracellular anaerobic CO2 production 
(A) and on adenine nucleotides during anaerobic fermentation (B). CO2 
production is reduced in pH <5 with concentrations of 2 mM and 5 mM in a 
dose-dependent manner. The effect of 5mM benzoic acid is eliminated at 
pH 5.5 (A). The ATP concentration fell dramatically after 5 minutes 
exposure to 10 mM of benzoic acid. An almost similar proportional increase 
was observed in the concentration of AMP, while the ADP showed a slight 
increase. It suggests an important inhibition in ATP synthesis caused by 
benzoic acid. Data source (A) and adapted image (B) from Krebs et al. 
198324. 
Increased CO2 production in low pH is a property common to all 
weak acids preservatives and does not explain all the antimicrobial effects 
of these substances, otherwise, the antimicrobial properties of all acid 
preservatives would be directly related to their dissociation properties, 
which is not true28. Stratford and Anslow 199828 investigated the effect of 
some weak acids on growth inhibition of many yeast species and found 
that the minimum inhibitory concentration (MIC) differ among them. They 
showed that yeast species that were more sensitive to ethanol, a known 
solvent capable of disrupting membrane compounds, were also more 
sensitive to specific weak acid preservatives, especially to sorbic acid and 
benzoic acid. This result suggests that benzoic acid may act as a hybrid 
compound, acting as a proton donor and as a membrane-active 
compound28. A possible effect mechanism involving anion toxicity has also 
been suggested27,29. 
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1.1.2 Food spoilage 
Food loss and waste is a massive burden on the whole society. 
Food loss happens in all stages of the food chain and involves losses in 
production site; post harvesting, handling and storage; processing and 
packing; distribution and retail stores; and finally at the consumer level30. It 
is estimated that one-third of all food produced along the entire food chain 
in the world is lost or wasted, this counts for 1.3 billion tons per year31. 
The percentage of food lost in the food chain vary according to the 
type of food (Figure 1-6), but independent of the type of food, the main 
losses happen of the bottom of the chain at the consumer level30. 
 
Figure 1-6: Percentage of food consumed and food loss in United States, 
Canada, Australia and New Zealand. Data source Food and Agriculture 
Organization of the United Nations, 201131. 
 
Consumers are responsible for an average 58% of all losses in the 
food chain and two-thirds of these losses are due to spoilage30. A report 
from the UK Waste & Resources Action Programme has estimated that a 
reduction in 50% of food waste would save around 300 billion US dollars 
per year. The USA and Europe are responsible for 60% of food waste and 
from it, 21% is due to spoilage32. Microbial growth is the main factor that 
causes food spoilage and on the top of the economic burden, food spoilage 
is a world health problem responsible for foodborne intoxication33. 
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According to the World Health Organization (WHO), there were 600 
million cases of foodborne illnesses and 420,000 deaths due to foodborne 
diseases in 2010. Among these deaths, one-third were children, who 
account for only 9% of the entire population. Low-income countries have 
the highest rate of foodborne disease, with a high prevalence in Africa, 
followed by Southeast Asia34.  
In the UK, the Food Standards Agency estimates that around 1 
million people suffer some type of foodborne illness, with 20,000 people 
requiring hospital treatment and 500 deaths per year. This consumes 
around £1.5 billion of the public funds yearly35.  
Many strategies can be used by the food industry to prevent 
microbial spoilage, which includes low-temperature storage, heat 
treatment, rich CO2 atmosphere, modified atmospheric packing system, pH 
control and preservatives36. Food preservatives, such as benzoates and 
sorbic acid are convenient products due to the low cost and easy 
manipulation and addition to food products. NaB had a growing market 
valued at US$ 122.94 million in 201516. 
 
1.2 Sodium benzoate and human diseases 
Sodium benzoate has been linked to human diseases in many ways, 
as a therapeutic drug to treat urea cycle disorders37,38, as an antioxidant39, 
as an immunomodulator in neurogenerative diseases (NDD) 1,6,40, and also 
as a trigger for symptoms in patients with orofacial granulomatosis (OFG) 
9,11,41. OFG and NDDs are both characterized by chronic inflammation, 
however, they show a completely different response to benzoate. Although 
some studies have tried to understand the effects of NaB on the immune 
system, these effects are still poorly understood. 
 
1.2.1 OFG and sodium benzoate 
OFG is a rare chronic inflammatory granulomatous disorder that 
causes enlargement of the orofacial soft tissues, with clinical 
characteristics similar to the oral manifestation of Crohn's disease (CD) 
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and sarcoidosis42,43,44,45. The causes of OFG are unknown and many 
theories have been postulated to explain its aetiology, but none of them 
has provided convincing evidence to date43,46. However, there is a growing 
evidence that supports an allergic cause and NaB is the most common 
allergen associated with OFG9,47. 
Currently, OFG is considered a distinct entity, which should be 
differentiated from oral CD, tuberculosis and sarcoidosis45. OFG presents 
with localized oral granulomatous lesions similar to granulomatous cheilitis 
and Miescher’s cheilitis; and characteristics that may overlap with the triad 
of Melkersson-Rosenthal syndrome (MRS) (orofacial swellings, facial 
nerve palsy and fissure tongue)48,49. Oral inflammation with 
indistinguishable features of OFG usually precedes CD, especially in 
adolescent patients50,51. 
The term OFG was first described in 1985 by Wiesenfeld et al., 
which encompassed two previously described entities: MRS and cheilitis 
granulomatosa48. OFG may present with different phenotypes, which 
include facial and lip swelling (upper and/or lower lip), mucosal 
cobblestoning, gingival enlargement, oral ulceration, mucosal tags and 
oedema, angular cheilitis and median lip fissures48,52,53,54. The most 
common clinical feature of OFG is lip swelling, affecting more than 50% of 
patients48,52,54. Other common clinical signs are oral ulceration48,52,54 and 
cobblestoning (Figure 1-7)52,54. Disfigurement of the face and/or lips due to 
tissue fibrosis after long-term swelling is the main complication of OFG and 
normally the reason why patients seek treatment42,52. 
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Figure 1-7: Clinical features of OFG. Disfiguring upper and lower lip 
swelling (A) with mucosal fissures (B). Hyperplasic mucosal folds (C) and 
oral ulcers are frequently found. Another painful lesion associated with 
OFG is angular cheilitis (D). Images kindly provided by Prof Stephen 
Porter. 
 
The prevalence of OFG is difficult to establish due to limited 
information. It appears that OFG is more common in developed countries, 
with the majority of publications coming from the United Kingdom and 
Ireland9, with a possible higher prevalence in Scotland55.  Although OFG is 
considered an uncommon disease, the increasing number of reports may 
suggest that its prevalence is rising52. 
The histopathological features of OFG are not pathognomonic and 
encompass a non-specific inflammatory infiltrate with non-caseating 
granulomas, the presence of multinucleated giant cells, lymphocytes and 
Langerhans cells. Oedematous changes of the superficial corium with 
dilated lymphatic and blood vessels may also be present48,52,54. The non-
caseating granulomas are usually small and loose, with lymphocytes in the 
surrounding tissue52,56. Some authors have associated the formation of the 
granulomas in OFG with lymphocytes, specifically T-cells57,58. 
A higher number of CD4+ T cells are found inside and outside the 
granulomas of OFG samples when compared to a control group of other 
granulomatous lesions that do not fit the inclusion criteria of OFG58. 
Furthermore, the T-cells found in the OFG lesion demonstrate a similar 
diversity of T-cell receptors (TCR) when compared to T-cells from 
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peripheral blood from OFG patients and healthy individuals57. According to 
the authors, the T-cell population surrounding OFG lesions do not undergo 
clonal expansion and are the result of a random influx of T-cells at the 
inflammation site rather than a response to a specific antigen57. 
The histopathological features of OFG are identical to the oral 
manifestation of CD49 and sarcoidosis43. Indeed, the diagnosis of OFG 
should be established after excluding these diseases first49,52. The 
differential diagnosis of OFG may be quite complicated because the main 
clinical symptoms are sometimes indistinguishable from other 
granulomatous disorders such as CD, sarcoidosis, infectious disease 
(tuberculosis and leprosy), reactions to foreign bodies, and delayed 
hypersensitivity reactions49. 
Thus, some authors have established the criteria for a true 
diagnosis of OFG that include: the presence of one or more clinical signs, 
such as facial and/or lip swelling, mucosal cobblestoning, gingival 
enlargement, oral ulceration, mucosal tags and oedema, angular cheilitis 
and median lip fissures; presence of non-caseating granuloma in 
histopathology assessment (not mandatory), and exclusion of other 
systemic granulomatous diseases (CD, sarcoidosis, tuberculosis, etc) 49,52. 
 
1.2.1.1 Causes of OFG 
The aetiology of OFG is unknown and has been a matter of 
discussion since it was first described. Some theories have tried to explain 
the causes of OFG, but all failed to find a consensus. These theories have 
tried to characterize OFG as a result of genetic predisposition, infection, 
allergy or immunological disorder, but controversial concepts have also 
been raised43,46. 
The first attempt to link OFG to a genetic predisposition investigated 
the human leucocyte antigen (HLA) in OFG patients. The HLA phenotype 
of peripheral blood of a small population of 16 OFG patients in Scotland 
was compared to 516 control individuals from West Scotland and found 
that HLA types A2, A3, B7, DR2, DR3, and DR4 of OFG patients were 
found in higher frequencies than in the control group. According to the 
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authors, data from a meta-analysis showed that HLA-A2 carries an 
elevated risk for CD, whereas HLA-A11 showed a negative correlation. 
They showed that 25% of the OFG patients tested for HLA-A11 and half of 
them were also positive for HLA-A2. These results suggest a different 
genetics from Crohn’s disease59,60. However, these results have never 
been replicated61. 
A Swedish cohort has investigated NOD2 polymorphisms in two 
groups of OFG patients, with (n=17) or without (n=12) CD and similar oral 
phenotype. Using DNA from buccal swabs the authors assessed the NOD2 
variants Arg702Trp, Gly908Arg and Leu1007fsinsC, all previously linked to 
gastrointestinal CD. None of the OFG only patients showed any of the 
NOD2 variants polymorphism, whereas one-third of patients with CD had 
the NOD2 variant Arg702Trp. The authors concluded that OFG patients 
with or without CD had a similar oral phenotype but genotypic differences 
regarding NOD262. 
In a larger cohort from the UK, 201 patients with OFG, also with or 
without CD, and 1023 healthy controls were genotyped for risk variants 
with some similarities to OFG: NOD2, IRGM, IL23R, ATG16L1 (CD), 
BTNL2 (sarcoidosis), and FLG (atopy). The results showed no association 
between known CD-risk variants of NOD2 and OFG. There was an 
association between NOD2 p.L1007insC and OFG with CD. When these 
groups were analysed together (OFG only and OFG + CD), there was an 
association with the CD-associated IL23R p.R381Q and the sarcoidosis 
risk variant rs2076530 in BTNL2. The authors suggested a genome-wide 
association scan to fully define the genetic architecture of OFG61. 
Another theory regarding the causes of OFG has linked it to  
infection. This theory relies on the implication of microorganisms in other 
granulomatous diseases with similar features, such as tuberculosis43,46. 
Apaydin et al. reported the presence of Mycobacterium tuberculosis in 3 of 
six biopsies of MRS/OFG patients and suggested a possible role of 
mycobacterium in the aetiology of OFG.63 Using a different approach, 
Ivanyi et al. investigated the presence of mycobacterium stress protein 
65kd (mSP65) in the serum of 10 patients, 6 OFG only and 4 with CD, and 
found positive levels of serum protein in 7, 4 CD and 3 OFG patients.64 A 
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supposed case of OFG due to Mycobacterium tuberculosis was reported65, 
however many of diagnostic criteria of OFG were not observed in this 
report. The current literature does not support the role of Mycobacterium 
tuberculosis in the pathogenesis of CD66.  
Another possible link of microorganisms in the cause of OFG relates 
to the beneficial response to antibiotic therapy. Five OFG cases were 
successfully treated with an azithromycin pulse therapy (an antibiotic 
scheme to treat inflammatory acne) and resulted in almost a complete 
improvement in all cases with a medium period of 3 months, according to 
the authors. They suggested that a continuous exposure to an unspecific 
antigen would be a possible cause, which may benefit from the 
antimicrobial effect as well as an additional anti-inflammatory and 
immunomodulatory properties of azithromycin. However, no evidence of 
microbial involvement was found in biopsies of these patients.67 
On the other hand, two studies involving Scottish68 and  Irish69 
populations have searched for the presence of Mycobacterium 
paratuberculosis by polymerase chain reaction (PCR) in biopsy samples of 
30 and 21 OFG patients respectively. Both failed to show the presence of 
Mycobacterium in these cases. Another study also failed to show the 
presence of Borrelia burgdorferi using a similar method in 12 patients70. 
Thus, there is insufficient and controversial support for a microbial role in 
the causation of OFG43. 
Inflammatory/immunological dysregulation as a cause of OFG has 
been postulated, mainly because of the histopathology of OFG that shows 
the presence of non-caseating granulomas, lymphoedema and an 
agglomeration of lymphocytes, all suggesting an altered immune 
response43,46. One report analysed the T-cell diversity on a patient with a 
history of 5 years swelling of the lips, gums and oral mucosa later 
diagnosed as OFG. This investigation was motivated by the similar 
histology of OFG to other granulomatous diseases that are characterized 
by a limited heterogeneity of alpha/beta and gamma/delta T cells. A high 
number of CD4+ T-cells within and outside the granulomas was found in 
the lip biopsy of this OFG patient, along with elevated expression of T-cell-
associated cytokines and chemokines, indicative of a T-cell mediated 
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immune response in this OFG patient that is similar to the inflammatory 
response observed in CD58. Another report has shown massive peripheral 
T-cell activation on an OFG patient, who had a similar TCR repertoire in 
lesion-associated lymphocytes and the peripheral blood lymphocytes, 
suggesting that there is a dysregulated T-cell response in OFG that causes 
a random influx of T-cells at the inflammation site57. 
On the other hand, clonal expansion of T cells was demonstrated in 
a single patient whose T-cells from the vicinity of the lesion used a limited 
repertoire of TCRVβ when compared to peripheral blood T-cells from the 
same patient, as well as mucosal T-cells from healthy individuals71. 
However, the role of T-cells in the causation of OFG remains unclear due 
to the reduced number of studies and lack of strong evidence46. 
An allergic reaction is another possible aetiology of OFG, which may 
be split into two main categories: allergy to dental materials; and allergy to 
food compounds. Few reports have been published associating OFG 
cases with an allergy to dental materials72,73,74,75. One case reported a two-
year long swelling of the cheek and lips further diagnosed as OFG74. The 
patient showed a positive reaction on a patch test to mercury and had many 
amalgam dental fillings. After total replacement of amalgam fillings, all 
signs and symptoms disappeared after six months. 
Tomka et al.  reported 3 cases of OFG that were successfully 
treated after replacement of amalgam filling for other dental materials.72 All 
patients showed high sensitivity to mercury on patch tests, which 
decreased after amalgam removal. Lazarov et al.  showed two cases of 
OFG associated with an allergy to dental materials based on positive 
reactions on patch tests75. One case was positive for gold in a patient with 
gold crowns on the upper incisors, who experienced a full recovery after 
crowns replacement with different dental materials. The other case was 
diagnosed with an allergy to mercury, however, in this case, the patient 
refused to replace her amalgam fillings. After two years, there was a 
worsening of the disease. The authors attributed the increased signs of 
disease to the maintenance of her amalgam fillings75. A case with 
documented hypersensitivity to cobalt has also been reported.73 
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Besides the small number, all cases of hypersensitivity to dental 
materials were diagnosed by patch test. In an investigation of the role of 
allergy in mucosal diseases performed by patch tests, 264 out of a total of 
1,252 patients had OFG. The OFG group showed 54% of hypersensitivity 
to food additives, 51% to benzoic acid and 38.3% to cinnamaldehyde.76  
Many food compounds and food additives have been associated to 
OFG 9,41,43,46,77, although their specific role, as a primary causative agent 
or as an agent that just exacerbate symptoms of the disease, has not been 
fully elucidated. The possible association between food allergy is 
supported by the fact that the majority of documented allergies in OFG 
patients are a result of atopic allergy due to a hyperallergic state76,78. 
Benzoic acid is the most prevalent allergen associated with OFG 
patients.9,76 The list of others common allergens include food additives 
(such as salicylic acid, glutamic acid, tartrazine, propylene glycol, etc), 
cinnamaldehyde, perfumes/flavourings, and chocolate9; and a number of 
less common agents such as wheat, dairy products, eggs, peanuts, 
piperitone, cocoa, carvone, carmoisine, sun yellow dye and monosodium 
glutamate, all have been associated with OFG46. 
Wray et al.  investigated the role of allergy in mucosal diseases and 
found that benzoic acid was the most prevalent single allergen to cause 
positive allergic reactions in all patients (41.5%) with the highest 
prevalence (51%) in OFG patients. They have carried out two different 
allergy tests: contact urticaria and delayed hypersensitivity (standard patch 
test). The results showed that majority of reactions were Type I 
hypersensitivity (contact urticarial – 46%) compared to delayed 
hypersensitivity (7.1%), supporting the role of atopic allergy in OFG76. 
Patel et al. sought for clinical evidence of allergy in patients with 
OFG in view of the recent link between OFG and dietary sensitivity. Their 
methods included the application of a questionnaire, skin prick tests, total 
and specific serum IgE levels. OFG patients were compared with a series 
of patients with inflammatory bowel disease (IBD) without oral involvement 
and to healthy controls. They observed an almost 3-fold increase in allergy 
rates when comparing OFG to healthy individuals, concluding that there is 
compelling clinical evidence of an association of OFG with allergy47. In a 
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double-blind randomized controlled trial using a placebo-controlled 
challenge with sodium benzoate, Nettis et al. investigated recurrent 
episodes of urticaria/angioedema in 47 healthy individuals who had 
previously reported episodes of urticaria after ingesting food containing 
benzoates. The results showed that there was only 1 patient out of 47 who 
had a reaction after ingestion of 75 mg NaB, which reinforces the low 
allergy rates to benzoates in non-OFG patients79. 
Another piece of evidence that supports the role of food allergy in 
the clinical course of OFG relies on the effects of restriction of known 
allergens from the diet of patients. Some reports have shown that 
cinnamon and/or benzoate free diets lead to improvement of symptoms in 
about 70% of patients11,19,80. Taibjee et al.  reported a case of a patient with 
a confirmed diagnosis of OFG, who experienced a worsening of symptoms 
after eating chocolate81. Patch testing identified a positive reaction to cocoa 
liquor; in addition, the patient experienced a flare-up of the disease during 
the patch test containing cocoa liquor, showing a clear association 
between the allergen and disease. Although reports of allergen-free diet 
have shown promising results, the mechanisms underlying this association 
have not been clarified. 
The use of exclusive enteral nutrition is a recognized treatment for 
induction of remission for Crohn's disease and the efficacy of this therapy 
was investigated in a retrospective study for the management of OFG in 
children. From 22 children who completed 6 weeks of exclusive enteral 
nutrition, 19 showed clinical improvement in the OFG appearance82. 
 
1.2.1.2 Treatment and prognosis of OFG 
The evolution of OFG is considered unpredictable and the majority 
of therapies focus on controlling the symptoms. Treatment choices are, in 
some instance, experience-based and follow the current hypothesis of 
OFG causation.  
Controlling the immune response through the use of anti-
inflammatory and immunomodulatory drugs is the commonest treatment 
and shows the most reliable evidence of a successful treatment45,49,52,83,84. 
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Corticosteroids are common agents for treating OFG and may be used 
topically, intralesionally and in systemic therapy. The criteria for treatment 
selection depend on the severity of the disease. Mild and superficial lesions 
like ulcers, mucosal tags, cobblestoning, and mild swelling can be treated 
with topic corticosteroids; moderate to severe swellings and unresponsive 
cases may require systemic corticosteroids and/or intralesional injections, 
immunosuppressants, or anti-tumour necrosis factor (TNF) therapy44,85,52. 
Fedele et al. demonstrated an initial success rate of 64% using 
intralesional injections of triamcinolone, especially for controlling lip 
swelling. Patients who presented recurrence were responsive to new 
injections of corticoid and were able to achieve remission of the disease 
and keep symptomless for a similar mean period than those who were 
responsive at the first injection42. 
The authors who associate the course of the disease to an allergy 
to dental materials are supportive of the conduct of replacement of the 
dental material (allergen), which normally is succeeded by the remission of 
symptoms.72,73,74,75 Failing to replace this material has been also linked to 
a worsening of the disease75. 
Even without clear evidence of microbial involvement in the 
pathogenesis of OFG, reports of successful treatment with antimicrobial 
agents have been encouraged51,67,86. A supposed reason for successful 
treatment of inflammatory conditions with antibiotics relies on the 
assumption that microbial components can modulate cytokine and 
chemokine secretion and thus be responsible for inflammatory events87. 
The anti-inflammatory and immunomodulatory effects of antibiotics would 
be responsible for controlling the inflammation87,88. 
A broad range of antibiotics agents has been used to treat OFG, 
such as metronidazole86, azithromycin67, tetracycline, isoniazid, 
minocycline and roxithromycin88. Since the treatment of OFG is mainly 
focused on controlling the symptoms, many authors have supported the 
theory that antibiotics are beneficial in the treatment of OFG based on 
successful control of symptoms using  antibiotics in their clinical 
experience67,86,87,88. 
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Dietary restriction is another popular therapy and has been 
employed with beneficial outcomes in 54-78% of patients9. These diets are 
based on benzoates restriction11,77 or a more limited diet with the removal 
of phenolic acids19. Avoidance of cross-reactive foods to confirmed plant 
allergens as determined by prick test has also been recommended10. All 
these therapies have shown improvements in 23% of patients requiring no 
further treatment9. 
The beneficial effects of selective diets such as exclusive enteral 
nutrition and benzoate-free diet have been proven efficient in the 
management of OFG, and in the case of benzoate-free diet, the effects can 
last longer than the period of dietary treatment itself, especially after 
controlled reintroduction of a normal diet19,82. Moreover, the benefits of this 
treatment can avoid or, at least, reduce the necessity for 
immunomodulatory treatment which has known side effects9,11. The main 
problems associated with dietary therapies are the necessity of nutrient 
supplementation19 and adherence of patients to the dietary restrictions9,19. 
Furthermore, others challenges are associated with dietary 
therapies, which include patient awareness about benzoate containing 
foods; the necessity of preparing individual meals, which is time-
consuming and may increase costs; and limitations for eating out19. It is 
also important to consider that restricted diets may have no effects on 
individuals, which is a common problem associated with OFG with about 
30% of patients remaining unresponsive to treatment9,52. 
The immunologically basis of OFG is poorly understood and more 
investigations are required9. The effects of benzoate-free diet are 
promising, achieving improvements in a similar rate to drugs-based 
treatments (≈70%)9,52.  
 
1.2.2 Neurodegenerative disease and sodium benzoate 
 NDD is an umbrella term to describe a series of conditions that affect 
the neurons in the human brain. NDDs are progressive and incurable 
diseases that cause serious movement problems and mental 
malfunctioning. NDDs include Alzheimer’s disease (AD) Parkinson’s 
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disease (PD) and PD-related disorders, Prion disease, Huntington’s 
disease (HD), spinocerebellar ataxia (SCA), and spinal muscular atrophy 
(SMA) among other less common diseases89. 
Neurons are the main cell in the nervous system, considered, the 
building blocks of the nervous system. There are many hypotheses 
underlying the pathogenesis of NDDs and include genetic defects, altered 
membrane metabolism, trace element neurotoxicity, excitotoxicity, 
reduced energy metabolism, and free-radical-mediated damage89.One 
important characteristic of neurons is that they differ from any other 
proliferative tissue in their lifespan and must survive for the entire lifetime 
of the organism. Thus, ageing plays a significant role in the pathogenesis 
of many NDDs90, acting isolated or in combination with other factors 
(Figure 1-8)91.  
 
Figure 1-8: Age-related neurodegenerative diseases can be caused by 
isolated or a combination of factors. Image from Awada et al. (2013)91.  
 
A notable characteristic of NDD is the neuronal loss due to cell 
death, where apoptosis appears as an important contributor to neuronal 
death. Neuronal apoptosis occurs as a result of a biochemical cascade that 
involves oxidative stress, perturbed calcium homeostasis, mitochondrial 
dysfunction, and caspase activation89. 
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Although the neuron is the primary target of NDD (AD, PD, HD, 
Prion's disease), other cells of the nervous system (astrocytes, microglial, 
Schwann cells) play important roles in the pathogenesis of these diseases. 
Astrocytes and microglia are known for their association with chronic 
inflammation in the central nervous system (CNS). With ageing, senescent 
cells secrete a variety of proinflammatory cytokines, chemokines, growth 
factors and proteases collectively termed as the senescence-associated 
secretory phenotype (SASP). These uncontrolled immune reactions 
contribute to neuronal dysfunction and death over time92.  Figure 1-9 
summarizes the current evidence for the role of different cell types in 
specific NDDs. 
 
Figure 1-9: Summary of current evidence of contributor cells to the 
pathogenesis of neurodegenerative diseases. Adapted from Ilieva et al. 
(2009)93. 
 
 Studies have shown that NaB may provide several beneficial effects 
on the CNS in different NDDs, including T-cell modulation (switching Th1 
to Th2 cells and enriching Treg cells); modulation of innate immunity by 
knocking down proinflammatory cytokines and attenuating co-stimulatory 
molecules on the surface of microglia; controlling astroglia activation; and 
44 
 
suppressing disease progression in a mouse model of multiple sclerosis 
(MS)4. 
 NaB attenuated the inflammatory markers, especially the secretion 
of proinflammatory cytokines, such as TNF and IL1β in mouse microglia 
after challenge with lipopolysaccharide (LPS) through inhibition of nuclear 
factor kappa-light-chain-enhancer of activated B cells (NFkB). NaB also 
inhibited the expression of inducible nitric oxide synthase (iNOS) in mouse 
microglia and primary human astrocytes1. 
 IL1β was found to induce iNOS expression in mouse astrocytes in 
a mouse model of PD. Nitric oxide (NO) downregulated the levels of Parkin 
and DJ-1, proteins associated with survival of existing dopaminergic 
neurons. IL1β-induced iNOS caused a downregulation effect on Parkin and 
DJ-1 and this effect was neutralized by NaB. In summary, NaB altered 
dopaminergic neuronal protection, normalized striatal neurotransmitters, 
and improved motor functions by cinnamon in MPTP-intoxicated mice. 
These effects are suggested to be beneficial for PD patients94. 
Another beneficial effect of NaB to the CNS is an increase of 
neurotrophic factors; brain-derived neurotrophic factor (BDNF) and 
neurotrophin-3 (NT-3) in primary human neurons and astrocytes. 
Neurotrophic factors are molecules that stimulate and control 
neurogenesis and support the survival of existing neurons. NaB increased 
levels of neurotrophic factors occurred through activation of protein kinase 
A (PKA) and cAMP response element binding (CREB) protein6. 
Mice fed with NaB showed increased levels of NaB in serum and 
brain after oral ingestion, suggesting that NaB can reach the CNS after 
crossing the blood-brain barrier6, which is an important property of NaB 
since it is an important challenge for therapeutic options that target the 
CNS94. 
NaB was tested in an experimental allergic encephalomyelitis 
(EAE), a mouse model of MS. NaB administration in drinking water 
ameliorated clinical symptoms and disease progression of EAE in recipient 
mice and suppressed the generation of encephalitogenic T cells in donor 
mice. It was achieved by reducing infiltration of mononuclear cells and 
demyelination in the spinal cord of mouse. NaB also switched the T cells 
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from Th1 to Th2 mode95. In another study, NaB also upregulated Tregs 
with a protective effect on a similar mice model of EAE. It was shown that 
NaB increased the expression levels of TGFβ, an important inducer of 
Tregs, through activation of STAT6. This mechanism has been attributed 
to the beneficial effects of NaB and predicted to be of therapeutic value for 
MS patients8. 
A few clinical trials have tested the efficacy of NaB on the treatment 
of neurological diseases5,96,97. NaB is considered a D-amino acid oxidase 
(DAAO) inhibitor, which can enhance the N-methyl-D-aspartate receptor 
(NMDAR) mediated neurotransmission. NMDAR is very important for 
memory and learning5 and has an important role in the pathophysiology of 
schizophrenia97. 
In the AD, glutamatergic neurotransmission, particularly through the 
NMDAR, leads to neurotoxicity, especially in the late phase. Enhancing 
NMDAR activation by inhibiting the activity of DAAO could be beneficial for 
the early declining process of the AD. NaB, as a DAAO inhibitor, was 
administered at a concentration of 250-750 mg/day to 60 patients in the 
early phase of the AD in a double-blind randomized clinical trial. There 
were no adverse effects observed in the test group (NaB) after 24 weeks 
therapy. NaB treatment resulted in a better improvement than placebo in 
cognition and overall functions than control, considered a promising novel 
approach for the early dementing processes5. 
Two other clinical trials assessed the effects of NaB as an add-on 
drug97 or as adjunctive therapy drug to sarcosine96, a glycine transporter I 
inhibitor in patients with schizophrenia. In both trials, patients were kept 
under their antipsychotic drug therapy regimen on a double bind 
randomized clinical trial with doses not higher than 1000 mg/day. As an 
add-on drug, NaB adjunctive therapy significantly improved a variety of 
symptom domains and neurocognition in patients with chronic 
schizophrenia97. A similar effect was also observed when NaB was used 
as an adjunctive drug to sarcosine, with better results for cognitive function 
found on the group sarcosine plus NaB than on placebo or sarcosine alone. 
The authors suggest that the cognitive improvement can be primary 
without improvement in clinical symptoms96. 
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Currently, there is an Australian clinical trial that aims to investigate 
the efficacy of NaB as an adjunctive treatment in early psychosis, using 2 
doses of 500 mg/day of NaB98. 
  
1.2.3 Urea cycle disorders (UCD) and sodium benzoate 
 UCD represent a group of rare inherited metabolic disorders caused 
by deficiencies in any of six enzymes and two carrier proteins involved in 
the urea metabolism (Figure 1-10)99,100. The incidence is 1 in 30,000 births, 
with the most common enzyme affected the Ornithine Transcarbamylase 
(OTC) resulting in OTC deficiency99. The urea cycle is the main pathway 
for the disposal of waste nitrogen derived from catabolism of dietary and 
endogenous proteins101. The link between NaB and UCD is that NaB is an 
approved drug used in the treatment for hepatic metabolic defects 
associated with hyperammonemia102. 
 
Figure 1-10: Schematic representation of the urea cycle. Nitrogenous 
products from protein or dietary catabolism are metabolized in the 
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mitochondria producing urea. Six enzymes participate in this pathway 
(numbered 1–6, with their associated gene in brackets). Image from Blair 
et. al. (2014)37. 
 
1.2.3.1 Sodium benzoate metabolism and nitrogen waste disposal 
NaB salt quickly dissociates in an aqueous medium to form benzoic 
acid as previously explained. After oral ingestion, undissociated benzoic 
acid is quickly absorbed by the gastrointestinal tract and metabolized in the 
mitochondrial matrix in the liver and kidney. This process requires energy 
consumption and involves conjugation of benzoic acid with coenzyme A 
and glycine, which results in the formation of hippuric acid and rapidly 
secreted in urine (Figure 1-11)103. 
 
Figure 1-11: Metabolism of benzoic acid in mammals. Benzoic acid reacts 
with HS-CoA to form benzoyl CoA. Then, benzoyl CoA reacts with glycine 
to form hippuric acid releasing free CoA (A). Reaction sequence of benzoic 
acid metabolism (B). Image 11A from Chipley (2005)13. 
 
Almost all of the administered NaB is metabolised to hippuric acid, 
only a small portion of non-metabolized NaB is detected in the urine (Figure 
1-12). This metabolism is well established and the secretion of hippuric 
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acid in the urine reflects the intake of benzoates. Thus, elimination of 
hippuric acid after a challenge with NaB served as a clinical test for 
evaluating liver function104. 
 
Figure 1-12: Urinary excretion of hippuric acid (circles) and benzoate 
(triangles) by normal control rats after intraperitoneal administration of 100 
mmol of benzoate per 100 g body weight. Adapted from Krähenbühl et al. 
(1997)105. 
 
NaB decreases the levels of ammonium through the elimination of 
nitrogen as hippuric acid, which appears to occur at the expense of 
nitrogen that otherwise would have been eliminated as urea. Thus, NaB 
metabolism diverts the waste of nitrogen from the urea production106. 
It is believed that NaB alters the urea production by interfering in 
two sites of the ureagenesis pathway by inhibiting the pyruvate 
carboxylase and the N-acetylglutamate-dependent carbamoyl phosphate 
synthetase I104,106,107. Benzoate may block the urea cycle through 
sequestration of CoA via the accumulation of benzoyl-CoA, thus affecting 
the acetyl CoA-dependent reactions, especially the synthesis of N-
acetylglutamate, the physiological allosteric activator of carbamoyl 
phosphate synthetase108. In the absence of glycine, there is an 
accumulation of benzoyl-CoA, an intermediate metabolite of NaB 
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metabolism, and consequent decrease in free CoA. The reduction of free 
CoA is the main mechanism responsible for NaB toxicity13,105,106,107. 
Although the toxicity of NaB is considered low, it needs to be used 
in moderation. Studies in animal models have shown that NaB can 
potentiate ammonium toxicity, increasing the levels of blood ammonia and 
mortality in mice104,108. In humans with cirrhosis, sodium benzoate caused 
an adverse effect increasing the basal and post-glutamine ammonia levels 
after treatment with high doses (10 g/day). Death after administration of 
high doses of NaB has also been reported109. 
 
1.2.3.2 Treatment of urea cycle disorders with sodium benzoate 
Treatment of UCD with NaB is usually made in conjugation with 
sodium phenylacetate. Many cases have been reported with successful 
control of ammonium levels after administration of therapeutic doses of 
NaB, which is considered at 250 mg/kg/day3,37,102. A randomized trial study 
in healthy volunteers has demonstrated the efficacy of NaB in nitrogen 
secretion, with a better response when NaB was used in association with 
phenylbutyrate101. 
In an uncontrolled study that reported the 25-year experience of 
treatment of 299 patients with UCD using NaB, the authors reported an 
overall survival of 84%. There were 1181 episodes of hyperammonemia 
with a survival rate of 96%. Patients who were comatose at admission had 
a survival rate of 81%3. NaB isn’t the sole therapy, it is usually used in 
combination with sodium phenylacetate and other therapies, such as 
intravenous arginine hydrochloride and a protein-restricted diet. Dialysis 
can also be used whenever necessary3,37. 
UCD is characterized by episodic life-threatening 
hyperammonemia. Mortality and morbidity are historically high, and 
survivors may experience devastating neurological sequelae3,100. NaB is 
one more therapeutic option to help to reduce nitrogenous waste, but to 
date, there is no treatment that has 100% efficiency to control the 
hyperammonemia and its complications, and patients are still dying from 
these disorders, especially neonates3,38,100. 
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1.3 The immune system (General overview) 
  The immune system can be defined as an integrated body system 
of organs, tissues, cells, and cell products that differentiates self from 
nonself resulting in the neutralization of potentially pathogenic organisms 
or substances. The recognition and combined efforts in opposition to a 
potentially pathogenic organism are termed an immune responses110.  
 In the battle against infection, the integrity of skin and mucosal 
surfaces plays a key role as the first line of defence, creating physical 
barriers against invading organisms. Microorganisms which breach these 
physical barriers initially encounter cells and molecules of the innate 
immune system111. 
 Tissue-resident macrophages can recognise invading microbes and 
specific pathogen-associated molecules. Recognition results in the 
activation of the macrophage which results in microbial phagocytosis and 
the secretion of cytokines and chemokines. These molecules recruit 
additional cells from the innate immune system, such as neutrophils and 
monocytes, and initiate the inflammation process. Neutrophils are the first 
cells recruited and are followed later by monocytes, which rapidly mature 
into activated macrophages. The principal role of these cells is the 
engulfment and eradication of the microbial stimulant110. This coordinated 
defence attempts to eradicate the infection, however, if it is unsuccessful, 
the adaptive immune response is then initiated. 
 A specialized group of cells known as antigen-presenting cells 
(APC), which include macrophages and dendritic cells (DC), are capable 
of processing and presenting antigenic molecules to the adaptive immune 
system. Antigenic peptides are presented by APC through the binding to 
major histocompatibility complex (MHC) proteins and these antigen-loaded 
complexes are recognized by T-cells, which express antigen-specific 
TCRs.  This interaction initiates T-cell activation, but for complete 
activation, a second signal is necessary. The second signal comes from 
the interactions between the co-stimulatory molecules (CD80 and CD86) 
expressed on the surface of APC and the T-cell expressed CD28. The 
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strength of T-cell activation is determined by a combination of antigen 
affinity to the TCR and the expression levels of the co-stimulatory 
molecules by the APC110,111. 
 
1.3.1 Anti-bacterial recognition and early response 
 The innate immune system is effective in dealing with a varied range 
of pathogens and achieves this through an invariant and limited repertoire 
of cellular receptors. Because of these receptors, macrophages, 
granulocytes, natural killer cells (NK) and DC can recognize simple 
molecules that are expressed by many microorganisms but are not 
expressed in host cells. These molecules contain conserved patterns 
(motifs) which are called pathogen-associated molecular patterns (PAMPs) 
and include mannose-rich oligosaccharides, peptidoglycans, LPS, nucleic 
acids, bacterial peptides, lipoproteins and others110.   
 There are distinct groups of cell receptors used for recognition of 
PAMPs that are generally known as pathogen recognition receptors (PRR). 
They include four main groups: Toll-like receptors (TLR), nucleotide-
binding oligomerization domain receptors or NOD-like receptors (NLR), C-
type lectin receptors (CLR), and retinoic acid-inducible gene I (RIG-I)-like 
receptors (RLR)112.  
 
1.3.2 Toll-like receptors 
 The TLRs are a family of PRRs that play key roles in the immune 
system, as activators of the innate immune system, and also recruiting and 
activating the adaptive immune response113. TLRs belong to an ancient 
class of proteins that were first described in the fruit fly Drosophila 
melanogaster114. It was discovered that the Toll gene is required for 
Drosophila to defend against bacteria and fungi infection more than 100 
years ago113,114. It is now known that Toll-homologues are present in 
almost all eukaryotes, such as plants, adult insects, and vertebrates, 
playing a pivotal role in facing pathogen invasion115. 
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 TLRs are type I transmembrane proteins with an extracellular amino 
(N)-terminal domain containing leucine-rich repeats (LRR), which give the 
TLRs their distinctive horseshoe-like shape; a transmembrane domain; 
and a cytosolic TIR domain, which interact with adaptor molecules for 
downstream signalling114,116. Adaptor molecules such as the myeloid 
differentiation primary response gene 88 (MYD88), Toll-interleukin 1 
receptor (TIR) domain containing adaptor protein (TIRAP), TRIF-related 
adaptor molecule (TRAM) and TIR domain-containing adaptor protein 
inducing interferon-β (TRIF) bind to intracellular TLR domain and initiate a 
protein kinase cascade that will stimulate transcriptions factors such as 
NFκB, AP1 and IRFs, resulting in pro-inflammatory cytokines secretion and 
type I interferon response116. 
 Thirteen TLRs (TLR 1-13) have been identified in human and 
mouse, there are 10 TLRs (TLR 1-10) found in human and 12 (TLR 1-9 
and 11-13) in mice114,115. Each TLR recognizes a specific PAMP, which 
vary from bacterial components such as LPS and flagellin, viral and 
bacterial RNA and DNA, lipoproteins, peptidoglycan and so on (Figure 1-
13)114. 
TLRs 1, 2, 4, 5, 6, and 10 are localized in the plasma membrane 
and the remaining TLRs (3, 7, 8, 9, 11, 12, and 13) are found in the 
membranes of intracellular vesicles. An exception is TLR4, which can be 
found in both locations113,114,116. TLRs located in the plasma membrane are 
more prone to recognize lipid or protein structures expressed on the 
surface of pathogens, while the intracellular TLRs are involved in the 
recognition of nucleic acids116. A general overview about the mammalian 
TLRs with their location, recognizing PAMP and signalling cascade can be 
found in Figure 1-13117. 
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Figure 1-13: Schematic location of TLRs and signalling pathway. TLR 
signalling initiates ligand-induced dimerization. Homodimerization occurs 
for the majority of TLRs, except for TLR1-TLR2, TLR2-TLR6 and TLR7-
TLR8 that form heterodimers. Signalling pathway uses adaptors proteins 
in a downstream cascade to activate transcriptor factors, which move to 
the nucleus to initiate transcription. Adapted from O’Neil et al. (2013)117. 
 
1.3.2.1 Toll-like receptors 1, 2 and 6 
 Lipopeptides or lipoproteins, the main TLR2 ligands, are recognized 
by TLR2 in complex with TLR1 or TLR6. TLR2-TLR1 heterodimer can 
recognize triacylated lipopeptide while TLR2-TLR6 complex recognises 
diacylated lipopeptide (Figure 1-14)118,119,120. TLR2 can recognize not only 
lipopeptides/lipoproteins but a variety of microbial components, which 
include: peptidoglycan and lipoteichoic acid from Gram-positive bacteria, 
lipoarabinomannan from mycobacteria, glycosylphosphatidylinositol 
anchors from Trypanosoma cruzi, a phenol-soluble modulin from 
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Staphylococcus epidermis, zymosan from fungi and glycolipids from 
Treponema maltophilum121. 
 
Figure 1-14: Structures of TLR2–TLR1/6 heterodimers induced by 
lipopeptides. (A) Crystal structure of TLR1/2–Pam3CSK4 complex. TLR1, 
TLR2, and Pam3CSK4 are coloured in sandy brown, hot pink, and black, 
respectively. (B) Lipid-binding pocket in TLR1/2–Pam3CSK4 complex (C). 
Crystal structure of TLR2/6–Pam2CSK4 complex. TLR2, TLR6, and 
Pam2CSK4 are coloured in hot pink, grey, and deep magenta, 
respectively. (D) Lipid-binding pocket in TLR1/2–Pam2CSK4 complex. 
Image from Manavalan et al.(2011)118. 
 
The mechanism of activation of TLR2-TLR1 and TLR2-TLR6 
complexes are similar to other TLRs, interaction with an agonist on the 
extracellular domain, which either induces the formation of a receptor 
dimer or changes the conformation of a pre-existing dimer. This 
conformation change brings together two intracellular TIR domains and 
makes them interact physically and is capable of recruiting downstream 
adaptor signalling molecules118. 
 TLR2-TLR1 and TLR2-TLR6 use the canonical MyD88 adaptor for 
pro-inflammatory signalling downstream of their activation. TIRAP adaptor 
protein is in the majority of cases, the link between MyD88 and the TLR 
complex TIR domain122. MyD88 activates IRAK family kinases, which in 
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turn, lead to a variety of downstream responses, including the MAPK 
pathway and the activation of transcriptor factors, Activator protein 1 (AP1) 
and NFkB, for proinflammatory cytokine responses, such as TNF, IL8, IL6, 
IL1β and IFNβ (Figure 1-15) 119,121,122,123. 
 
Figure 1-15: TLR2 signalling pathway. PAM3CSK4 (TLR2/1) and 
PAM2CSK4 (TLR2/6) ligands lead to the NF-κB and AP1 activation 
through the adaptor protein MyD88 and induce production of 
proinflammatory cytokines, such as TNF, IL8, IL6, IL1β and IFNβ. Adapted 
from Cheng et al. (2015)123. 
 
1.3.2.2 Toll-like receptor 4 
The TLR4 recognizes LPS which forms part of the outer membrane 
of Gram-negative bacteria. TLR4 can also bind to lipoteichoic acids (LTA), 
viruses, fungi, and mycoplasma110,124. Activation of TLR4 by LPS leads to 
an acute inflammatory response with the release of a set of inflammatory 
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cytokines. An overly strong response to LPS can lead to a collapse of the 
circulatory and respiratory system which is known as septic shock110,125. 
A wide variety of pro- and anti-inflammatory cytokines and 
chemokines can be produced by macrophages after TLR4 activation such 
as IL-1, IL6, IL8, IL-12, IL-10, interferon gamma-induced protein 10 (IP10), 
monokine induced by gamma interferon (MIG) and TNF. This cocktail of 
inflammatory mediators results in the induction of inflammation and 
recruitment of inflammatory cells to the infection site110,126. 
 TLR4 requires dimerization for effective activation and uses adaptor 
molecules not only for signalling but also for helping in this process. 
Dimerization occurs predominantly in its TIR domain after initial 
stabilization and recruitment of adapters proteins127. Besides that, two 
molecules are fundamentally important to TLR4 function, lymphocyte 
antigen 96 (LY96, also known as MD2) and the cluster of differentiation 14 
(CD14). The complex formed by the TLR4 and MD2 (TLR4/MD2 complex) 
is critical for LPS full response (Figure 1-16)128. 
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Figure 1-16: Overall structure of the TLR4-MD2-LPS complex. Top view 
of the symmetrical dimer of the TLR4-MD2-LPS complex (A). The primary 
interface between TLR4 and MD2 is formed before binding LPS, and the 
dimerization interface is induced by binding LPS. Side view of the complex 
(B). The lipid A component of LPS is coloured red, and the inner core 
carbohydrates of LPS are coloured pink. The module numbers of the LRRs 
in TLR4 and the names of the b strands in MD-2 are written in black. Image 
from Park et al. (2009)129. 
 
CD14 is considered a co-receptor of LPS and its presence is not 
mandatory for TLR4 signalling, however, it can enhance in many folds the 
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intensity of the signal.130 An interaction between these molecules are 
crucial for initiating and modulating the inflammatory response to 
pathogens. 
 TLR4 signalling can lead to pro-inflammatory cytokines induction 
and/or a type I interferon response. It is dependent on the type of stimuli 
and the type of recruited adaptor proteins. Two main pathways follow TLR4 
activation and are called MyD88-dependent and MyD88-independent 
pathway114,131,132. 
The MyD88-dependent pathway involves a complex formed by 
MyD88/TIRAP that binds to the TIR domain of the TLR4 and interacts with 
the protein kinases IRAK 1 and 4. Upon activation, IRAK4 phosphorylates 
IRAK1 that in turn causes ubiquitination of the TNF receptor-associated 
factor 6 (TRAF6)133. Then, TRAF6 can lead to activation of the transcriptor 
factor NFkB or a member of the MAPK family. MAPK signalling uses the 
AP1 as a transcriptor factor. Both cases will result in pro-inflammatory gene 
activation and the release of cytokines such as IL1β, IL6, IL12 and 
TNF128,134. The MyD88-dependent pathway can be modulated by CD14 but 
is CD14-independent when activated by the rough variant of LPS (Figure 
1-17)125. 
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Figure 1-17: The TLR4 signalling pathway upon LPS activation. Upon 
ligand binding, TLR4 recruits downstream adaptor molecules such as 
MyD88/MAL and TRIF/TRAM to mount an inflammatory response. The 
activated MyD88/MAL then activates IRAK4, TRAF6, TAK1, and IKK 
complexes, while TRIF/TRAM signals through RIP1 to TRAF6/TAK1 and 
IKK. After this, both these pathways converge at NFκB. Besides activating 
NFκB, TAK1 also phosphorylates MAPKs to further reinforce the 
inflammatory response. TheTRIF/TRAM pathway not only activates NFκB 
but also triggers IRF3 to mount an antiviral response. Image from 
Yesudhas et al. (2014)135. 
 
On the other hand, the MYD88-independent pathway, also known 
as the TRIF pathway, responds via TRAM/TRIF adaptor molecules and is 
CD14-dependent for activation125,130. TRAM acts as a bridge between the 
TLR4-TIR-domain to TRIF, which in turn interacts with the effector proteins 
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TANK-binding kinase 1 (TBK1) and the inhibitor of kappa light polypeptide 
gene enhancer in B-cells (IKKε) to phosphorylate and dimerise IRF3 and 
to a lesser extent IRF7. The IRFs then translocate to the nucleus inducing 
IFN-α and IFN-β synthesis, and the subsequent release of IFN inducible 
chemokines such IP10 and MIG130,136,137,138. 
Furthermore, activation of the TRAM-TRIF signalling pathway 
induced by LPS requires TLR4 endocytosis139.  This process is controlled 
by dynamin, which is a GTPase that regulates endocytosis by controlling 
the ‘pinching off’ of plasma membrane invaginations, which creates early 
endosomes140. LPS induces assembly of the ligand-binding complex 
consisting of CD14, MD-2 and TLR4 at the plasma membrane. From this 
location, which is probably a PtdIns(4,5)P2-rich subdomain of the plasma 
membrane, signalling is initiated and the receptor is endocytosed by a 
dynamin-dependent process139. 
Blockage of dynamin by dynasore, a highly specific inhibitor of 
dynamin, abolished the LPS-induced TRAM-TRIF-dependent 
phosphorylation of IRF3139. This process occurs later, after activation of 
TRAM/MyD88. Internalization of TLR occurs 60-120 minutes after LPS 
stimulation141. 
Internalized TLR in endosomes, colocalizes with MD2 and CD14 
after LPS stimulation141. CD14 is an important molecule for ligand-receptor 
signalling, depending on the type of LPS. The LPS is composed of 3 parts 
and typically consist of a hydrophobic domain known as lipid A (or 
endotoxin), a nonrepeating “core” oligosaccharide, and a distal 
polysaccharide (or O-antigen)142. Modifications on LPS structure occurs on 
the O antigen, the outermost domain of the LPS molecule. The side O-
chains are not required for cell survival and require energy expenditure. 
Thus, whenever the environmental conditions require, the bacteria stop the 
production of the O-chain. The “wild-type“ and full form of LPS is called 
smooth LPS (sLPS), while the “mutant” form, lacking O-chains, is called 
rough LPS (rLPS)143. 
sLPS requires CD14 for efficient activation of TLR4, while the rLPS 
is CD14-independent (Figure 1-18)125. There are functional differences in 
immune activation between these forms of LPS, while rLPS releases high 
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amounts of TNF and IL1β, stimulation of mouse and human macrophages 
with sLPS show a reduced secretion of both cytokines143,144. On the other 
hand, interferon secretion is higher in sLPS compared to rLPS. CD14 
deficient mice present a very low inflammasome and type I interferon 
response, suggesting that CD14 is required for their activation143.  
 
Figure 1-18: CD14-independent and CD14-dependent signalling by TLR4-
MD2. TLR4-MD2 can bind rough but not smooth LPS without a requirement 
for CD14. Signalling by this complex is limited to the MyD88-dependent 
pathway, using the adaptors Mal and MyD88 to activate NF−κB, resulting 
in transcription of TNF. TLR4-MD2 can bind both rough LPS (rLPS) and 
smooth LPS (sLPS) in a CD14-dependent process. In addition to MyD88-
dependent signals, these complexes also signal MyD88-independent 
responses via TRAM and TRIF, leading to IRF-3 activation and IFN-β 
transcription. Adapted from Godowski (2005)125. 
 
1.3.3 Reactive oxygen species (ROS) 
 ROS were historically viewed as purely harmful molecules that are 
byproducts of aerobic metabolism145,146. Nowadays they are recognized as 
important signalling molecules in several cellular processes and especially 
in inflammation145,147. ROS can be defined as partially reduced metabolites 
of oxygen that possess strong oxidizing capabilities and include the 
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superoxide anion (O2−), hydrogen peroxide (H2O2), and hydroxyl radicals 
(OH·)145,147. 
ROS production via nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase-dependent respiratory burst is a necessary effector 
response for the destruction of intracellular microbes by macrophages. 
This process takes place mainly in the mitochondria downstream of TLR 
activation148. 
 ROS can be produced exogenously (pollutants, tobacco, smoke, 
drugs, or radiation) or intracellularly as result of multiple mechanisms. 
Although ROS can be produced by other mechanisms, the main generator 
is a family of membrane-bound enzymes; NADPH oxidases146. The 
superoxide forms from the one-electron reduction of molecular oxygen (O2) 
and, within the cell, is rapidly converted by superoxide dismutases 1 and 2 
(SOD 1 and 2) into H2O2145. This process is very unstable and 
nonenzymatic dismutation is rapid and can be accelerated 10-fold by 
SODs149. It prevents accumulation of superoxide that can damage and 
inactivate proteins145. H2O2, which is not a radical, is highly diffusible and 
relatively unreactive, but in the presence of a reduced transition metal as 
in Fenton chemistry, H2O2 can react to produce a hydroxyl radical. The 
hydroxyl radical is so reactive that it will oxidize any type of 
macromolecules and thereby damage molecules nearby149. The hydroxyl 
radical has a very short half-life within the cell due to its high reactivity, 
lasting around 10-9 seconds150.  
Finally, hydrogen peroxide can be reduced to water by catalytic 
enzymes such as glutathione peroxidases (GPXs), peroxiredoxins (PRXs), 
or catalase151.  Figure 1-19 shows a summary of the production of ROS 
within the cell. 
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Figure 1-19: Production and interconversion of reactive oxygen species. 
O2− is formed from molecular O2 by gaining a single electron from an 
NADPH oxidase (NOX) enzyme or from electron leak in the electron 
transport chain of the mitochondria. Superoxide dismutase enzymes 
convert two superoxide molecules into H2O2 and H2O molecules. Hydrogen 
peroxide can undergo Fenton chemistry with Fe2+ to form OH·. 
Alternatively, hydrogen peroxide can be reduced to water by glutathione 
peroxidases, peroxiredoxins, or catalase. Adapted from Sullivan and 
Chandel (2014)151. 
 
 Due to its stability, hydrogen peroxide is the main ROS signalling 
molecule during inflammation, activating NFkB via the MAP kinase 
pathways (ERK, JNK, and p38)147. ROS signalling has been shown to 
stimulate the secretion of proinflammatory cytokines; TNF, IL6 and IL1β147. 
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1.4 Summary of investigations conducted and hypotheses 
In this thesis, the effects of NaB on the innate response of 
monocytes/macrophages is characterized after bacteria and TLR ligand 
challenge. The effects of NaB was studied using assays to investigate gene 
transcription, cytokine secretion, cell signalling pathways, protein 
expression. Large-scale studies of genes and proteins were carried using 
gene expression microarrays and high-performance liquid 
chromatography-mass spectrometry-based proteomics, respectively. 
Intracellular location of proteins was investigated by using subcellular 
fractionation.  
NaB is better recognized as a food preservative to reduce microbial 
growth in an acidic environment, but it has been also considered as a 
substance that helps the disposal of nitrogenous waste, a D-amino acid 
oxidase inhibitor, and a free radical scavenger. The link between NaB and 
the chronic inflammatory disorder OFG motivated this thesis to investigate 
whether NaB would interfere with the inflammatory response of 
monocytes/macrophages using the monocytic cell line THP-1. 
 Since the information available on the literature about the effects of 
NaB on monocytes is limited, the hypotheses were very general. 
 
The hypotheses investigated in this thesis are: 
1- What are the effects of NaB on the innate immune response after 
TLR stimulation? 
2- What are the mechanisms of action of NaB that interfere with the 
immune response? 
3- What are the consequences of changes caused by NaB on the 
immune response? 
4- What is the overall change in the cell caused by NaB treatment 
before and after TLR challenge? 
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Chapter 2 Materials and methods 
2.1 Cell culture 
2.1.1 THP-1 cells 
The THP-1 cell line (ATCC® TIB-202™), a cell line derived from the 
peripheral blood of a 1-year-old male patient with acute monocytic 
leukaemia, is a monocyte-derived and spontaneously immortalized cell 
line152. THP-1 cells were cultured and maintained in enriched RPMI/THP-
1 culture medium. Cells were grown in flasks at a concentration of 2-4x105 
cells/mL prior to being stimulated. THP-1 cells were maintained by addition 
or replacement of fresh medium of medium and split 3x times per week 
and kept no longer than 2 months.  
 
2.1.1.1 THP-1 culture media 
The THP-1 culture medium contained RPMI 1640 Medium, 
GlutaMAX™, plus 10% foetal bovine serum (Sigma F9665), 100 U/mL of 
Penicillin and 100 μg/mL Streptomycin (Gibco 15140-122), 20 mM HEPES 
solution (Sigma H0887), and 20 nM 2-mercaptoethanol (Gibco 31350). 
 
2.1.2 Peripheral blood monocyte-derived macrophages (PBM-DM) 
100 mL of peripheral venous blood was collected from healthy 
patients in 5 U/mL heparin by adding 300 μL of 1,000 IU/ml heparin sodium 
(Wockhardt) to each 50 mL syringe. Peripheral blood monocytes were 
isolated using Lymphoprep™ (Axis-Shield) by layering 25 mL of blood onto 
15 mL of Lymphoprep in 50 mL Falcon tubes. Tubes were centrifuged at 
900 g for 30 minutes at 20 °C with low brakes. The lymphocyte-monocyte 
layer at the interface of the serum at the top and the Lymphoprep in the 
middle was harvested and pooled into two 50 mL Falcon tubes. The cell 
suspension was topped up with PBS and centrifuged at 500 g for 5 minutes 
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at 20 °C with the brakes on. The cells were washed two further times with 
PBS but centrifuged at 500 g.  
The cell pellet was resuspended in 10 ml of RPMI 1640 Medium 
GlutaMAX™ Supplement (Gibco) containing 100 U/mL of Penicillin and 
100 μg/mL Streptomycin (Gibco) and 20 mM HEPES (Sigma) and plated 
onto 92 mm Nunclon™ surface coated tissue culture plates (Nunc). The 
cells were incubated in a humidified tissue culture incubator at 37 °C, 5% 
CO2 for 2 hours in a Heraeus BB15 incubator (Thermo Scientific) to allow 
for monocyte adherence induced by serum starvation. After 2 hours, the 
RPMI media was tipped off, cells were washed with PBS once to remove 
non-adherent lymphocytes and fed with 10 mL of RPMI 1640 Medium 
GlutaMAX™ Supplement containing 10% FBS (Sigma), 100 U/ml 
penicillin, 100 µg/ml streptomycin and 20 mM HEPES. After 24 hours, cells 
were fed with a further 10 ml of RPMI containing 10% FBS and incubated 
for a total of 5 days to obtain adherent monocyte-derived macrophages as 
previously described153. 
 After 5 days, MDMs were washed in PBS, scraped, counted and 
cultured overnight in X-VIVO™ 15 medium (Lonza) at 1x106 cells/mL on 
tissue culture plates and were ready for stimulation on the following day. 
 
2.2 Reagents for biological assays 
2.2.1 NaB 
 Sodium benzoate BioXtra, ≥99.5% (B3420 Sigma-Aldrich) was 
diluted at 1 M concentration in Endotoxin-Free Ultra-Pure Water (TMS-011 
EMD Millipore) and filtered with a Nalgene 0.45µm filter (Thermo Scientific 
190-2545) to remove undissolved residue and stored at room temperature 
in 50 mL Falcon tube. 
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2.2.2 Heat-killed bacteria 
2.2.2.1 Luria-Bertani (LB) broth and agar plates 
20 g of LB Broth powder (L3022 Sigma) was added to 800 mL of 
dH2O, mixed with a magnetic stirrer and made up to 1000 mL then 
autoclaved and plated. LB broth was made up as above without the agar. 
 
2.2.2.2 Heat-killed Escherichia coli (HkEc) stock 
The fully antibiotic sensitive clinical isolate, E. coli NCTC 10418 was 
cultured by adding 1 μL of glycerol stock into 10 mL LB broth (Sigma 
L3022) and incubated at 37 °C, 250 rpm in an Innova™ 4000 incubator 
shaker (New Brunswick Scientific) overnight. E. coli was centrifuged at 
3000 g for 20 minutes, room temperature in a Heraeus Multifuge X1R 
(Thermo Scientific), washed once with 20 mL PBS, resuspended in 1 mL 
PBS. The killing of E. coli was carried out by incubating 1 mL of bacteria in 
PBS at 60 °C for 1 hour in a Grant GD100 circulating immersion bath. The 
killing of E. coli was checked by plating 80 μL of HkEc onto LB agar plates 
with no antibiotics. 
HkEc solution was counted at 1:20 dilution using a Cecil BioQuest™ 
CE2502 spectrophotometer. The E. coli optical density at 600 nm (OD600) 
of 1108 bacteria/mL in PBS is 0.365 as previously established in our 
laboratory. The concentration of E. coli in PBS was adjusted to 11010 
bacteria/mL and stored at -20 °C. 
 
2.2.2.3 Heat-killed Porphyromonas gingivalis (HkPg) stock 
The P. gingivalis ATCC 33277 strain was kindly provided by Dr. 
Helen Petersen (Manchester University Hospital, UK) after being cultured 
from frozen stocks under anaerobic conditions (85% N2, 10% H2, 5% CO2) 
into Trypticase soy broth supplemented with 1 mg of yeast extract/mL, 5 
μg of hemin/mL, and 1 μg of menadione/mL. The killing of P. gingivalis was 
carried out by incubating 1 mL of bacteria in PBS at 60 °C for 1 hour in a 
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Grant GD100 circulating immersion bath. The concentration of P. gingivalis 
used to stimulate the cells was determined by titration, after stimulation of 
THP-1 cells with different concentrations of HkPg. The levels of the 
secreted IL8 was used as the output. The lowest concentration that showed 
the maximum secretion of IL8 was chosen as the working concentration, 
which was 1 μL/mL. 
 
2.2.3 Mixed biological reagents 
 The list of reagents containing the description of each item, 
catalogue number, supplier, and usual working concentration can be found 
in Table 2. If in any case, the experiment required the use of a different 
concentration, this information will be available in the results description. 
The working concentration was established based on usual concentrations 
found in the literature and/or titrated and toxicity determined by MTT assay 
(see section 2.4.1). 
 
Table 2: List of reagents containing the description, catalogue number, 
supplier, and usual working concentration. 
Item description Catalog # Supplier Work Conc Preinc 
Pam3Cys-Ser-(Lys)4, 
trihydrochloride  
ALX-165-
066 
Alexis 
Biochemicals 10 μg/mL 
 
LPS from Salmonella 
abortus equi S-form  
ALX-581-
009 
Alexis 
Biochemicals 200 ng/mL 
 
LPS from Salmonella 
Minnesota R595 
ALX-581-
008 
Alexis 
Biochemicals 200 ng/mL 
 
N-Acetyl-L-cysteine A7250 Sigma-Aldrich 1 mM 
30’ 
TEMPO 214000 Sigma-Aldrich 1 mM 
30’ 
N, N′-Dimethylthiourea D188700 Sigma-Aldrich 2 mM 
30’ 
Curcumin (high purity) ALX-350-028 
Alexis 
Biochemicals 12.5 μM 
30’ 
HUMIRA® 
(adalimumab) 
 AbbVie Inc. 100 μg/mL  
Tyrphostin AG 490 T3434 Sigma-Aldrich 20 μM 
30’ 
PD98059 tlrl-pd98 InvivoGen 20 μM 30’ 
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Recombinant Human 
TNF 210-TA 
R&D 
Systems 10 ng/mL 
 
Recombinant Human 
IL6  206-IL 
R&D 
Systems 10 ng/mL 
 
Actinomycin D A9415 Sigma 2 μg/mL  
Bafilomycin A1 
from Streptomyces 
griseus 
B1793 Sigma-Aldrich 200 nM 
 
Brefeldin A B5936 Sigma-Aldrich 1 μM 
 
Ammonium chloride A4514 Sigma-Aldrich 10 mM 
 
Monensin sodium salt M5273 Sigma-Aldrich 2.5 μM 
 
z-Leu-Leu-Leu-CHO 
(MG-132) I-130 Bio-Techne 10 μM 1h 
12-myristate 13-acetate 
(PMA) P8139 
Sigma-
Aldrich 2 μM  
Abbreviations: Catalog #, catalogue number; Work conc, working 
concentration; Preinc, preincubation 
 
2.3 Cell stimulation 
2.3.1 NaB treatment 
THP-1 cells or PBM-DM were incubated with 5 mM NaB overnight 
pre-challenge with bacteria or TLR ligands. The cells were then harvested 
and centrifuged at 500 g for 5 minutes. The supernatant was removed, and 
the cell pellet was resuspended and washed 2X with PBS after 
centrifugation at 500 g for 5 minutes. The washing steps were also carried 
out with the cells that were not treated with NaB. 
The cells pre-treated with NaB were resuspended in medium 
containing 5mM NaB at a concentration of 1 X 106 viable cells/mL. Cells 
were counted, and viability determined using the TC20™ Automated Cell 
Counter (Bio-Rad) with Trypan Blue (1450021 Bio-Rad). 
 
2.3.2 Stimulation of cells 
 Cells were stimulated with HkEc with a multiplicity of infection (MoI) 
20:1 (bacteria/cell). HkPg was added at a concentration of 1 μL/mL, 
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established after titration. The TLR ligands LPS (TLR4) smooth (200 
ng/mL) and rough (200 ng/mL) types, and 10 μg/mL PAM3CSK4 (TLR1/2) 
were used for the immunological challenge of specific TLRs. 
The list of all the biological reagents with their working concentration 
and time required of preincubation are described in Table 1. Any alteration 
in concentrations used in the described experiments will be documented in 
the results section.  
 
2.4 Cell viability assays 
2.4.1 MTT cell viability assay  
2.4.1.1 MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium 
bromide) 
A 0.5% solution of MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl 
tetrazolium bromide) was made by dissolving 500 mg of MTT (Sigma 
M2128) in 100 mL of PBS and stored at 4 °C in the dark. Cells were 
cultured in 96-wells plate within 100 μL of the medium under different 
conditions and time frames depending on the experimental protocol. The 
viability of the cells at the end of the protocol was determined by adding 
30% of total volume of MTT (30 μL) to the wells and incubated for at least 
4 hours. 
 
2.4.1.2 MTT lysis solution 
One litter of lysis solution was prepared using 900 mL of 
isopropanol, 47 mL of dH2O, 50 mL of 10% sodium dodecyl sulfate (SDS) 
and 3 mL of concentrated HCl, which was kept at room temperature. 
 
2.4.1.3 MTT assay 
After MTT incubation, the plate was centrifuged at 8000 rpm for 5 
minutes. The supernatant was removed with a multi-channel pipette and 
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100 μL of MTT lysis solution added to the cells and pipetted multiple times 
until all formazan crystals were dissolved. Results were read on a 
FLUOstar Omega microplate reader (BMG LABTECH) at 563 nm.   
 
2.4.2 CCK-8 cell viability assay  
 The Cell Counting Kit-8 (B34306 Biotool) ready-to-use solution was 
added to each well to a concentration of 10% v/v and kept in a humidified 
tissue culture incubator at 37 °C, 5% CO2 for 1 hour. Results were read on 
a FLUOstar Omega microplate reader (BMG LABTECH) at 450 nm.   
 
2.5 pH measurements 
 The pH of solutions and medium were monitored after NaB solution 
preparation, pre and after addition to RPMI enriched medium using a pH 
meter from Mettler Toledo, type Delta 340 (Gemini bv) previously 
calibrated with standard pH solutions. pH changes of the THP-1 medium 
after HkEc ± NaB stimulation were also monitored over the next 3 days. 
 
2.6 Cytokine assay 
2.6.1 Enzyme-linked immunosorbent assay (ELISA) assay  
Cytokine levels from supernatants or total cell lysates (see section 
2.8.1.1) from cultured THP-1/PBM-DM cells under several conditions were 
collected and stored at -80°C prior to use. After removal of supernatants 
for storage, cell viability was assessed using the MTT assay. Total cell 
lysates were standardized prior to testing using the Pierce™ BCA Protein 
Assay Kit (23225 Thermo Fisher Scientific) and stored at -80°C. Samples 
were diluted with reagent diluent for ELISA. The ELISAs were carried out 
using Duo-Set ELISA kits according to manufacturers’ instructions and 
read on a FLUOstar Omega or CLARIOstar microplate readers (BMG 
LABTECH).  Microplate readers were set to 450 nm and 570 nm, the last 
used for wavelength correction, for ELISA kits supplied by R&D Systems. 
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The wavelength correction was done using MARS Data Analysis Software 
by subtracting readings at 570 nm from the readings at 450 nm for (Table 
3). For ELISA kits provided by PeproTech, colour development was 
monitored and read on the plate readers at 405 nm with wavelength 
correction set at 650 nm (Table 3). The full description of each kit used is 
shown in Table 3. 
 
Table 3: Description of ELISA kits used, catalogue number, supplier, and 
supernatant dilutions.  
Kit Catalog # Manufacturer Dilution 
Human IL8/CXCL8 DuoSet ELISA DY208 R&D Systems 1:40 
Human TNFlpha DuoSet ELISA DY210 R&D Systems 1:10 
Human IL6 DuoSet ELISA DY206 R&D Systems 1:10 
Human IP10 DuoSet ELISA DY266 R&D Systems 1:40 
Human IL-1 beta DuoSet ELISA DY201 R&D Systems 1:10 
Human IP10 ELISA Development Kit 900-K39 PeproTech 1:40 
Human IL-10 ELISA Development Kit 900-K21 PeproTech 1:10 
Abbreviations: Catalog #, catalogue number 
 
2.6.2 MSD® multiplex immunoassay 
Supernatant from THP-1 cells stimulated with HkEc ± NaB for 24 
hours was measured using the V-PLEX Proinflammatory Panel 1 Human 
Kit (K15049D-1 Meso Scale Discovery) containing the analytes IFNγ, IL10, 
IL-2p70, IL13, IL1β, IL2, IL4, IL6, IL8, and TNF. The assay was performed 
according to the manufacturers’ instructions and read on a SECTOR® 
Imager 6000 (Meso Scale Discovery). 
 
2.7 Gene expression 
2.7.1 RNA purification 
Total RNA was extracted and purified from THP-1 cells after several 
treatments. Cells were harvested, and the supernatant was removed (or 
collected) and 350 μL of RLT lysis buffer (Qiagen) with 1% 2-
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mercaptoethanol (M3148 Sigma) was added and stored at -80 oC prior to 
extraction. RNA was extracted using the RNeasy Mini Kit columns with 
RNase-free DNase treatment (Qiagen) and processed according to the 
manufacturer’s instructions with a RNase-free DNase treatment (Qiagen) 
step. The concentration of total RNA in RNase-free H2O (Qiagen) was 
measured with a NanoDrop ND-1000 spectrophotometer (Thermo 
Scientific) and/or Qubit 2.0 Fluorometer (Invitrogen). Additionally, 
OD260/OD280 and OD260/OD230 were measured, which assessed protein 
and solvent contamination.  For microarray expression profiling, RNA 
integrity (RIN) was analysed by measuring ribosomal RNA band 28S/18S 
ratios using high-resolution electrophoresis on an Agilent Bioanalyzer 
(Agilent Technologies, Inc), samples which attained RIN scores which were 
>8 were taken forward for whole transcriptome analysis. 
 
2.7.2 Complementary DNA (cDNA) synthesis 
Total RNA was converted to cDNA using the Moloney Murine 
Leukemia Virus Reverse Transcriptase (M-MLV RT) kit (M1705 Promega). 
500 ng of total RNA diluted in 15 μL of RNase-free water was added to 1 
μL of oligodT primer (Sigma) and incubated for 10 minutes at 70 °C for 
primer annealing and then placed on ice for 5 minutes. After that, a master 
mix containing 1 μL of M-MLV Reverse Transcriptase, 5 μL of 5X Reaction 
Buffer, 1 μL Recombinant RNasin® Ribonuclease Inhibitor (Promega), and 
2 μL of dNTP Mix (NU-0010-10 Eurogentec) was added to each RNA 
sample making a total volume of 25 μL. Samples were incubated at 40 °C 
for 10 minutes for DNA polymerization and heated at 70 °C for 5 minutes 
for enzyme deactivation on a DNA Engine Tetrad 2® Peltier Thermal 
Cycler (Bio-Rad). Samples were made up to 100 μL with RNase-free water 
and stored at -20 °C. 
 
2.7.3 Gene Expression Microarray 
1.5 ng of total RNA was amplified using the HumanHT-12 v4 
Expression BeadChip Kit (Illumina) and normalised to 150 ng/µL. 750 ng 
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was hybridised to Illumina Human-WG6 v3.0 Expression BeadChips 
(Illumina) for 16 hours at 58ºC. After hybridization, BeadChips were 
washed and stained with streptavidin-Cy3 (GE Healthcare, Little Chalfont, 
United Kingdom), scanned using the BeadArray Reader (Illumina), and 
processed using Illumina Genome Studio software (Illumina). 
The original expression data contained 47,213 probes under 6 
different conditions: untreated, NaB treated, HkEc, HkEc + NaB, HkPg, and 
HkPg + NaB, stimulated for 4 hours and 4 replicates each split into 2 chips 
with duplicates in each. These data were log2 transformed and quantile 
normalised, and analysed using the LUMI and LIMMA packages in the R 
programming language (Bioconductor)154155. The probes were mapped 
and annotated using the BioMart and BioConductor package 
illuminaHumanv4156. 
Probes that reached a minimum detection P-value of < 0.01 in at 
least 50% of the samples were included in the subsequent analyses (n = 
16,348). Batch effects were corrected using combating batch effects when 
combining batches of gene expression microarray data (ComBat) 
normalization and efficacy of normalization was verified by density x 
intensity plot157. Differential gene expression analysis was conducted using 
LIMMA software (Bioconductor)155.  The P-value was adjusted for multiple 
testing as described by Benjamini and Hochberg158. 
 
2.7.4 Semi-quantitative PCR 
 cDNA originated as previously described were amplified by PCR 
with primers created using Primer3 (Table 4). Stock primers at 100 μM 
were diluted to 5 μM i.e. 50 μL per 1 mL of RNase-free water for and stored 
at -20 °C. The PCR reaction was made up of 12.5 μl of HotStarTaq Master 
Mix (1000 U), 1 μL forward primer, 1 μL reverse primer, 2 μL cDNA and 
8.5 μL RNase-free water, to a total volume of 25 μl. The final concentration 
in each reaction volume was 1.25 U HotStar Taq DNA polymerase, 1X 
PCR buffer containing 0.75 mM MgCl2, 100 μM of each dNTP, 0.25 μM of 
each primer and ~10 ng of RNA equivalent. The RT-PCR was activated at 
95 °C for 15 minutes, denatured at 95 °C for 30 s, annealed at 60 °C for 45 
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s, extended at 72 °C for 60 s, for a total of 35 cycles, then extended for a 
final time at 72 °C for 10 minutes before being cooled to 4 °C on a DNA 
Engine Tetrad 2® Peltier Thermal Cycler (Bio-Rad). The annealing 
temperature of 60 °C was chosen after a temperature gradient was run for 
the primer pair. 
After the PCR, 5 μL of 6X Orange Loading Dye (R0631 Thermo 
Fisher Scientific) and loaded on 1% agarose gel containing 0.01% ethidium 
bromide. The gels were cast on horizontal electrophoresis and ran at 100V 
for 25 minutes. Images were captured using Thermo Scientific MYECL 
Imager. 
Table 4: List of primers used for PCR/qRT-PCR. 
GENE Forward primer Reverse primer Target exons 
IL6 5’-CACTGGCAGAAAACAACCTG-3’ 5’-TGTACTCATCTGCACAGCTCT-3’ 3-4 
CXCL10 (IP10) 5’-AGTGGCATTCAAGGAGTACC-3’ 5’-TGATGGCCTTCGATTCTGGA-3’ 1-3 
IL1B 5’-ACTGAAAGCTCTCCACCTCC-3’ 5’-CTCTCCAGCTGTAGAGTGGG-3’ 4-6 
IL8 5’-CAGTTTTGCCAAGGAGTGCT-3’ 5’-CCAGTTTTCCTTGGGGTCCA-3’ 2-3 
TNF 5’-GGACCTCTCTCTAATCAGCCC-3’ 5’-TGGTTATCTCTCAGCTCCACG-3’ 2-4 
CD80 5’-ATCTGACGAGGGCACATACG-3’ 5’-GAGAGGTGAGGCTCTGGAAA-3’ 2-3 
CD86 5’-GAAGAAGAAGAAGCGGCCTC-3’ 5’-TCACTTTTGTCGCATGAAGATG-3’ 5-7 
CXCL9 (MIG) 5’-GCCCTTCCTGCGAGAAAATT-3’ 5’-GCTGACCTGTTTCTCCCACT-3’ 2-4 
TRAF3 5’-CAGCGTGTCAAGAGAGCATC-3’ 5’-GGACGCACACATGGAAGTTC-3’ 2-4 
IKBKE 5’-TTCAGCACAGCCATCCCTAA-3’ 5’-CCCCGAAACATTAGCTCCTG-3’ 8-10 
TRIF 5’-ACCTCCTGCATGCCATGGTTCT-3’ 5’-TCAGCCAGCAGGTGGTACAA-3’ 1 
TLR4 5’-GTTTCCCAGAACTGCAGGTG-3’ 5’-TGTCTCCACAGCCACCAG-3’ 2-3 
PPIA 5’-GTGTTCTTCGACATTGCCGT-3’ 5’-CCATTATGGCGTGTGAAGTCA-3’ 1-3 
 
 
 
2.7.5 Quantitative reverse transcription PCR (qRT-PCR)  
cDNA originated as previously described were amplified using 
several primers from Table 4. qRT-PCR was performed using the 
QuantiFast SYBR® Green PCR kit (Qiagen), in duplicate on a 
Mastercycler® ep realplex (Eppendorf). Stock primers at 100 μM were 
diluted to 5 μM i.e. 50 μl per 1 mL of RNase-free water for qRT-PCR and 
stored at -20 °C. The qRT-PCR reaction was made up of 12.5 μl 2 
QuantiFast SYBR Green PCR Master Mix, 0.5 μl forward primer, 0.5 μl 
reverse primer, 2 μl cDNA and 9.5 μl RNase-free water, to a total volume 
of 25 μl. The final concentration in the reaction volume was 1 QuantiFast 
SYBR Green PCR Master Mix, 0.1 μM of each primer and ~10 ng of RNA 
equivalent per reaction. The PCR mix was activated at 95 °C for 15 
minutes, denatured at 95 °C for 15 s and annealed/extended at 60 °C for 
60 s, for a total of 40 cycles, then a melting curve was performed. The 
annealing temperature of 60 °C was chosen after a temperature gradient 
was run for each primer pair.  
Normalized mean gene expression values ± SD were determined 
from duplicate cycle threshold (Ct) values for each gene and the 
housekeeping gene peptidylprolyl isomerase A (PPIA). Relative transcript 
levels were determined by the 2−ΔΔCt method159. 
 
2.8 Immunoblot 
2.8.1 Cell lysate preparation 
2.8.1.1 Whole cell lysate preparation 
THP-1 cells were plated in a 24-well plate with a cell count of 2 x 
106 cells under several treatments. At the planned stimulation time, cells 
were scraped with sterile 24 cm cell scrapers (SLS 99002T) and 
transferred to Eppendorf tubes and centrifuged with a Beckman Coulter 
Microfuge 22R for 1 minute at 2500 rpm. The supernatant was discharged 
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(or collected and stored at -80 oC) and the cell pellet resuspended and 
washed with 1 mL of ice-cold PBS and centrifuged again using the same 
settings. The PBS was removed by aspiration and cells were lysed in 250 
μL of ice-cold radioimmunoprecipitation assay (RIPA) buffer containing 
protease inhibitor cocktail (Roche 11697498001) and PhosSTOP™ 
(4906845001 Sigma) and vortexed (Table 5). 
The cell lysate was then sonicated using a MSE Soniprep 150 
(MSE) for three 10 seconds burst with an amplitude of 7 microns 
intercalated with periods of 10 s on ice for disrupting cellular membranes, 
releasing the cell contents and shearing of DNA. After the sonication, the 
lysates were centrifuged for 10 minutes at 4 oC at ≥ 10,000 rpm.  
 
2.8.1.2 Cell fractionation preparation 
 Subcellular fractionation for separating nuclear and cytoplasmic cell 
fractions was carried out using different buffer and centrifugation steps. 
Cells were prepared similarly to described above until the washing step 
with PBS. The cytoplasmic fraction was extracted using a cytoplasmic lysis 
buffer (Table 5). 100 μL of cytoplasmic buffer was added to the cell pellet 
and incubate on ice for 3 minutes. Then, samples were centrifuged at 200 
g for 4 minutes and the cytoplasmic fraction collect in a new tube. The pellet 
containing the nuclei was carefully resuspended and washed using a wash 
buffer (the same cytoplasmic buffer without the detergent IGEPAL) and 
then centrifuged at 200 g for 3 minutes. 100 μL of nuclear extraction buffer 
(RIPA buffer with a higher concentration of SDS 1%) and incubated for 10 
minutes on ice. Both buffers contained protease inhibitor cocktail and 
PhosSTOP™. 
The cell lysates were then sonicated using a similar protocol 
described above. After the sonication, the lysates were centrifuged for 10 
minutes at 4 oC at ≥ 10,000 rpm.  
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Table 5: Cell lysate buffers for immunoblot 
RIPA EDTA/EGTA lysis buffer  
Reagent/Manufacturer Stock Final concentration 
Trizma® base (T1503 SIGMA) 1 M 50mM 
Sodium chloride (S3014 SIGMA) 5 M 150mM 
Sodium-deoxycholate (D6750 SIGMA) 5% 0.50% 
EDTA solution (03690 SIGMA) 500 mM 1mM 
EGTA (E3889 SIGMA) 500 mM 0.5mM 
IGEPAL® CA-630 (I8896 SIGMA) 100% 1% 
SDS (L3771 SIGMA) 10% 0.10% 
PBS (P4417 Sigma) 10X 1X 
Cytoplasmic lysis buffer 
Reagent Stock Final concentration 
HEPES (H0887 SIGMA) 1 M 10 mM 
MgCl2 (M8266 SIGMA) 150 mM 1.5 mM 
KCl (P9541 SIGMA) 1 M 10 mM 
DTT (D0632 SIGMA) 0.5 M 0.5 mM 
EDTA 100 mM 1 mM 
IGEPAL 100% 0.05% 
PBS 10X 1X 
 
2.8.2 Sample preparation 
The protein concentration of each sample was measured using the 
Pierce™ BCA Protein Assay Kit (23225 Thermo Fisher Scientific) 
according to the manufacturer’s instructions and read on a CLARIOstar or 
FLUOstar Omega microplate reader (BMG LABTECH) at 562 nm. Samples 
were then standardized with appropriated amounts of cell lysate and lysis 
buffer. One volume of sample buffer mix made of 3 volumes of 4X 
NuPAGE® LDS Sample Buffer (NP0007 Thermo Fisher Scientific) and 1 
volume of 2-mercaptoethanol (Gibco 31350) was added to 2 volumes of 
standardized lysis buffer and then boiled at 95 oC for 5 mins and stored at 
-20 °C. 
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2.8.3 SDS-PAGE gels 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) gels were cast using the Mini-PROTEAN® System (Bio-Rad) with 
30% w/v Acrylamide/ProtoFLOWGel (SLS H16996), 1.5 M Tris-HCl pH 8.8 
(resolving gel), 1 M Tris-HCl pH 6.8 (stacking gel), dH2O, 10% SDS (Sigma 
L3771), freshly made 10% ammonium persulphate (Sigma A7460) in 
plastic tubes. TEMED (Sigma T9281) was added last, previous to addition 
to a gel casting apparatus. 
10% SDS-PAGE gels were used and loaded onto 15-well SDS-
PAGE gels and run in ~700 ml of 1X transfer buffer without methanol (Table 
6) at 100 V (constant voltage) for 40 minutes. 
Alternatively, precast Novex 4-12% Bis-Tris Midi Protein Gels 
(WG1403 Thermo Fisher Scientific) were used on XCell4 SureLock Midi-
Cell Chambers and run in ~1000 mL of 1X NuPAGE MOPS SDS Running 
Buffer (NP0001 Thermo Fisher Scientific ) at 120 V for 2 hours. 
 
Table 6: Buffers for SDS-PAGE gels. 
10X Tris-buffered saline (TBS) pH 7.4 
Reagent Stock Final concentration 
Trizma® base 24.2 g 20 mM 
NaCl 80.06 g 137 mM 
dH2O   800 mL 
HCl (H1758 SIGMA) 5 M pH to 7.4 
dH2O   top up to 1 L 
10X Transfer buffer 
Reagent Stock Final concentration 
Glycine (G8898 SIGMA) 144 g 191 mM 
Trizma® base 30.2 g 25 mM 
dH2O   top up to 1 L 
10X Running buffer 
Reagent Stock Final concentration 
Glycine 144 g 191 mM 
Trizma® base 30.2 g 25 mM 
SDS 10% 0.1% 
dH2O   top up to 1 L 
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2.8.4 Protein transfer to membrane 
 Proteins were transferred from gels using a wet transfer system to 
methanol-activated Immobilon-P PVDF Membranes (IPVH00010 
Millipore). 400 mL of 1X transfer buffer (Table 6) containing 20% methanol 
on a Novex™ Bolt™ Vertical Mini Blot Module (B1000 Invitrogen™) and 
Invitrogen™ Mini Gel Tank (A25977 Invitrogen™) at 20V for 1 h following 
the manufacturer’s instructions. 
The SDS-PAGE gel was removed from its mould in the transfer 
buffer, the stacking gel was gently cut off with spatulas and the gel was 
placed on the bottom layer of a sandwich formed by a sponge and a piece 
of blotting paper. The PVDF membrane was placed on the top of the gel 
and a roller was used to remove all the trapped bubbles. The membrane 
was topped by another layer of blotting paper and sponge. The Mini Blot 
Module was then closed and mounted in the tank and the chamber filled 
with transfer buffer and ran at 20 V for 60 minutes. 
 
2.8.5 Antibody staining 
Membranes were blocked with 5% BSA (A2153 Sigma) in TBS 
(Table 6) plus 1% Tween 20 for 1 hour. Membranes were probed with 
primary antibody overnight at 4 oC (Table 7) then washed 3 times for 5 
minutes with TBS-Tween. Membranes were probed with secondary 
antibody for 1 hour at room temperature then washed 3 times for 5 minutes 
with TBS-Tween. Bound antibody was detected using Luminata Crescendo 
Western HRP substrate (WBLUR0500 Merck) and exposed to Hyperfilm 
ECL (Amersham) in a film cassette and scanned with an Epson Perfection 
V700 Photo or image capture using Thermo Scientific MYECL Imager. 
Band intensity was quantified and normalised to actin using Image 
StudioTM Lite software (LI-COR). 
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Table 7: List of antibodies used for western blotting 
Antibodies MW (kDa) Manufacturer Catalog # WB Conc 
Secondary 
Ab 
Cofilin 19 Cell Signalling 5175 1:1000 Rabbit 
TNF 15 R&D System MAB610 1 μg/mL Mouse 
IL6 26 Sigma i7901 1:1000 Mouse 
HMOX1 33 Abcam ab52947 1:2000 Rabbit 
UCP2 33 Abcam ab67241 1:500/1000 Mouse 
IkBa  39 Cell Signalling 9242 1:1000 Rabbit 
P38 40 Cell Signalling 9218 1:1000 Rabbit 
PSAT1 40 Abcam ab96136 1:1000 Rabbit 
p-P38  43 Cell Signalling 4511 1:1000 Rabbit 
p-c-Jun (Ser73) 48 Cell Signalling 9164 1:1000 Rabbit 
ERK 1/2 42 / 44 Cell Signalling 9102 1:1000 Rabbit 
p-ERK 1/2) 42 / 44 Cell Signalling 9101 1:1000 Rabbit 
α-Tubulin 50 Thermo MA1-19162 1 μg/mL Mouse 
p-IRF3 45 / 55 Cell Signalling 4947 1:1000 Rabbit 
p-SAPK/JNK 46 / 54 Cell Signalling 9255 1:2000 Mouse 
AKT 60 Cell Signalling 9272 1:1000 Rabbit 
p-AKT (Ser473) 60 Cell Signalling 9271 1:1000 Rabbit 
Catalase 60 Cell Signalling 12980 1:1000 Rabbit 
KEAP1  60-64 Cell Signalling 8047 1:1000 Rabbit 
P62 62 Abcam ab56416 1 μg/mL Mouse 
p-C-FOS (Ser32) 62 Cell Signalling 5348 1:1000 Rabbit 
NFkB p65 65 Cell Signalling 8242 1:1000 Rabbit 
p-NFkB p65 65 Cell Signalling 3033 1:1000 Rabbit 
p67phox (NCF2) 67 
Home 
prepared   1:2250 Rabbit 
Lamin B1 70 Abcam ab133741 1:1000 Rabbit 
p-STAT3 79 / 96 Cell Signalling 12640 1:2000 Rabbit 
STAT3 79 / 96 Cell Signalling 12640 1:1000 Rabbit 
pTBK1/NAK 84 Cell Signalling 5483 1:1000 Rabbit 
NRF2 97-100 Cell Signalling 12721 1:1000 Rabbit 
p-STAT6 110 Cell Signalling 9361 1:1000 Rabbit 
Vinculin 117 Milipore MAB3574 1:1000 Mouse 
iNOS 135 Abcam ab3523 1:500 Rabbit 
ASK1 155 Cell Signalling 3762 1:1000 Rabbit 
p-ASK1 155 Cell Signalling 3765 1:1000 Rabbit 
List of secondary antibodies used for western blotting 
Antibodies Manufacturer Catalog # WB Conc 
Goat Anti-Rabbit Dako P044801-2 1:2500 
ECL Anti-mouse IgG Amersham NA931 1:2500 
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2.9 Confocal microscopy 
THP 1 cells were plated out in a 96-well plate at a density of 1 x 105 
cells/mL in a total volume of 200 μL/well in RPMI enriched medium and 
stimulated with HkEc (MoI 20:1) and incubated in a humidified tissue 
culture incubator at 37 °C, 5% CO2 for 1 hour, in the presence or absence 
of NaB. Two μL (1 μg) of a pre-diluted (50 µg vial in 100 µL of DMSO) 
carboxy-S-1 succinimidyl ester 5-(and-6)-Carboxy SNARF®-1, 
Acetoxymethyl Ester, Acetate (C1272 Thermo Scientific) was added to 
each well and incubated for 5 minutes. 
The Ibidi µ slide 8 well ibiTreat (IB-80826 Thistle Scientific) chamber 
slide was used for plating the THP-1 cells prior imaging. The chambers 
were pre-treated with 200 μL of poly L-lysine for 20 minutes at RT, the 
excess of poly L-lysine was removed and washed twice with PBS and left 
for air-drying. After the stimulation and labelling step, the cells were 
harvested and washed twice in balanced salt solution (BSS) buffer (Table 
8) and centrifuged at 500 g for 5 minutes to remove all the excess of 
SNARF®. Then, cells were resuspended in 200 μL of BSS buffer and 
added to the chambers and taken for imaging. 
Cells were imaged with a Zeiss 710 confocal microscope using a 
63× oil immersion. SNARF-1 fluorescence was excited at 555 nm and the 
emission was split between two detectors measuring fluorescence 
emission simultaneously between 560–600 nm and >610 nm.  
The cytoplasmic pH was measured by confocal ratiometric 
fluorescence microscopy and the SNARF fluorescence ratios were 
calibrated to pH values using standard curves derived from separate 
calibration experiments as previously described160. 
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Table 8: Recipe for preparation of BSS buffer. 
Reagent Stock Final Concentration 
NaCl 3 M 156 mM 
KCl (P9333 Sigma) 250 mM 3 mM 
MgSO4 (M2643 Sigma) 250 mM 2 mM 
KH2PO4 (P9791 Sigma) 1 M 1.25 mM 
CaCl2 (C5670 Sigma) 1 M 2 mM 
Glucose (G7528 Sigma)   10 mM 
Hepes (H4034 Sigma)   10 mM 
NaOH (71687 Sigma)  Adjust to pH 7.4 
dH2O  Top up to volume 
Filter sterilize 0.2 μm   
 
2.10 Hydrogen peroxide assay 
 The release of H2O2 by THP-1 cells stimulated with PMA (P8139 
Sigma) or HkEc was assessed by Amplex® Red Hydrogen 
Peroxide/Peroxidase Assay Kit (A22188 Molecular Probes). The assay is 
based on oxidation of Amplex Red by hydrogen peroxide in the presence 
of horseradish peroxidase (HRP), which gives rise to a coloured product, 
resorufin on a stoichiometry reaction of the Amplex Red reagent with H2O2 
in a proportion of 1:1.  
Cells were plated in a 96-well flat-bottomed plate at a density of 105 
cells/well. H2O2 production was measured at 37°C in the presence of 3 µM 
Amplex® Red (Molecular Probes), 0.1 U/ml horseradish peroxidase (HRP) 
(Sigma-Aldrich) and, where appropriate, 1 µg/mL PMA or HkEc 20:1 (MoI) 
in the presence or absence of NaB in sterile RPMI 1640 Medium without 
phenol red (Gibco 11835030) or BSS buffer.  Measurements were taken 
on a CLARIOstar OMEGA microplate reader (BMG LABTECH Ltd.). 
Excitation was set at 544 nm and emission was set at 590 nm, with 
measurements taken at 30 seconds intervals for 1 hour. The rate of H2O2 
production per hour (nM/h) was calculated on the exponential phase using 
the MARS Data Analysis Software (BMG LABTECH Ltd.). 
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2.11 ROS / Superoxide assay 
 Production of ROS/superoxide by THP-1 cells stimulated with HkEc 
was assessed by Cellular ROS/Superoxide Detection Assay Kit (ab139476 
Abcam). The assay has two non-fluorescent cell permeable dyes, ROS 
detection dye (green probe) reacts directly with a wide range of reactive 
species, such as hydrogen peroxide (H2O2), peroxynitrite (ONOO⎯), 
hydroxyl radicals (HO), nitric oxide (NO), and peroxy radical (ROO), 
yielding a green fluorescent product indicative of cellular production of 
different ROS/reactive nitrogen species (RNS) types. However, the 
sensitivity of the green probe for O2⎯, as well as hypochlorous acid (HClO) 
and nitric oxide (NO), is very low relative to other free radicals. The 
superoxide detection dye (orange probe) is a cell-permeable probe that 
reacts specifically with superoxide (O2⎯), generating an orange fluorescent 
product. 
 Cells were plated in a 96-well flat-bottomed plate at a density of 105 
cells/well. H2O2 production was measured at 37°C in the presence of 2 nM 
of ROS/Superoxide dyes and, where appropriate, HkEc 20:1 (MoI) in the 
presence or absence of NaB in sterile BSS buffer. 
To evaluate the immediate effect of sodium benzoate as a radical 
scavenger, a 2-phase experiment was performed. During phase 1, cells 
were stimulated as previously described for 90 minutes, allowing the 
formation of ROS/superoxide and then, during phase 2, titrated doses of 
NaB were added to the wells, with a similar amount of buffer added to 
controls. And the experiment carried out for a total period of 3 hours. 
Measurements were taken on a CLARIOstar OMEGA microplate 
reader (BMG LABTECH Ltd.). Excitation was set at 490 nm and emission 
was set at 525 nm for the green fluorescein, and excitation was set at 550 
nm and emission was set at 620 nm for the orange rhodamine with 
measurements taken at 3-minute intervals for 3 hours. The rate of 
ROS/superoxide production per hour were calculated on the exponential 
phase using the MARS Data Analysis Software (BMG LABTECH Ltd). 
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2.12 Proteomics profile using mass spectrometry 
 For liquid chromatography-tandem mass spectrometry (LC-MS/MS) 
analysis, whole protein lysates were analysed under reducing conditions 
and samples were labelled using the TMTsixplex™ Isobaric Label Reagent 
Set (90061 Thermo Fisher Scientific). 
 5 X 106 THP-1 cells were plated in 5 mL of enriched RPMI medium 
a 6-well tissue culture plate and stimulated with 200 ng/mL LPS (smooth) 
in the presence or absence of NaB. Samples were stimulated or not 
(untreated) for 2 hours, 4 hours, 6 hours, 12 hours, and 24 hours and lysed 
in SDS/Hepes buffer pH 7.4 (0.1% SDS, 50 mM Hepes (H0887 Sigma)) 
with 1 tablet of PhosSTOP and 1 tablet of cOmplete™, Mini, EDTA-free 
protease inhibitors cocktail (5892970001 - Sigma) in RNase free water for 
a total volume of 10 mL. 
 Briefly, 100 μg of total protein in 100 μL of lysis buffer was used for 
labelling each tagged sample. Samples were reduced in 10 mM DL-
Dithiothreitol (DTT 43815 Sigma) for 1 hour at 37 oC, alkylated in 25 mM 
Iodoacetamide (I6125 Sigma) for 2 hours at RT protected from light and 
then precipitated overnight with 10 volumes of 100% acetone at -20 oC. 
 Samples were centrifuged at 16,000 g for 20 minutes at 4 °C. The 
supernatant was removed, and the pellet left to air dry to allow residual 
acetone to volatilize. The pellet was resuspended in 100 µl of 100 mM 
HEPES, pH 8.5 (pH adjusted with KOH), vortexed and sonicated for proper 
solubilization. Samples were digested in 2-steps with 2.5 μg of sequencing 
grade modified trypsin (V5111 Promega), the first step for 1 hour at 37 °C, 
and after a second aliquot of 2.5 μg trypsin was added to samples and 
incubated overnight at 37 °C (no longer than 16 hours). The TMTsixplex™ 
tags were resuspended in 53 μL of acetonitrile (1.00017 EMD Millipore) 
and samples were added to each tag for 2 hours at room temperature, with 
constant agitation. 
 The reaction was quenched with 8 µl of 5% hydroxylamine (100 mM 
HEPES; pH 8.5) for 1 hour at room temperature, on a shaker and further 
quenched with 100 µL H2O overnight at 4°C. All six labels were pooled 
together and pelleted down at 200 g and dried on a Savant SpeedVac 
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System SPD1010 (SPD1010A-230 Thermo Fisher Scientific) overnight. 
Solid phase extraction clean-up step was done using SepPak C18 
cartridges (WAT023590 Waters) prior to reversed-phase high-
performance liquid chromatography (RP-HPLC). 
 Dried peptide samples combined into a total of 100 µl of 5% organic 
mobile phase (80% acetonitrile, 20 mM ammonium formate (78314 
Sigma); pH 10). Fifty μL of sample was injected on a RP column (40°C) 
and run at a flow rate of 0.244 mL/minute over 75 minutes run using mobile 
phase A (20 mM ammonium formate; pH 10) and mobile phase B (80% 
acetonitrile, 20 mM ammonium formate; pH 10). 
LC-MS/MS with the LTQ-Orbitrap mass spectrometer (Thermo 
Fisher Scientific), was performed as previously described161. Raw MS files 
were analysed by the Mascot search engine 2.3.02 (Matrix Science) and 
searched against a SwissProt human database 2013_10 (containing 
39,696 entries including common contaminants). Mascot search analysis 
parameters included: trypsin enzyme specificity, allowance for 2 missed 
cleavages, peptide mass tolerance of 20 ppm for precursor ions and 
fragment mass tolerance of 0.8 Da. 
 
2.13 Experimental conditions tested 
2.13.1  Lysosomal inhibition and cytokine release  
1x106 THP-1 cells were plated in 24-well tissue culture plates in 
RPMI enriched medium and stimulated for 24 hours with HkEc at a MoI of 
20:1 ± 5 mM NaB, with 2.5 μM monensin, 10 mM NH4Cl, 50 μM 
chloroquine, 1 μM brefeldin A or 200 nM bafilomycin A (see Table 1).  
After 24 hours, supernatants were collected and stored at -80 °C 
and ELISAs performed (see section 2.6.1). 
 
2.13.2  Antioxidants 
1x106 THP-1 cells were plated in 24-well tissue culture plates in 
RPMI enriched medium and stimulated for 24 hours with HkEc at a MoI of 
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20:1 in the presence of either 5 mM NaB (pre-treated overnight), 1 mM N-
Acetyl-L-cysteine (NAC), 2 mM TEMPO, 2 mM N,N’-dimethylthiourea 
(DMTU), and 12.5 μM Curcumin (high purity). All the other antioxidants 
were pre-incubated for 30 minutes before HkEc stimulation (see Table 1). 
After 24 hours, supernatants were collected and stored at -80 °C and 
ELISA assays were performed (see section 2.6.1). 
After the pre-treatment with the antioxidants (NAC, TEMPO, DMTU, and 
curcumin), the release of H2O2 by THP-1 cells stimulated with Phorbol 12-
myristate 13-acetate (PMA) or HkEc was assessed by Amplex® Red (see 
section 2.10). 
 
2.13.3 Immunomodulators Tyrphostin AG 490 and PD98059 
The immunomodulators Tyrphostin AG 490 (AG490), a specific and 
potent inhibitor of the Janus kinase 2 protein and signal transducer and 
activator of transcription 3 (JAK2/STAT3) was used at a concentration of 
20 μM and added 30 minutes prior to bacterial challenge. PD98059, a 
potent and selective inhibitor of MAP kinase kinases (MAPKK), MEK1 and 
MEK2, was used at a concentration of 20 μM and added 30 minutes before 
or 4 hours after HkEc stimulation (see Table 1).  
 
2.13.4 Recombinant cytokines stimulation 
 1x106 THP-1 cells were plated in 24-well tissue culture plates in 
RPMI enriched medium and stimulated for 4 or 24 hours ± HkEc and/or 
NaB, 10 ng/mL of recombinant TNF or 10 ng/mL of recombinant IL6 were 
added to cell culture medium to investigate their effects on THP-1 cells 
cytokine production and release (see Table 1). 
After the specific stimulation time, cells were harvested, and the 
supernatant was collected and stored at -80 °C and ELISAs were 
performed (see section 2.6.1). The cell pellet was placed in either RLT 
buffer (see section 2.7.1) or RIPA buffer (see section 2.8.1.1), for mRNA 
extraction or protein analysis respectively.  
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2.13.5 Cytokine neutralization assays 
1x106 THP-1 cells were plated in 24-well tissue culture plates in 
RPMI enriched medium and stimulated for 24 hours ± HkEc and/or NaB, 
100 μg/mL HUMIRA®, an anti-TNF medication, or 1 μg/mL of anti-IL6 
antibody were added to cell culture medium to investigate the effects of 
these cytokines on THP-1 cells cytokine production and release (see 
Tables 1 and 5). 
After the specific stimulation time, the supernatant was collected 
and stored at -80 °C and ELISAs were performed (see section 2.6.1 
Enzyme-linked immunosorbent assay). 
 
2.14 Statistical analysis 
All data are presented as mean ± SEM using GraphPad Prism 7.0 
(GraphPad Software, Inc). Statistical significance was calculated using 
paired or unpaired two-tailed Student’s t-test when 2 groups were 
analysed. When more than two groups were analysed, statistical 
significance was calculated using one-way ANOVA with Tukey’s multiple 
comparison test or Dunnet’s multiple comparison test when a 
control/reference group was used. Simple linear regression analysis, area 
under the curve and analysis of covariance (ANCOVA) was used to 
compare to linear regressions were calculated using GraphPad Prism 7.0. 
Microarray and proteomic data were analysed using multiple testing in R 
program with the BioConductor and LIMMA packages. 
 
2.15 Ethics 
For the human study, ethics was approved by the Joint University 
College London (UCL)/University College London Hospitals (UCLH) 
Committee for the Ethics of Human Research (project numbers 02/0324) 
and the NHS National Research Ethics Service, London-Surrey Borders 
Committee (project number 10/H0806/115). The ethics committee 
approved consent forms were signed by all participants. 
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Chapter 3 Effects of NaB on immune response 
of THP-1 cells 
3.1 Introduction 
 Although NaB is widely used by the food and cosmetic industry, little 
is known about the effects of this compound has at the cellular level. Just 
a few studies have been published using primary or immortalized cells that 
could help the basis of this investigation39,94,95,162. Besides that, the main 
motivation to study NaB was the link between the negative effects of 
benzoate-containing diets observed in patients with OFG11,19,163. Reports 
of patients with OFG experiencing flare-up of the disease symptoms after 
ingestion of NaB contrasts with the potential therapeutic benefits in 
reducing inflammation in NDDs41,95. To affect the CNS, NaB probably 
needs to be absorbed and distributed by the blood and cross the blood-
brain barrier (BBB), whereas at sites such as the mucosal surfaces and on 
the skin NaB may act in a more localized manner. In support of this, NaB 
has been constantly reported as one of the main allergens responsible for 
contact urticaria and delayed hypersensitivity on contact skin tests76. 
Since the most commonly affected area of OFG involves the oral 
mucosa, it is possible that NaB could act directly through absorption in 
addition to being delivered through a systemic route. Another crucial factor 
that differentiates the effects of NaB in OFG from those potentially 
beneficial to NDDs, relies on the greater exposition of the oral mucosa to 
all sort of irritants and allergens, ranging from microorganisms to 
unaccountable variety of substances that can cause irritation and/or 
inflammation. 
We have decided to investigate effects of NaB on human monocytes 
(THP-1) and its potential to cause systemic inflammation, which in patients 
with OFG, could be sufficient to trigger the flare-up of the disease. The first 
part of these results aimed to study the effects of NaB on the inflammatory 
response of THP-1 cells, especially when challenged with bacteria or TLR 
ligands. 
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3.2 THP-1 differentiation to macrophage-like cells 
 THP-1 is a human monocytic cell line that can be differentiated in to 
macrophage-like cells using low doses of PMA or immune activation. They 
are large rounded cells resembling circulating monocytes from peripheral 
blood (Figure 3-1A) and, upon stimulation and differentiation, they 
experience a massive change in shape and size (Figure 3-1B-D). 
 
Figure 3-1: Phase-contrast microscopy images of the unstimulated THP-
1 cells (A) and stimulated cells (B-D). Unstimulated THP-1 cells are 
rounded non-adherent cells (A). NaB alone does not differentiate the cells, 
keeping the round shape similar to untreated cells (data not shown). Upon 
HkEc stimulation, they differentiate in to macrophage-like cells, becoming 
adherent and spread on the glass surface (B). LPS stimulation also leads 
to THP-1 differentiation, but in a less intense way than with HkEc (C). NaB 
treatment does not affect differentiation of THP-1 cells into macrophage-
like cells upon HkEc stimulation (D). Magnification 63X. 
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3.3 NaB toxicity 
 The toxicity of NaB on THP-1 cells was investigated using the MTT 
assay. In this assay, the MTT salt, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl 
tetrazolium bromide, is taken up by viable cells and reduced by the action 
of mitochondrial dehydrogenases into insoluble purple formazan that is 
colourimetrically measured. Purple formazan formation was used as a 
measure of cell viability. NaB toxicity worked in a dose- and time-
dependent manner (Figure 3-2). THP-1 cells were cultured in different 
concentrations of NaB (0-80 mM) for 24 h (Figure 3-2A). NaB was very 
toxic to THP-1 cells at high concentrations ≥ 20 mM killing almost all the 
cells. The cell viability was tested at 4, 8 and 24 h after the addition of 
several concentrations (0-160 mM) of NaB, the absence or presence of 
immune stimulation (HkEc). There was no change in THP-1 viability at 4 h 
(Figure 3-2B), but by 8 h, a loss in cell viability was evident at 
concentrations above 80 mM (Figure 3-2C). By 24 h NaB concentrations 
above 5 mM reduced the viability of THP-1 cells (Figure 3-2D). Therefore, 
the concentration of 5 mM was established as our standard working dose.  
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Figure 3-2: The effects of NaB on THP-1 cell viability using MTT assay. 
NaB is toxic to THP-1 cells at concentrations ≥ 10 mM after 24 h (A). THP-
1 cells stimulated or not with HkEc in the presence of NaB (0-160 mM) 
were evaluated over 24 h (B-D). No cell loss was observed at 4 hours even 
at the highest NaB concentrations (B). At 8 hours of NaB exposure, cell 
viability started to decrease at NaB concentrations of 160 mM irrespective 
of HkEc stimulation(C). Over a period of 24 hours, concentrations above 5 
mM showed a reduction in the number of viable cells irrespective of HkEc 
exposure (D). The straight grey and blue lines represent the average of the 
control groups (no NaB) for unstimulated and HkEc stimulated, 
respectively. Cell viability and proliferation rates were influenced by HkEc 
stimulation, but not for NaB treatment at 5 mM (E). THP-1 cells cultured in 
the absence or presence of 5 mM NaB were maintained and monitored for 
two weeks. There was no significant effect of 5 mM NaB on THP-1 cell 
viability, measured by Trypan blue exclusion test (F). Results shown are 
mean ± SEM of an individual experiment. The results of a single 
experiment are limited to establish a proper cause-effect of the 
experimental conditions. 
 
We tested the effect on THP-1 cell proliferation of long-term 
exposure to 5mM NaB and observed that there was no alteration in cell 
viability or cell proliferation (Figure 3-2E). It is important to note that THP-
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1 cells are spontaneously immortalized cancer cells, which proliferate 
indefinitely and double their population every 48-72 h. Upon activation with 
pathogens, HkEc for instance, these monocytes become activated, 
differentiate in macrophages, (Figure 3-2B), and stop proliferating (Figure 
3-2E)164. At ≤5 mM, there was no change in cell proliferation or cell death 
due to NaB treatment (Figure 3-2).  Changes in cell number resulting from 
bacterial challenge were not influenced by the presence of 5 mM NaB 
(Figure 3-2E). Finally, THP-1 cells were cultured in a tissue culture flask 
containing 5 mM NaB for 2 weeks in parallel with cells cultured in normal 
RPMI enriched medium. Whenever the cells needed to be subcultured, an 
appropriated volume was discharged and fresh medium containing the 5 
mM of NaB was added to the flask. Cell viability was measured on 
automated cell counter based on cell density and Trypan blue exclusion, 
demonstrating that NaB is not toxic or capable of inducing maturation and 
cell cycle arrest in THP-1 cells at a concentration of 5 mM (Figure 3-2F). 
 
3.4 THP-1 cytokine secretion response to HkEc stimulation 
3.4.1 Cytokines secretion in THP-1 cells and effects of NaB 
exposure 
 Although there are some limitations when compared to primary 
monocytes, especially due to a lower expression of CD14, THP-1 cells are 
a good model for a basic translational study of primary monocytes.  Upon 
activation with TLR ligands, these cells initiate an immune response and 
release a range of cytokines165,166. 
 THP-1 cells were stimulated with HkEc (20:1 MoI) in the presence 
and absence of NaB. After 24 hours, the supernatant was collected and 
screened with a panel of inflammatory cytokines using a multiplex 
immunoassay (Figure 3-3). 
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Figure 3-3: Stimulation of THP-1 cells with HkEc causes the release of 
IL8, TNF, IL6 and IL1β. NaB (5 mM) treatment caused a deregulation in 
pro-inflammatory cytokines secretion, with a reduction in IL6 and IL1β, and 
an increase in TNF. NaB had no effect on the release of IL8. All the other 
cytokines tested were either detected at a very low level or were below the 
detection limit of the high-sensitivity assay. Results shown are mean ± 
SEM, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001; n=1 individual 
experiment with 4 biological replicates, (two-tailed, unpaired t-test). This 
was a preliminary result that will be expanded later.  
 
NaB treatment showed an ambiguous effect, reducing the levels of 
IL6 and IL1β in increasing the levels of TNF (Figure 3-3). This result 
suggests a selective effect of NaB on the innate immune response, which 
cannot be attributed to a purely anti-inflammatory effect or through the 
effects of an elevation in IL10 (Figure 3-3). 
 
3.4.2 THP-1 cytokines response of TNF and IL6 to HkEc occurs in a 
dose- and time-dependence manner upon NaB treatment 
 To investigate if the effects on cytokine secretion were dependent 
on NaB dose, THP-1 cells were stimulated with HkEc for 24 h in the 
presence of a range of NaB concentrations (0-10 mM). IL6 levels were 
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reduced at very low concentrations (0.1 mM) and constantly reduced with 
increasing doses of NaB (Figure 3-4A). On the other hand, lower doses of 
NaB (0.1 – 2.5 mM) had no effect on TNF secretion, whereas 5 and 10 mM 
resulted in an elevation in TNF release (Figure 3-4B). The effects of NaB 
on IL6 secretion lasts even after NaB was removed from the medium 
(Figure 3-5).  
 
Figure 3-4: THP-1 cells stimulated with HkEc (MoI 20:1) for 24 hours were 
treated with increasing concentrations of NaB (0-10 mM) and the levels of 
IL6 (A) and TNF (B) measured by ELISA. An increase in the concentration 
of NaB correlated with an increase in secretion of TNF and inversely 
correlated with IL6 levels. Results shown are mean ± SEM, *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001; n=1 individual experiment with 4 
biological replicates, (two-tailed, unpaired t-test). The results of a single 
experiment are limited to establish a proper cause-effect of the 
experimental conditions. 
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Figure 3-5: Effects of NaB on cytokine secretion after NaB removal from 
the culture medium. THP-1 cells were preincubated with NaB (5 mM), 
washed twice in PBS and stimulated in medium with either NaB 
(coincubation), replaced in a medium free of NaB and stimulated with HkEc 
(20:1 MoI) immediately (0 h) or left in the NaB-free medium for 24 and 48 
hours prior stimulation (A). The total HkEc stimulation time was 24 hours 
in all samples. IL6 levels were reduced in all samples that were previously 
treated with NaB when compared with HkEc alone. TNF was increased 
only when THP-1 cells were costimulated in the presence of NaB. After 
removal of NaB, the levels of TNF returned to normal or even decreased 
over time. Results shown are mean ± SEM, *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001; n=1 individual experiment with 4 biological replicates, (two-
tailed, unpaired t-test). The results of a single experiment are limited to 
establish a proper cause-effect or if they were an accidental finding. 
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3.5 Transcriptome analysis of THP-1 cells upon bacterial 
stimulation  
3.5.1 HkEc and HkPg stimulation of THP-1 cells and the effects of 
NaB 
THP-1 cells were exposed to either 5 mM NaB, HkEc (20:1 MoI) or 
HkPg alone, or in combination for 4 hours. Unstimulated THP-1 cells were 
used as a reference for basal gene expression levels. Data from the 2 chips 
were merged and then analysed. Batch variation was minimised using 
ComBat (for a detailed description see section 2.7.3), an established R 
algorithm for minimizing batch effects in microarrays (Figure 3-6)157. 
 
Figure 3-6: Density plot graph before (A) and after ComBat normalization 
(B). This normalization corrected variations between chips allowing the 
data to be merged and analysed.  
 
A total of 47,213 probes were tested in the microarray chip, from 
those, 16,348 remained after quality control check and were further 
analysed. Bacterial stimulation regulated a specific number of genes 
(≈1%), with half of them commonly regulated in both, HkEc or HkPg 
stimulated samples (Figure 3-7). The cutoff p-value was set at p<0.05. 
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Figure 3-7: Venn diagram showing a summary of results obtained from 
whole gene transcriptomic analysis after quality control check (as 
described in section 2.7.3). Approximately 1% of the total probes were 
regulated by bacterial stimulation. 
 
 When we analysed the overall effects of NaB exposure on THP-1 
cells, 1116 probes were affected across all three conditions: unstimulated, 
HkEc and HkPg stimulated. Thirty-six probes were statistically different in 
all three conditions (Figure 3-8). 
 
Figure 3-8: Venn diagram showing differences between expression 
profiles of the 3 different stimulation groups (Un, HkEc and HkPg) and the 
effects of NaB on gene expression. Unstimulated THP-1 cells treated with 
NaB showed changes in 200 probes with a predominant downregulating 
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effect (64%). Upon HkPg stimulation, NaB affected the expression of more 
genes (330) but downregulating effect still dominated (78% of the probes 
were downregulated). On the other hand, NaB regulated the expression of 
several genes after HkEc stimulation, but with predominance for an 
upregulation in genes expression (55% of the probes). In total, 36 genes 
were affected by NaB regardless of any other treatment (These are 
covered in more detail later). 
 
Principal component analysis (PCA) was conducted to determine 
whether global gene expression profiles could be separated based on NaB 
or bacterial stimulation. PCA is a mathematical algorithm for reducing the 
dimensionality of datasets, by finding the principal components (directions) 
along which the variation is maximal. PCA analysis showed a clear 
difference between bacterial stimulation (Figure 3-9). A dendrogram 
showing the hierarchical clustering is shown in Figure 3-10. 
 
Figure 3-9: PCA plot for microarray data showing the relatedness between 
all samples. The plot clearly shows that most of the variance in the 
microarray data can be attributed to the bacterial stimulation. Slight 
changes can also be attributed to NaB treatment, which is observed as a 
shit to the left in the two bacterial stimulated samples in PC1. 
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Figure 3-10: Dendrogram illustrating the hierarchical clustering of all 
microarray samples including all probes (16,348 probes) that passed the 
quality control. Three main clusters can be observed depending on the type 
of stimulation. 
 
Figure 3-11: Heatmap of 1116 differentially expressed genes influenced 
by NaB treatment under 3 different conditions with an adjusted p-value less 
than 0.05 are shown. Hierarchical cluster generated based on gene 
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expression (rows). A dendrogram showing sample cluster (top) and colour 
scale coded values in the heatmap (right). 
 
The list of all genes regulated by NaB was uploaded to the Database 
for Annotation, Visualization and Integrated Discovery (DAVID) v6.8  
(http://david.abcc.ncifcrf.gov/) and the functional annotation tool was used 
to generate active pathways167,168. The top two pathways originated from 
the Kyoto Encyclopaedia of Genes and Genomes (KEGG) with the lowest 
p-value were related to the TLR (p= 2.1E-4 KEGG path: hsa04620) and the 
cytokine-cytokine receptor interaction (p=3.3E-4 KEGG path: hsa04060) 
pathways, with 19 and 15 genes involved in each pathway respectively, 
and 4 genes were found in both (Figure 3-12A). Another important pathway 
affected by NaB treatment was the glutathione metabolism (p= 8.9E-2) 
pathway (Figure 3-12B).  
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Figure 3-12: Heatmap of genes involved in TLR and cytokine-cytokine 
receptor interaction pathways (A) and glutathione metabolism (B). Many 
genes associated with TLR and TNF pathways have essential functions in 
innate immunity (A). The glutathione pathway is involved in amino acid 
metabolism, which includes glycine, and has an important role in redox 
regulation and detoxification reactions. 
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There were 32 genes that were controlled by NaB exposure and 
showed the same type of change, up- or downregulating gene expression 
regardless of the stimulation with bacteria or not. It suggests a strong link 
between NaB and these specific genes. Using DAVID Bioinformatics 
Resources and String (https://string-db.org/) online databases, these 
genes didn’t show any significant interactions in terms of pathways or 
function, however, more than 50% of them shared the same nuclear 
location (Figure 3-13). 
 
Figure 3-13: Heatmap of 36 genes controlled by NaB treatment regardless 
of bacterial stimulation. All of them had a similar pattern up- or 
downregulating gene expression regardless the type of stimulation. 
Nuclear location is a common feature to more than 50% of the genes. It is 
important to note that the hierarchical cluster now shows an increased 
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height when compared samples ± NaB. The phosphoserine 
aminotransferase 1 (PSAT1) is upregulated in all samples treated with 
NaB. The role of PSAT1 will be better explored in chapter 7. 
 
PSAT1 is an enzyme that catalyses the reversible conversion of 3-
phosphohydroxypyruvate to phosphoserine and plays a key role in the 
serine/glycine biosynthesis. So far, the results pointed to a more potent 
effect of NaB when THP-1 cells were stimulated with HkEc than with HkPg, 
in view of the number of genes regulated in these samples. To reduce the 
size of the thesis, HkPg groups were not included in further analysis. 
 
3.5.2 Gene expression analysis of HkEc stimulation and the effects 
of NaB on THP-1 cells 
 In the previous section, the overall effect of NaB was evaluated in 
combination with other samples. Now, a more focused approach will 
investigate the alterations induced by NaB on the THP-1 immune 
response. From those genes regulated by NaB treatment, 909 out of 1,116 
(81.4%) were observed upon HkEc stimulation. 
 Similar to what was seen in the previous section, the main pathways 
involved in HkEc response were related to important functions in innate 
immunity, particularly associated with the TLR4 pathway (Figure 3-14). The 
data was originated from microarray and further confirmed by qRT-PCR. 
Genes responsible for cytokines production and adaptor proteins showed 
statistical alteration in expression when THP-1 cells were stimulated with 
HkEc compared to HkEc plus NaB. IL6 was the gene with the second 
lowest p-value (4.16E-07). 
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Figure 3-14: THP-1 gene expression in response to HkEc stimulation is 
altered by the co-incubation with NaB. Data originated from microarray 
analysis and further validated by qRT-PCR. The presence of NaB during a 
HkEc response resulted in the upregulation (red) of many adaptors 
proteins and downregulation (green) of important cytokines and 
chemokines. Simplified TLR4 signalling pathway adapted from DAVID 
Bioinformatics Resources website. 
 
 Another important pathway associated with the innate immunity was 
associated with genes from the cytokine-cytokine receptor interaction 
(KEGG pathway hsa04060) (Figure 3-15). 
107 
 
 
Figure 3-15: Heatmap of THP-1 gene expression comparing HkEc ± NaB 
in the cytokine/cytokine receptor pathway. NaB treatment downregulate 
many genes associated with the synthesis of pro-inflammatory cytokines. 
The TNFRSF1B gene is responsible for the synthesis of TNFR2, which is 
a soluble receptor and controls TNF activity by sequestering the cytokine 
and antagonizing TNF activity. 
 
The CC chemokine family (from C-C motif ligands proteins) is 
involved in the acute inflammatory state in the recruitment and activation 
of polymorphonuclear leukocytes. Together with some CCL genes, the 
chemokine receptor family (CCR1 and CCR2) were downregulated by 
NaB, suggesting an attenuated response to these chemokines. 
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3.6 Characterization of pro-inflammatory cytokine dynamics in THP-
1 upon HkEc stimulation and the effects of NaB 
 The early inflammatory process occurs immediately after 
recognition of antigenic stimuli and macrophages are very often the first 
cells to respond to these stimuli. This stage involves the production and 
release of pro-inflammatory cytokines in a coordinated response to harmful 
stimuli110.  
 To characterize the cytokine dynamics to bacterial response, a time-
course was carried out to investigate the cytokine secretion and gene 
induction of the main cytokines produced by THP-1 cells (Figure 3-2). The 
protein levels of IL8, IP10, TNF, IL6 and IL1β were investigated by ELISA 
and the gene induction by qRT-PCR (Figure 3-16). 
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Figure 3-16: Time course of cytokine secretion (left panel) and gene 
expression (right panel) in THP-1 cells stimulated with HkEc ± NaB. The 
secretion of IL8 and IP10 are unaffected by NaB treatment (A and C), even 
though some differences in gene expression can be observed (B and D). 
TNF was detected as soon as in the first hour, reaching a peak at 6 hours, 
decreasing from this time and accentuated decline after 12 hours (E). The 
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message level rises very quickly peaking at one hour and then decreases 
with the almost complete loss of expression after 6 hours (F). NaB 
treatment showed an increased mRNA expression and a slower decline of 
the released TNF. The cytokines that demonstrated the greatest sensitivity 
to NaB at both the secretion and transcription level were IL6 and IL1β (G-
J).  
 
 Taken together, these results suggest that NaB affects specific 
cytokines, downregulating IL6 and IL1β and deregulating TNF. Twenty-four 
hours after stimulation seemed to be the best point for investigating the 
majority of these cytokines, except for TNF, which showed an earlier gene 
induction that is practically gone after 6 hours. These data were used for 
planning further experiments. 
 
3.7 NaB reduces IL6 and IL1β levels, and deregulate TNF in THP-1 
cells upon HkEc stimulation 
 A few studies have shown a predominant anti-inflammatory effect of 
NaB, reducing the levels of IL6,  IFNγ and TNF in splenocytes,  and IL1β 
and TNF in microglia, both stimulated with LPS1,169. Here, monocytes were 
stimulated with HkEc for 24 hours in the presence or absence of NaB. 
 The induction and release of IL8 and IP10 in response to HkEc were 
unaffected by the presence of NaB (Figure 3-17).  They are both induced 
downstream of TLR4 signalling but use different pathways. IL8 follows the 
MyD88-dependent pathway, while IP10 is linked to a type-I interferon 
response downstream a MyD88-independent/TRIF pathway114,125,131,134. 
On the other hand, IL6 and IL1β were negatively regulated by NaB and 
showed a reduced level of protein and mRNA expression (Figure 3-18). 
These reduced levels of IL6 and IL1β did not result in the increased 
expression of the anti-inflammatory cytokine IL10. Only a very low 
concentration (≈10 ng/mL) of IL10 was detected in HkEc ± NaB samples 
using the high-sensitivity multiplex immunoassay (Figure 3-3), whereas all 
attempts to detect IL10 with an ELISA failed. TNF secretion was increased 
in the presence of NaB (Figure 31-9), an evaluation of TNF induction and 
secretion will be detailed later in chapters 5 and 6. 
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Figure 3-17: IL8 and IP10 secretion (A and C) and gene expression (B and 
D) in THP-1 cells stimulated with HkEc ± NaB. The addition of NaB had no 
significant effect on HkEc induced secretion of IL8 and IP10. Results 
shown are mean ± SEM, n= 5 and 3 independent experiments for protein 
levels and mRNA expression, respectively (two-tailed, unpaired t-test). 
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Figure 3-18: IL6 and IL1β cytokine secretion levels (A and C) and gene 
expression (B and D) in THP-1 cells stimulated with HkEc ± NaB. These 
cytokines were reduced in both levels as result of NaB treatment. n= 10 
(IL6 protein), 5 (IL1β protein) and 3 independent experiments for protein 
levels and mRNA expression, respectively. Results shown are mean ± 
SEM, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001; (two-tailed, unpaired t-
test). 
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Figure 3-19: TNF (A, ELISA) and IL10 (B, MSD® multiplex immunoassay) 
cytokine secretion levels in THP-1 cells stimulated with HkEc ± NaB. TNF 
was increased because of NaB treatment. IL10 was not detected in ELISA 
(data not shown) and detected in a similar very low level. n= 10 (TNF) and 
n=1 (IL10) independent experiments. Results shown are mean ± SEM, 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001; (two-tailed, unpaired t-test). 
 
3.8 NaB reduces IL6 and deregulate TNF in THP-1 cells upon TLR4 
and TLR1/2 stimulation 
 Heat-killing bacteria is a well-established method used to stimulate 
the immune system but maintain sterility in the culture dish and since the 
immune response is similar to that of the equivalent live bacteria it is 
assumed that most of the PAMPs are preserved170,171,172. However, they 
carry multiple antigens and generate a complex signal. HkEc is capable of 
activating multiple receptors including TLRs (TLR 1/2, 2/6, 4, 5,9), 
especially TLR4 and TLR2173. 
To investigate if NaB was affecting a particular pathway 
downstream TLR activation, the specific TLR ligands LPS (TLR4) and 
PAM3CSK4 (TLR 1/2) were used to stimulate THP-1 cells. The inclusion 
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of NaB downregulated IL6 and IL1β regardless of whether the cells were 
stimulated with LPS or PAM3CSK4 (Figure 3-20). 
 
Figure 3-20: Cytokine secretion levels from THP-1 cells stimulated with 
LPS (A) or PAM3CSK4 (B) ± NaB. IL6 and IL1β secretion were reduced 
and showed the biggest effect size downstream of both TLR ligands by the 
inclusion of NaB. Results shown are mean ± SEM, for n= 5 (LPS) and n=3 
(PAM3CSK4) independent experiments. *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001; (two-tailed, unpaired t-test). 
 
3.9 Initial TLR signalling downstream stimulation is not affected by 
the inclusion of NaB 
In light of the reduced mRNA expression, the signalling pathway 
downstream of TLR4 and TLR2 were assessed to investigate if NaB could 
potentially interfere with the protein kinase cascade. Downstream of TLRs, 
the main signal to induce IL6 and IL1β follow the MyD88-dependent 
pathway and uses the transcription factors NFkB and AP1. NFkB is kept in 
the cytoplasm bound to its inhibitor nuclear factor of kappa light polypeptide 
gene enhancer in B-cells inhibitor, alpha (IKBa). When activated, the IKBa 
is ubiquitylated and degraded by the proteasome, releasing the activated 
NFkB that translocates into the nucleus and initiates gene transcription. 
Furthermore, the AP1 complex can also induce transcription of 
proinflammatory cytokines downstream of the MAPK pathway (Figure 1-
15). The initial response to HkEc stimulation seemed to be unaffected by 
NaB, which suggests that NaB does not interfere with this initial TLR 
signalling (Figure 3-21). 
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Figure 3-21: The major signal molecules downstream of TLR stimulation 
were visualized after HkEc stimulation. There was no obvious difference in 
any of the major signalling molecule during the initial TLR response 
between HkEc and HkEc plus NaB. Immunoblots for the phosphorylated 
MAPKs P38 (pP38) and ERK (pERK), and the subunits of the AP1 
complex, phospho-c-JUN (pC-JUN) and phosphor-C-FOS (pC-FOS), 
showed a similar phosphorylation pattern. The NFkB response was also 
not affected by NaB treatment, as determined by increased 
phosphorylation (phospho-Ser536) and degradation of its inhibitor IKBa. α-
tubulin is shown as loading control. Results shown are representative of 3 
independent experiments. 
 
3.10 Protein transport and lysosomal inhibition 
Inhibition of lysosomal proteases has been shown to increase 
intracellular cytokine levels in HkEc stimulated human MDMs174. Monensin 
is an antibiotic derived from Streptomyces cinnamonensis and is an 
ionophore that disrupts intracellular Na+ and H+ gradients, affecting the 
final stages of secretory vesicle maturation from Golgi apparatus175. 
Bafilomycin A is an antibiotic that specifically inhibits the vacuolar-type H+-
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ATPase and prevents acidification and fusion of autophagosome-
lysosome, which can lead to cytokine degradation176. 
Brefeldin A is a macrocyclic lactone produced by a variety of fungi 
and appears to inhibit protein secretion early in a pre-Golgi compartment 
(between the endoplasmic reticulum and Golgi)175. NH4Cl is a weak base 
and has been shown to accumulate in acid intracellular compartments such 
as in lysosomes raising the vacuolar pH and inhibiting lysosomal enzymes 
177. 
To investigate if the deregulated secretion of cytokines caused by 
NaB is replicated through the use of known blockers of protein secretion 
THP-1 cells were stimulated with HkEc in combination with either 5 mM 
NaB, 2.5 μM monensin, 10 mM NH4Cl, 2.5 μM brefeldin A or 200 nM 
bafilomycin A and IL6 and TNF release determined (Figure 3-22). 
 
 
Figure 3-22: IL6 (A) and TNF (B) secretory levels were measured after 24 
h HkEc stimulation upon exposure to either NaB, monensin, NH4Cl, 
bafilomycin A, and brefeldin A. Results shown are mean ± SEM, *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001 (one-way ANOVA with Dunnett’s test, 
control group HkEc). 
Abbreviations: Mon, monensin; BafA, bafilomycin A; BrefA, brefeldin A.
  
 The effects of NaB on IL6 and TNF secretion was not replicated by 
the inclusion of any of the classic trafficking inhibitors (Figure 3-22). The 
results did demonstrate that IL6 and TNF respond differently to monensin 
suggesting that IL6 is highly dependent on the generation of an intracellular 
Na+ and H+ gradient, which facilitates the final stages of secretory vesicle 
maturation from Golgi apparatus175. TNF release was unaltered in the 
presence of monensin and therefore is not dependent on the intracellular 
Na+ and H+ gradient. IL6 and TNF secretion were reduced in the presence 
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of NH4Cl and brefeldin A demonstrating a shared requirement for ER to 
Golgi transport and acidification of intracellular organelles. Finally, 
inhibition of the vacuolar-type H+-ATPase and autophagosome-lysosome 
fusion elevated both IL6 and TNF. This demonstrates that an active 
autophagy pathway may have a regulatory role in IL6 and to a lesser extent 
TNF secretion. None of the inhibitors replicated the cytokine secretion 
response of NaB suggesting that it is acting via a different mechanism. 
 
3.11 Differences in IL6 and TNF cytokine levels resulting from NaB 
exposure are a consequence of altered synthesis rather than 
secretion 
 Brefeldin A is a potent inhibitor of IL6 and TNF secretion in THP-1 
cells since it blocks the vesicle formation and fusion involved in ER to Golgi 
transport175. The total amount of IL6 and TNF synthesised upon HkEc ± 
NaB stimulation can be determined by the inclusion of brefeldin A, which 
trapping the cytokines inside the ER and builds up the intracellular levels.  
 THP-1 cells were stimulated with HkEc in the presence of either 
NaB, brefeldin A or a combination of both. In this experiment, cells were 
stimulated for 6, 12 and 24 hours and the supernatant collected, the cell 
pellet washed and lysed in RIPA buffer, and extracellular (supernatant) and 
intracellular (cell lysate) cytokines measured by ELISA. When brefeldin A 
was used, it aimed to trap the cytokines for specific periods of time, always 
starting from the previous time point. For instance, when samples were 
collected at 6 hours, brefeldin A was added at time 0 with HkEc. Samples 
collected at 12 hours, were stimulated with HkEc at time 0 and the cells 
were kept without brefeldin A for 6 hours, allowing the normal cytokine 
secretion until brefeldin A was added to the culture medium. Similarly, 
samples that were collected at 24 hours had HkEc added at time 0 and 
were kept without brefeldin A for 12 hours. At 12 hours initial stimulation 
with HkEc, brefeldin A was added to the culture medium (Figure 3-23). 
 This approach permitted the investigation of cytokine synthesis and 
secretion for the periods of 0-6, 6-12 and 12-24 hours. Figure 3-23 
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summarizes the experiment design and the results are shown in figures 3-
24 to 3-26. 
 
Figure 3-23: Experiment design to investigate the cytokine synthesis and 
secretion over specified time periods in unstimulated and HkEc stimulated 
THP-1 cells ± NaB. Brefeldin A (BrefA) was used to trap cytokines 
intracellularly. This experiment was performed in parallel with samples 
without addition of brefeldin A. 
 
 
Figure 3-24: IL6 (A) and TNF (B) levels were measured by ELISA in HkEc 
stimulated THP-1 cells ± NaB in the supernatant and whole protein lysates, 
for the secreted and intracellular levels, respectively. The intracellular 
levels of both IL6 and TNF remained constant, suggesting that the 
cytokines produced are released or degraded as quickly as they are 
synthesised without accumulating intracellularly and NaB had no obvious 
effect on intracellular trafficking. IL6 is mainly released after 12 hours (A), 
while almost all the TNF was produced and released during the first 6 hours 
(B). In HkEc samples only, TNF decreases after 6 hours, while upon 
exposure to NaB, it showed an increase after 12 hours, suggesting a 
second peak in TNF induction. Results shown are mean ± SEM, *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001; for comparisons between the same 
time point (two-tailed, unpaired t-test). Black asterisks, intracellular levels; 
red asterisks, secreted levels. 
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Figure 3-25: IL6 (A) and TNF (B) levels were measured by ELISA in HkEc 
stimulated THP-1 cells ± brefeldin A. The supernatant and whole protein 
lysates were quantified for the secreted and intracellular levels, 
respectively. By using brefeldin A and trapping the cytokines inside the cell, 
it is possible to understand their dynamics. IL6 started to be synthesised 
between 6 and 12 hours and showed a massive increase between 12 and 
24 hours. On the other hand, all TNF was produced and secreted within 
the first 6 hours. Addition of brefeldin A at later time points had limited effect 
on the secretion and intracellular levels of TNF. Black asterisks, 
intracellular levels; red asterisks, secreted levels. 
 
Brefeldin A effectively blocked the secretion of both cytokines when 
the cells were exposed to it. The stacked bar graph shows secreted levels 
of HkEc in top blue bars, secreted levels of HkEc + brefeldin A in top blue 
and white bars, and the intracellular levels of both groups in black bottom 
bars. 
 
Figure 3-26: IL6 (A) and TNF (B) levels were measured by ELISA, in HkEc 
stimulated THP-1 cells exposed to brefeldin A ± NaB. The supernatant and 
whole protein lysates were quantified for the secreted and intracellular 
levels, respectively. NaB exposure led to an impaired synthesis of IL6, 
which is subsequently observed as reduced secretion of this cytokines (see 
figure 3-24). Conversely, TNF was synthesized in higher amount upon 
exposure to NaB (B, 6 hours) and resulted in higher secretion levels when 
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compared to HkEc alone (B, 12 and 24 hours). Results shown are mean ± 
SEM, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001; for comparisons 
between the same time point (two-tailed, unpaired t-test). Black asterisks, 
intracellular levels; red asterisks, secreted levels. 
 
 Through the use of brefeldin A it has been shown that IL6 and TNF 
are synthesised and secreted at a similar rate and at any given time there 
is only a limited amount of intracellular cytokines. NaB does not seem to 
alter this cellular transit and seems to be acting almost exclusively at the 
level of transcription and translation.  
 
3.12 NaB and pH changes 
 External pH can influence the intracellular pH177, and thus hinder the 
cytokine trafficking and release174. To investigate if NaB would be acting 
by simply changing the concentration of protons, the pH of the THP-1 
medium was directly measured with a calibrated pH meter under different 
conditions (Figure 3-27). 
 
Figure 3-27: pH measurements of NaB solutions. The pH was measured 
in 1 M solution and 5 mM NaB in RPMI enriched medium (A). 1 M NaB 
aqueous solution was slightly alkaline. The pH of the complete RPMI 
medium was 7.44 and did not change after addition of 5 mM NaB. THP-1 
cells were stimulated with HkEc ± NaB and the pH measured over 3 days. 
The pH continuously dropped in the NaB-free medium after the first 24 
hours, while in 5 mM NaB, the pH seemed to be more stable and a 
reduction was observed after 48 hours stimulation. Results shown are of a 
single measure. The results of a single experiment are limited to establish 
a proper cause-effect of the experimental conditions. 
 
 
 Addition of 5mM NaB to RPMI complete medium was buffered in 
solution resulting in no change to the pH. The inclusion of stimulated THP-
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1 cells in RPMI ± 5 mM NaB demonstrated that the NaB reduced the 
acidification of the media over time. This demonstrated that NaB may be 
acting as a buffer during stimulation or because it affects the immune 
response activity of the THP-1 cells, resulting in a reduced acidification of 
the extracellular medium. Confocal microscopy was used to measure the 
intracellular pH using SNARF®, a fluorescent dye that changes the colour 
according to pH. No changes in cytoplasmic pH were observed due to NaB 
exposure (Figure 3-28). 
 
Figure 3-28: Confocal microscopy image of THP-1 cells stimulated with 
HkEc for 1 hour ± NaB using SNARF®. There was no major difference 
between HkEc stimulation (A) and NaB exposure (B). Comparable results 
were observed in untreated and NaB exposed THP-1 cells when compared 
to any condition (data not shown). pH colour scale on the right. 
 
 Taken together, these results suggest that NaB may have a different 
mechanism of action rather than simply altering cytosolic pH in THP-1 cells. 
 
3.13 Deregulated cytokine secretion caused by NaB treatment may 
interfere with the whole innate immune response 
An orchestrated early immune response is required for an adequate 
bacterial clearance and may prevent the development of chronic 
inflammation. Defective production of pro- and anti-inflammatory cytokines 
can have a profound effect on human health and is known to contribute to 
the pathogenesis of CD 174,178. The release of the pro-inflammatory 
cytokines IL6 and TNF demonstrate a strong positive linear correlation in 
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monocyte-derived macrophages (MDM) from healthy individuals and this 
correlation was shown to be significantly perturbed in MDM from patients 
with CD (Figure 3-29A)178. 
NaB exposure was found to reduce IL6 and increase the TNF levels 
in THP-1 cells stimulated with HkEc, which caused a major disruption in 
the expected correlation between these two cytokines (Figure 3-29B). 
 
Figure 3-29: The positive linear correlation between IL6 and TNF is 
disturbed by NaB exposure. The Linear correlation between cytokines 
release in MDM stimulated with HkEc (A). NaB-treated HkEc-stimulated 
THP-1 cells showed reduced IL6 and increased TNF levels when 
compared to HkEc alone. Regression lines are different in HkEc compared 
to HkEc plus NaB. Results shown in B used simple linear regression 
analysis and ANCOVA for 10 individual experiments, *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001, (ANCOVA). Image A adapted from Smith et. al. 
(2014)178. 
 
In view of the different dynamics in cytokine production and 
secretion, the relationship between IL6 and TNF, I hypothesized that NaB 
would act in 3 distinct phases (signals). The first signal, downstream of TLR 
activation and responsible for the early TNF induction. The second signal 
comes from the formation of intracellular ROS in combination with an 
autocrine/paracrine TNF signal via TNF-receptors. This signal would play 
a key role in IL6 and IL1β induction. Finally, the third signal originated from 
the autocrine/paracrine IL6 secretion and activation of the JAK/STAT3 
signalling pathway which regulates TNF secretion (Figure 3-30). The 
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following chapters will deal with understanding these signalling events and 
how NaB alters them. 
  
 
Figure 3-30: Relationship between IL6 and TNF dynamics and possible 
mechanisms underlying NaB disruption of cytokine secretion. THP-1 cells 
stimulated with HkEc would undergo three distinct signals that would 
influence the immune response. These signals would contribute to cytokine 
induction and regulation (A). Signal 1 originated downstream TLR 
activation, signal 2 comes from intracellular ROS formation and 
autocrine/paracrine TNF stimulation, and a third signal originates from IL6 
binding to its receptor IL6R and activating the JAK/STAT3 pathway. THP-
1 cells were stimulated with HkEc ± NaB for a total period of 72 hours. The 
third signal starts with the secretion of IL6 and controls the secretion of 
TNF. Because NaB treatment reduces IL6, the third signal is impaired, 
resulting in an elevation in the secretion of TNF. Filled circles and 
continuous line shows levels of TNF. Empty diamonds and dashed lines, 
IL6 levels.  
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3.14 Discussion 
In this chapter, the main effects of NaB on the immune response were 
investigated. NaB exposure deregulated the cytokine response at mRNA 
and protein levels in THP-1 cells stimulated with heat-killed bacteria or TLR 
ligands, despite a similar initial signal downstream of TLR activation. To 
date, our literature search suggests we have conducted the first 
transcriptomics analysis upon NaB exposure, which showed that NaB 
regulated 1% of probes upon heat-killed bacterial stimulation. 
NaB was found to have a toxic effect on THP-1 cells in a dose- and 
time-dependent manner, with a concentration of 5 mM being well tolerated 
by these cells, even after 15 days of exposure, which includes 
approximately 7 cell-cycles. The FDA approved concentration of NaB in 
foods is 0.01% of total weight, which is around 7 mM. However, it is difficult 
to know how it would affect the human body: it could conceivably work 
locally on the mucosal surfaces of the gastrointestinal tract, or systemically 
after absorption and distribution around the body. Most of the NaB ingested 
is metabolized in the mitochondrial matrix within the liver and kidney to 
hippuric acid and secreted in the urine103,105. Nevertheless, it is currently 
impossible to say how it is distributed to the diverse tissues in the body. In 
any case, from absorption to metabolism, NaB will be distributed through 
the bloodstream and will be available to circulating monocytes. 
 The gene expression profile showed that NaB affects many genes 
related to the TLR signalling and cytokine-cytokine receptors pathways 
after bacterial stimulation. Upon HkEc stimulation and NaB exposure, there 
was an attenuation of the overall response due to partial activation or 
deactivation of genes related to innate immunity compared to HkEc 
stimulation only. Furthermore, this effect targeted specific genes rather 
than the whole cell immune response, which suggests that NaB is a 
selective modulator of the immune response. 
Another important finding was that NaB exposure required metabolic 
adaptations of the cell. Changes in gene expression of amino acid 
synthesis, especially involving glycine biosynthesis, suggest that the NaB 
uptaken results in its conversion to hippuric acid as previously shown to 
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occur in the liver and kidney103,105. This detoxification/clearance of NaB 
requires a metabolic adjustment within the THP-1 cells, which could 
account for the toxicity of this compound. The toxic levels may in part 
correspond with the cells ability to up-regulate the glycine biosynthesis 
pathway. If this is the case, then the sensitivity to NaB may differ depending 
on the cell type. The role of NaB metabolism will be better investigated in 
Chapter 7. 
NaB exposure caused a profound change in IL6 and IL1β induction 
and secretion, significantly reducing the expression of these cytokines. A 
few studies that investigated the effects of NaB in cell types, such as 
mouse microglia, astroglia, splenocytes, and primary human astrocytes, 
have shown a similar reduction in IL6 and IL1β14169. To date, all reports 
have shown an inhibitory effect of these two cytokines, suggesting that NaB 
might involve a similar inhibitory mechanism that is independent of the cell 
type or stimulant. 
 While these inflammatory cytokines are important to initiate an 
adequate immune response and control bacterial infection179180181, 
deregulation of cytokine secretion from the normal physiology is 
fundamental in diseases associated with chronic inflammation, such as in 
NDDs92,182. IL6 and IL1β play a pivotal role in neuroinflammation, which is 
underlying the pathogenesis of many NDDs182,183,184, and the ability of NaB 
to reach the CNS after crossing the blood-brain barrier6 suggest that it may 
be beneficial in controlling neuroinflammation. Despite any side effect 
associated with NaB ingestion, this versatility of NaB in attenuating IL6 
levels in multiple cell types is potentially useful for many diseases 
associated with chronic inflammation, such as atherosclerosis185, cancer, 
diabetes, and rheumatoid arthritis186. 
On the other hand, we found increased levels of TNF at a 
concentration of 5 mM NaB, while the previous reports have found a 
reduced level of TNF upon LPS stimulation in mouse microglia (1 mM NaB) 
and astrocytes (≈7 mM NaB)1,169. In THP-1 cells, TNF hypersecretion was 
dose-dependent and observed at concentrations of 5 and 10 mM, 
concentrations below 5 mM were unable to increase TNF secretion. The 
regulation of TNF by NaB will be further investigated in Chapter 5. 
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The alterations in cytokines seemed to be associated with their 
induction since their intracellular trafficking and secretion seemed to be 
unaffected by NaB. Our results showed that there was no accumulation of 
IL6 and TNF intracellularly and almost all the synthesized proteins were 
secreted. If any degradation occurs, it is not affected by NaB. It is important 
to mention that NaB alone, without any bacterial or TLR ligand stimulation, 
did not induce any inflammatory response, all the effects observed in 
cytokine release were found after TLR/bacterial stimulation. 
In THP-1 cells, the changes in cytokines secretion should be seen 
not only in isolation but as a major disruption of the innate immune 
response. There is a positive correlation between IL6 and TNF, which is 
found in primary MDM178 and also observed in THP-1 cells, which was 
disturbed by NaB exposure (Figure 3-29). Disruption of inflammatory 
signals is associated with disease status and severity in conditions 
characterized by chronic inflammation178,187,188. Dysregulation of cytokine 
release may be behind some of the negative effects observed on NaB 
consumption in patients with OFG. This condition will be analysed in more 
detail in Chapter 8. 
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Chapter 4 Effects of NaB on the THP-1 cell 
immune response (Signal 2) 
4.1 Introduction 
 NaB exposure caused an altered innate immune response because 
of a deregulated secretion of pro-inflammatory cytokines in human 
monocytes, as demonstrated in chapter 3. A reduced secretion of IL6 and 
IL1β has been shown in other cells rather than monocytes, such as 
microglia1,4 and splenocytes169. However, the mechanism by how NaB 
affects the immune response is unknown. 
 In the previous chapter, it has been shown that the altered cytokine 
secretion is mainly because of their synthesis and not due to any major 
impairment in intracellular trafficking or a deficiency in the secretory 
mechanism. There was also no abnormality in the early signals 
downstream of TLR activation, generating a hypothesis that a second 
signal would be responsible for a boost in IL6 and IL1β that is reduced or 
lacking due to NaB exposure.  
 TNF has been shown to induce the secretion of pro-inflammatory 
cytokines IL6 and IL1β through MAPK signalling pathway189,190,191, mainly 
via TNFR1192. In breast cancer cells expressing a dominant negative form 
of the ERK1, TNF-induced IL6 production was blunt, suggesting that TNF 
induction of IL6 is mediated via ERK1 activation191. 
ROS have an established role in inflammation and are 
predominately produced from mitochondrial respiration145,147 and NADPH 
oxidase in professional phagocytic cells such as neutrophils and 
macrophages149,193. ROS generated downstream TLR activation lead to 
pro-inflammatory cytokine production194 especially IL6 upon LPS 
stimulation195. 
In this chapter, the mechanisms underlying NaB inhibition of 
cytokine synthesis were investigated, with a focus on ROS generation and 
TNF receptor signalling.  
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4.2 NaB acts as a free radical scavenger and impairs IL6 production 
by neutralization of ROS 
4.2.1 Characterization of ROS induction 
 ROS function as mediators in many cell-signalling pathways under 
normal conditions. However, harmful stimuli such as those generated by 
microbial antigen significantly induce the generation of ROS which, causes 
the level to exceed body's antioxidant defence system196. HkEc-induced 
ROS was investigated by evaluating the expression of proteins associated 
with ROS using western blot (Figure 4-1). 
 ROS are critical components of the antimicrobial repertoire of 
macrophages. Macrophages, as professional phagocytes, generate ROS 
using the NADPH oxidase complex during the respiratory burst. Here we 
show that the P67phox (NCF2 gene), one of the subunits of the NADPH 
oxidase complex is overexpressed upon HkEc stimulation. Under oxidative 
stress, there is an increase in ROS that the cell tries to compensate. The 
mitochondrial uncoupling proteins (UCP) 1–3 are mitochondrial anion 
carrier proteins that are overexpressed to minimize ROS emission from the 
electron transport chain. ROS or their by-products are thought to activate 
UCP proteins to induce proton leak, thus providing a negative feedback 
loop for mitochondrial ROS production197,198. The UCP2 has been found to 
be activated by ROS197. 
 Signals generated by ROS can activate the apoptosis signal-
regulating kinase (ASK1), through oligomerization and, 
autophosphorylation198. ASK1 is one of the mechanisms responsible for 
the activation of the MAPK signalling pathway146,199. 
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Figure 4-1: Immunoblots showing the expression of ROS-associated 
proteins in THP-1 cells stimulated with HkEc. Upon bacterial challenge, 
there was an increase in the phosphorylation of ASK1 and increased 
expression of P67phox. At 30 minutes of stimulation, there was an increase 
in the expression of the UCP2, suggesting an attempt of the cells to 
compensate the extra ROS produced. Protein quantification for pASK1 (B), 
P67phox (C), and UCP2 (D). iNOS expression was not identified in any of 
the immunoblots performed (Data not shown). Vinculin was used as a 
loading control. 
 
4.2.2 ROS formation and effects of NaB 
 To investigate the competence of NaB to act as a radical scavenger 
and thus, neutralize the ROS generated by bacterial stimulation, two 
assays were used: the Amplex® Red, which indirectly measures the 
superoxide/peroxidase activity by reacting with hydrogen peroxide 
released by the cell; and the Cellular ROS/Superoxide assay, which has 
two dyes that reacts selectively with ROS (green dye) and specifically with 
superoxide (red dye). These two assays test different aspects of ROS 
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activation, while the Amplex® Red uses an impermeable dye and only 
reacts with extracellular H2O2, the Cellular ROS/Superoxide assay uses 
two cell permeable dyes, which allows the formation of intracellular 
ROS/superoxide to be determined. By combining these two assays, it was 
possible to understand the mechanism underlying ROS moderation by 
NaB. 
 Activation of macrophages by pathogens leads to the generation of 
ROS in a process called respiratory burst. In this process, there is a marked 
increase in non-mitochondrial oxygen consumption and generation of 
superoxide (0-) by the NADPH-oxidase complex200. Superoxides are very 
unstable molecules and are quickly dismutated by enzymatic and 
nonenzymatic reactions, resulting in oxygen-derived species such as H202 
(see Figure 1-19). Thus, monitoring the release of H202 is an established 
method to evaluate the respiratory burst201. 
THP-1 cells were stimulated with either phorbol 12-myristate 13-
acetate (PMA), an activator of NADPH oxidase, or HkEc ± NaB and the 
generation of extracellular H202 measured using Amplex® Red (Figure 4-
2). 
 
Figure 4-2: H2O2 production by THP-1 cells stimulated with PMA (A) or 
HkEc (B) ± NaB. NaB exposure reduced the levels H2O2 upon stimulation 
with PMA (A). Upon HkEc stimulation, there was an increase in H2O2 
production, which is neutralized when NaB was in the culture medium. 
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Cells pre-incubated with NaB were washed 2X with PBS and assayed 
without the presence of NaB (± NaB). By doing it, the decomposing effect 
of NaB was abolished, which suggests that NaB reacts with H2O2.  Results 
shown are mean ± SEM of 4 (A) and 2 (B) independent experiments, 
*p<0.05, **p<0.01, ***p<0.001, and ****p<0.0001 (two-tailed, unpaired t-
test; one-way ANOVA with Dunnett’s test) 
 
 To investigate the specific production of ROS and superoxide, the 
ROS/Superoxide assay was used. The ROS dye can react mainly with 
H2O2 and HO- and is permeable to the cell membrane, reacting with the 
intracellular and extracellular ROS (Figure 4-3). 
 
Figure 4-3: ROS and superoxide production was investigated in THP-1 
cells stimulated or not with HkEc ± NaB. Upon stimulation, there was a 
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significant increase in superoxide and ROS production. NaB exposure 
neutralized the burst in superoxide production (A) and decreased the levels 
of ROS below than recorded in unstimulated cells (B). NaB strongly 
reduced the levels of ROS in stimulated and unstimulated cells. Cells pre-
incubated with NaB were washed 2X with PBS and assayed without the 
presence of NaB (± NaB). This experiment aimed to exclude the effects of 
the NaB from the medium and determine the role of the intracellular NaB 
previously uptaken by the cell on ROS levels (C). Removal of NaB from 
the medium had minimal effect on the ability of intracellular NaB to restrict 
the levels of HkEc-induced ROS production. Results shown are mean ± 
SEM of 4 (A and B) and 2 (C) independent experiments and analysed using 
one-way ANOVA with Tukey’s test (A and B) and Dunnett’s test (C). In C, 
the basal level of ROS was established based on the control group of 
unstimulated cells (*p<0.05, **p<0.01, ***p<0.001, and ****p<0.0001). 
  
 To test the scavenging capability of NaB, THP-1 cells were 
stimulated with HkEc and ROS production was monitored using the 
ROS/superoxide assay. At 1 hour of stimulation, the experiment was 
paused and several concentrations (0-40 mM) of NaB were added to the 
cells and the ROS production was monitored for an extra hour (Figure 4-
4). 
 
Figure 4-4: ROS scavenging activity of NaB is dose-dependent and occurs 
almost immediately of NaB addition. THP-1 cells were stimulated for 1 hour 
with HkEc and the ROS production was monitored. At 1 hour, the 
experiment was paused and concentrations from 0-40 mM of NaB were 
added (black arrow) and ROS production was monitored for an extra hour. 
Concentration from 1.25 mM and above showed significant ROS 
scavenging activity of NaB in a dose-dependent manner. At 40 mM NaB, 
almost all the ROS generated was decomposed. Results shown are mean 
± SEM of 3 independent experiments and analysed using one-way ANOVA 
with Dunnett’s test, (*p<0.05, **p<0.01, ***p<0.001, and ****p<0.0001). 
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Next, a range of antioxidants was used to determine their effects on 
cytokine secretion. NAC, a prodrug to L-cysteine that is a precursor to the 
biologic antioxidant glutathione; 2,2,6,6-tetramethylpiperidine-N-oxyl 
(TEMPO), an intracellular scavenger of superoxide anion39; and curcumin,  
a phenolic compound naturally found in some plants and known for its 
H2O2, HO-, ROO-, O2- scavenging activity202,203 (Figure 4-5). 
 
Figure 4-5: THP-1 cells were incubated with either NaB and known 
antioxidants NAC, TEMPO and curcumin, and stimulated with HkEc. The 
cytokine levels of TNF, IL6 and IL1β were measured by ELISA (A-C). The 
H2O2 production was measured using the same antioxidants. NaB and the 
antioxidants NAC and TEMPO induced a hypersecretion of TNF (A). 
However, only NaB and TEMPO showed a reduction of IL6 and IL1 β (B 
and C). Similarly, only these two compounds showed an effective 
scavenging activity and reduced H2O2 production (D). Results shown are 
mean ± SEM of 9 (A and B), 4 (C) and 1 (D) independent experiments, 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, (one-way ANOVA with 
Dunnett’s test, HkEc as control group). 
 
 In the results shown in Figure 4-5, only the antioxidants NaB and 
TEMPO that effectively reduced the H2O2 production were capable of 
reducing the secretion of IL6 and IL1 β. It suggests a correlation between 
H2O2 production and IL6 and IL1 β release.  
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 Taken together, these results suggest that ROS is required for 
maximal induction of IL6 and IL1β upon immune stimulation. Effective 
inhibition of HkEc-induced superoxide/ROS generation causes a reduction 
in IL6 and IL1β secretion. On the other hand, NAC and TEMPO treatment 
resulted in a hypersecretion of TNF, but the mechanisms behind this 
response are not clear. 
To examine if the reduced levels of ROS found in NaB treated 
samples were caused by any deficiency of the NADPH oxidase complex 
or if it could potentiate the expression of antioxidant enzymes, the 
expression of genes associated with key elements of this system was 
carried out (Figure 4-6). 
 
Figure 4-6: mRNA Expression analysis of ROS associated genes in THP-
1 cells stimulated with HkEc ± NaB for 24 hours evaluated by qRT-PCR. 
The expression of cytochrome b genes (CYBA and CYBB) and the 
antioxidant enzymes SOD1, SOD2 and catalase were similar. Results 
shown are mean ± SEM for 3 independent experiments, *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001; (two-tailed, unpaired t-test). 
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4.3 TNF induces IL6 production, but it is similarly affected by NaB 
exposure 
 Experiments were designed to investigate the role TNF plays in IL6 
induction using recombinant TNF (rTNF) and neutralizing antibodies.  
THP-1 cells were stimulated with either HkEc, LPS, rTNF or a 
combination of these ± NaB. HUMIRA® (adalimumab), an anti-TNF 
therapeutic drug used for several inflammatory conditions (e.g. rheumatoid 
arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, 
ankylosing spondylitis, CD), is a recombinant human IgG1 monoclonal 
antibody that binds to TNF, preventing it from binding to and activating TNF 
receptors204. Recombinant TNF induced IL6 secretion in the absence of 
TLR stimulation (Figure 4-7A). THP-1 cells stimulated with HkEc in the 
presence of HUMIRA® for 24 hours, demonstrated the efficiency of this 
monoclonal antibody to bind and block TNF (Figure 4-7B). The effects on 
IL6 secretion resulting from TNF were tested in THP-1 cells stimulated with 
LPS for 24 hours (Figure 4-7C). 
TNF is a major inducer of IL6 downstream of LPS stimulation and 
blocking TNF results in a substantial reduction in IL6 release. The 
stimulation of THP-1 cells with rTNF and NaB resulted in more than 2-folds 
increase, while blocking TNF abrogated IL6 secretion, therefore 
demonstrating that TNF signalling is a major inducer of IL6 upon LPS 
stimulation (Figure 4-7D). 
The effects on IL6 levels resulting from TNF were tested in THP-1 
cells stimulated or not with HkEc ± NaB for 24 hours (Figure 4-8). The 
influence of TNF on IL6 secretion downstream of HkEc was still observed 
but was not as dramatic as seen with LPS. There was no secretion of IL6 
when rTNF was added in combination with NaB. TNF-induced ROS 
generation was reduced by NaB exposure (Figure 4-9). 
 
136 
 
 
Figure 4-7: The effects on IL6 secretion upon TNF manipulation. THP-1 
cells were stimulated with TNF (A), HkEc plus an anti-TNF antibody (B), 
LPS in combination with rTNF and anti-TNF (C and D), and in the presence 
of NaB (D). The levels of IL6 (A, C and D) and TNF (B) were measured by 
ELISA. Results shown are mean ± SEM of 2 independent experiments, 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, (two-tailed, unpaired t-test). 
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Figure 4-8: THP-1 cells were stimulated with HkEc ± NaB for 24 hours with 
either TNF or anti-TNF antibody, and the levels of IL6 were measured by 
ELISA. TNF induction of IL6 was completely inhibited by NaB. Addition of 
TNF to HkEc stimulated cells even reduced the levels of IL6, regardless of 
NaB treatment. However, neutralization of TNF reduced the secretion of 
IL6. Results shown are mean ± SEM and analysed using one-way ANOVA 
with Tukey’s test (B). In B, statistical analysis was applied separately 
depending on NaB exposure (*p<0.05, **p<0.01, ***p<0.001, and 
****p<0.0001). 
 
Figure 4-9: ROS production in THP-1 cells stimulated with recombinant 
TNF and measured by ROS/Superoxide assay. TNF generates ROS that 
is partially neutralized by NaB. Results shown are mean ± SEM of 2 
independent experiments, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, 
(two-tailed, unpaired t-test). 
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These results suggest that TNF plays a role in the IL6 production, 
which is clearly observed when the cells were stimulated with LPS. TNF 
induction of IL6 seemed to be related to the generation of ROS, which is 
neutralized by NaB (Figure 4-9). HkEc stimulation already induces very 
high levels of TNF (8 times more than LPS), that is the probable reason 
why no additional effect was observed by the supplementary TNF. 
 
4.3.1 ROS reduction induced by NaB attenuates the oxidative 
stress response signalling pathway KEAP1 -NRF2  
 The Kelch-like ECH-associated protein 1 (KEAP1 )-nuclear factor 
(erythroid-derived 2)-like 2 (NRF2) regulatory pathway plays a central role 
in the protection of cells against oxidative stress. Under normal conditions, 
NRF2 is bound to the endogenous inhibitor KEAP1  that facilitates the 
ubiquitination and proteasomal degradation of NRF2205,206. Under oxidative 
stress, modifications in cysteine residues of KEAP1  (e.g. via oxidation of 
sulfhydryl groups or phosphorylation) apparently weakens the interaction 
with NRF2, and NRF2 can no longer be ubiquitylated and degraded. This 
saturates KEAP1  and allows the newly-synthesized NRF2 to accumulate 
and translocate to the nucleus205.  In the nucleus, NRF2 forms 
heterodimers with other transcription factors such as c-Jun and small Maf 
proteins (G/F/K), binds to the antioxidant response element (ARE) and 
regulates the expression of more than 200 genes involved in cellular 
antioxidant defence207 (Figure 4-10). 
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Figure 4-10: KEAP1 -NRF2 regulatory system. Under normal condition, 
KEAP1  is bound to NRF2 and facilitates NRF2 ubiquitination and 
proteasome degradation. Oxidative stress causes conformation changes 
that inhibits polyubiquitylation of NRF2, that accumulates and saturates 
KEAP1 . Newly synthesized NRF2, can translocate to the nucleus and 
activate the antioxidant response elements. (Image was taken from 
http://multiple-sclerosis-research.blogspot.com/2015/06/tecfidera-and-
nrf2.html, accessed on 16/11/2017) 
 
 To investigate the effects of reduced ROS in consequence of NaB 
exposure, subcellular protein fractions were prepared to analyse the 
expression of nuclear and cytoplasmic expression of the KEAP1 -NRF2 
signalling pathway (Figure 4-11).  
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Figure 4-11: Immunoblot showing the protein expression of the cellular 
fractions: cytoplasmic (A, top) and nuclear (A, bottom) of THP-1 cells 
stimulated with HkEc ± NaB. 10 μM of the MG132, a proteasome inhibitor, 
was used 1-hour prior stimulation. Cellular fractions were prepared using 
differential centrifugation steps (see section 2.8.1.2). Quantification is 
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shown in B-D. qRT-PCR mRNA expression of KEAP1  and NRF2 in THP-
1 cells stimulated with HkEc ± NaB for 24 hours (E). Protein expression of 
the KEAP1 /NRF2 complex in the cytoplasmic fraction is maintained 
relatively stable over time (A, top). HkEc stimulation NRF2 total expression 
(D) and nuclear translocation (B) to initiate transcription of antioxidant 
responsive elements (ARE). This NRF2 nuclear translocation is attenuated 
on NaB treatment. Expression of phosphor-C-JUN in the nucleus was also 
attenuated in NaB samples. At 6 hours, the expression level of nuclear 
NRF2 and p-C-JUN is significantly weaker on NaB exposure (C). Gene 
expression levels of NRF2 increased more than 20 times (compared to 
untreated control, not shown) the presence of HkEc after 24 hours, but NaB 
had no effect on message levels (E). Loading controls for the cytoplasmic 
and nuclear fractions used were vinculin and lamin B1, respectively. 
Results shown are mean ± SEM of 3 independent experiments, *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001, (two-tailed, unpaired t-test). 
 
Immunoblots of nuclear and cytoplasmic fractions showed an 
attenuated NRF2 nuclear expression upon NaB exposure, whereas there 
was no difference in the cytoplasmic expression of KEAP1 and similar 
mRNA levels of both proteins, NRF2 and KEAP1. NRF2 is the main protein 
responsible for an antioxidant response, activating several genes related 
to antioxidant defence207. These results suggest that, by buffering ROS, 
NaB reduces the need for a robust antioxidant response, resulted in  the 
reduced levels of NRF2 in the nucleus and higher nuclear expression of c-
JUN, a downstream target of NRF2 activation.  
Activation of NRF2 regulates the expression of numerous 
cytoprotective genes, including antioxidants. Genes involved in the 
synthesis and regeneration of glutathione, detoxifying molecules, 
regulators of transcription factors and growth factors. Heme oxygenase 1 
(HMOX1) is one of those proteins regulated by NRF2 and degrades heme, 
generating biliverdin and CO208. HMOX1 expression appeared to be lower 
on exposure to NaB (Figure 4-12). 
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Figure 4-12: Immunoblot showing the protein expression HMOX1 and 
Catalase after an extended period of THP-1 cells stimulation with HkEc ± 
NaB. HMOX1 is one of the main antioxidant proteins induced by NRF2 
activation. HMOX1 expression appears to be reduced in all NaB treated 
samples irrespective of stimulation. However, catalase (CAT), a well-
expressed protein that participates in degradation of hydrogen peroxide, 
was similarly expressed in both samples. Results shown are for 1 
experiment. 
 
4.3.2 Effects of ERK1/2 signalling pathway on cytokine secretion  
There is a strong link between ROS generation and the MAPK 
ERK1/2 since it participates in the ROS signalling cascade inducing 
cytokines synthesis193, and increasing NRF2 protein expression206. Signals 
generated by ROS through the MAPK pathway, activate the transcription 
factor AP1. C-JUN is one of the subunits that form the AP1 complex, and 
upon its phosphorylation, C-JUN translocates to the nucleus to initiate 
transcription. Phospho-C-JUN was found overexpressed in the nucleus at 
6 hours in HkEc stimulated cells compared to HkEc + NaB (Figure 4-11). 
A rise in the intracellular production of ROS, dependent or not of the 
NADPH oxidase machinery, results in activation of the ERK1/2 pathway149.  
To investigate the participation of the ERK pathway, downstream of 
HkEc exposure and IL6 secretion, PD98059 was used. PD98059 is a 
potent and selective inhibitor of MAP kinase kinases (MAPKK), MEK1 and 
MEK2. By adding PD98059 to THP-1 cells there was an abolishment of 
ERK1/2 phosphorylation and strongly reduced phosphorylation of its 
downstream transcription factors C-JUN and C-FOS (Figure 4-13). 
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Figure 4-13: Immunoblots showing the phosphorylation of ERK1/2 and the 
AP1 transcription factor subunits C-JUN and C-FOS in HkEc ± 
PD98059.PD98059 abolished ERK1/2 phosphorylation and reduced the 
phosphorylation of C-JUN and C-FOS. This shows that PD98059 is a 
potent inhibitor ERK1/2 and, therefore, reduces the phosphorylation of 
downstream proteins. α-tubulin was used as a loading control. Results 
shown are for 1 experiment. α-Tubulin was used as a loading control. 
  
An experiment was designed to identify the temporal effect of p-
ERK1/2 using PD98059 in cytokines secretion. PD98059 was added to the 
cells at two specific time points during HkEc stimulation: the first, 30 
minutes prior to HkEc stimulation in order to block ERK1/2 signalling at the 
beginning of the bacterial stimulation. The second, 4 hours after HkEc 
stimulation, allowing the initial signalling downstream of TLR activation and 
aimed to investigate if ERK1/2 would be activated later by a second signal. 
The total stimulation period was 24 hours for all samples (Figure 4-14).  
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Figure 4-14: THP-1 cells were treated with ERK1/2 inhibitor PD98059, 30 
minutes prior bacterial stimulation (+) or 4 hours after HkEc stimulation (±), 
in the presence or absence of NaB. The cytokine levels of TNF, IL6 and 
IL1β were measured by ELISA. PD98059 reduced the levels of TNF when 
added prior stimulation, but had no effect when it was added after 4 hours 
regardless NaB treatment (A). However, the levels of IL6 and IL1 β were 
similarly reduced regardless the time when PD98059 was added. Results 
shown are mean ± SEM of 3 independent experiments for comparisons 
between groups ± NaB, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, (one-
way ANOVA with Tukey’s test). 
 These results showed that ERK1/2 signalling is important to TNF, 
IL6 and IL1β but with important temporal differences. While TNF induction 
requires ERK1/2 signalling during the first 4 hours, for IL6 and IL1β 
secretion it is important at later stages, since inhibition of ERK1/2 signalling 
by PD98059 had a similar effect if applied prior or 4 hours after bacterial 
stimulation. 
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4.4 Discussion 
In this chapter, the mechanism underlying NaB inhibition of IL6 and 
IL1β was revealed. NaB acts as intra and extracellular free radical 
scavenger neutralizing ROS induced by immune activation. NaB can react 
with hydrogen peroxide and other intermediate by-products of oxidative 
stress. We demonstrated that ROS is generated in THP-1 cells upon TLR 
and TNF signalling and NaB reacts with and sequesters ROS, resulting in 
a diminished induction of IL6 and IL1β. IL8 and IP10 were not affected by 
NaB upon HkEc stimulation, suggesting these cytokines are less reliant on 
ROS signalling and use alternative activation pathways. 
ROS are important signalling molecules in inflammation145,147 and are 
generated by aerobic respiration in response to harmful stimuli196. ROS are 
constantly generated under aerobic conditions and their levels are 
controlled by the body's antioxidant defence system196. Upon HkEc 
stimulation, there is an increase in non-mitochondrial oxygen consumption 
(respiratory burst) through the NADPH oxidase complex200, which is 
necessary for the digestion and clearance of intracellular microbes by 
macrophages148. 
In order to understand the role of NaB in the ROS regulation we used 
a range of approaches, which included, bioassays for direct measure of 
ROS and its by-products, indirectly evaluation by investigating the cellular 
response for ROS generation, HkEc stimulation increased ROS production 
which acted as a secondary signal that boosted IL6 and IL1β and in THP-
1 cells is completely dissociated from TNF induction. 
Our results showed that upon HkEc stimulation, there was an 
increase in P67phox expression, one of the subunits of the NADPH oxidase 
complex. An increasing phosphorylation of ASK1, which is a protein kinase 
that is a known ROS dependent signalling molecule that regulates 
downstream effectors such as the C-JUN. ROS and ASK1 phosphorylation 
were evident upon HkEc stimulation. ASK1 is kept inactivated by 
thioredoxin (Trx) in a redox-dependent interaction. ROS leads to direct 
oxidation of Trx and its subsequent dissociation from ASK1146, which 
oligomerizes and autophosphorylates, becoming activated198. To control 
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the excessive ROS production, cells trigger an antioxidative mechanism to 
decrease ROS production through uncoupling mitochondrial proteins that 
cause a leakage of protons bypassing the ATP synthase and decreases 
the mitochondrial inner membrane's potential197. We showed that there 
was an induction in the expression of UCP2, one of the mitochondrial 
uncoupling proteins, in an attempt to curtail ROS production in THP-1 cells 
stimulated with HkEc. 
In order to gain a greater insight into the role of NaB on ROS 
regulation, we used a combination of bioassays that directly measure a 
variety of ROS products. Using Amplex® Red, a cell-impermeable 
fluorescent dye that reacts with extracellular H2O2, NaB reduced the levels 
of H2O2 by about a third. When the cells previously treated with NaB were 
washed before being assayed, removing all the NaB from the supernatant, 
the levels of H2O2 were similar to those observed in cells that were 
stimulated with HkEc only. These results confirmed the ability of 
extracellular NaB to react with released H2O2 and suggest that this process 
is similar in THP-1 cells stimulated with HkEc irrespective of NaB. 
Another bioassay that uses two different cell-permeable dyes that 
identify intracellular levels of superoxide and ROS was used, NaB 
exposure neutralized the superoxide production induced by HkEc 
stimulation resulting in similar levels to that seen in unstimulated cells.  The 
ROS levels are even below the basal of unstimulated cells. In contrast to 
the Amplex® Red assay removing NaB from the supernatant maintained 
the ability of intracellular NaB to restrict the levels of HkEc-induced ROS 
production. This confirms the uptake of NaB and its accumulation in the 
cells, which maintains its ability to block ROS induced signalling in THP-1 
cells. A similar residual effect was observed in IL6 cytokine secretion when 
NaB was removed from the supernatant.  
The antioxidant activity of NaB was identified as the probable cause 
of the reduced IL6 and IL1β secretion through the use of a range of 
additional antioxidants.  The inclusion of either NaB or TEMPO, an 
intracellular scavenger of superoxide anion39, were capable of reducing the 
secretion of IL6 and IL1β. Interestingly, at the concentrations used in these 
experiments, NAC and curcumin had no effect on ROS levels or IL6 and 
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IL1β secretion. The ROS neutralization ability of NaB is immediate and 
dose-dependent and stimuli-independent. It suggests that NaB could 
interfere with any cell type that uses ROS as a second messenger. 
 ROS increases the expression of macrophage scavenger receptor 
type I, which was shown to be negatively regulated by the use of 
antioxidants including NaB39. Superoxide, but not hydrogen peroxide, has 
been shown to induce IL6 secretion in human bronchial epithelial cells. 
TNF-induced IL6 secretion was suppressed by the use of several 
antioxidants, which reinforces the role of ROS in IL6 induction209.   
So far, we have shown that HkEc stimulation increases the 
generation of ROS, which is actively linked to the rise in expression of 
ROS-associated proteins. One of the major cellular processes associated 
with immune activation is a rise in the antioxidant response in order to 
protect the cells from the ROS. The main antioxidant response mechanism 
is the KEAP1 /NRF2 pathway207. Briefly, NRF2 is bound in the cytoplasm 
by KEAP1 in non-oxidative stress condition. This results in NRF2 
ubiquitylation and proteasomal degradation. Under oxidative stress, the 
interaction between KEAP1 /NRF2 is weakened resulting in the loss of 
NRF2 ubiquitylation and degradation. NRF2 is then able to translocate to 
the nucleus and induce transcription of proteins associated with the 
antioxidant response205. The inclusion of NaB during a HkEc stimulation 
resulted in a reduction in NRF2 nuclear localisation. This attenuated 
response of NRF2 provides additional evidence that NaB sequesters 
intracellular ROS and this is sufficient to alter the cellular response to 
bacterial stimulation. 
Translocation of NRF2 to the nucleus and bindings to the ARE 
orchestrates the antioxidant defence response207. NRF2 regulates genes 
related to anti-oxidant, anti-inflammatory and detoxifying proteins such as 
HMOX1208, which was found to be reduced in all NaB treated samples 
irrespective of stimulation. In NRF2 knockout mice, a range of inflammation 
markers, including inducible IL6, TNF and microglia activation, is increased 
compared with wild-type littermates210. The brain is particularly susceptible 
to oxidative damage because this organ consumes about one-third of the 
inspired oxygen in humans211. Inability to deal with oxidative stress through 
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NRF2 is underlying the mechanisms of neuroinflammation in this 
model205,207,210. 
 Aggregation of misfolded proteins is a hallmark of 
neurodegenerative diseases in a disease-specific manner90. This 
aggregation of misfolded proteins leads to the activation of microglia, which 
results in an increased generation of ROS and release of pro-inflammatory 
cytokines, especially IL690,182,183. NaB has the potential to control these two 
pivotal problems associated with NDDs. 
Finally, it was shown that IL6 induction requires activation of the 
ERK1/2 signalling pathway. It occurs in the later stages of an immune 
response and needs ROS as a secondary signal for full activation. There 
is a strong link between ROS and ERK1/2, which was evident when  
PD98059 an ERK1/2 inhibitor was shown to block ROS generation and 
cytokine induction147. Therefore, in THP-1 cells exposed to NaB and an 
immune stimulant, the reduction in ROS could have a profound effect on 
the ERK1/2 effect accounting for the diminished activation of IL6 and IL1
In this chapter, we have provided strong evidence of ROS generation 
upon HkEc stimulation, and superoxide and ROS neutralization by NaB. 
ROS neutralization by NaB attenuates the cell's response to oxidative 
stress, resulting in a suboptimal signal through the ERK1/2 pathway and a 
diminished activation of the immune response especially the release of IL6 
and IL1β. This ability of NaB as a ROS scavenger and immune suppressor 
has potential therapeutic benefits on diseases that have been shown to 
over-activate these molecules. 
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Chapter 5 TNF is hyper-secreted in the early 
stage of the immune response and is linked to 
ERK1/2 signalling pathway (Signal 1) 
5.1 Introduction 
 In chapter 4, it was shown that the antioxidants NAC and TEMPO 
have a similar hypersecretion of TNF as seen with NaB, and this 
hypersecretion is not related to generation/scavenging of ROS (Figure 4-
8). It was also shown that TNF requires ERK1/2 signalling during the first 
4 h to a proper TNF response, which was strongly reduced by the addition 
of the MEK1 and MEK2 inhibitor PD98059 prior to bacterial stimulation 
(Figure 4-14). 
 In view that TNF is a cytokine that participates in the very early 
immune response, being induced and secreted during the first 6 hours after 
bacterial sensing (Figure 3-16), experiments were designed to focus on 
this period. In this thesis, the early immune response is considered the 
period dominated by TLR signalling after bacterial or ligand stimulation and 
encompasses the first 4 hours. The late immune response starts after the 
4th hour when other signals, such as ROS and cytokines, start to play 
important roles. 
 
5.2 NaB itself disturb the phosphorylation state of ERK1/2  
To investigate the signal for induction of TNF, an in-depth look at 
the signalling cascade downstream of TLR activation was carried out 
(Figure 5-1). 
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Figure 5-1: The major signal molecules downstream of TLR stimulation 
were visualized after HkEc stimulation for a total time of 4 h (A). There were 
differences in the phosphorylation pattern involving the ERK/C-JUN 
signalling pathway between HkEc and HkEc plus NaB. The 
phosphorylation pattern of ERK1/2 seems to fluctuate up and down in 
HkEc, but it is always high upon NaB exposure (B-D). At 4 h, the 
expression of phospho-C-JUN was less intense on HkEc plus NaB 
samples. Vinculin was used as a loading control. Results shown are mean 
± SEM of 4 independent experiments, *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001, (two-tailed, paired t-test). 
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 In Figure 5-1 demonstrates that the majority of the signalling 
molecules downstream of TLR activation showed a similar pattern 
regardless of NaB treatment. While pERK1/2 showed a fluctuating pattern 
during the initial 4 hours after HkEc stimulation, treatment with NaB 
stabilized ERK phosphorylation, which may be involved in a deregulated 
TNF secretion upon NaB exposure.  
To provide supporting evidence of an effect of NaB on ERK1/2 
signalling, an experiment was designed using a higher concentration of 
NaB (20 mM) to try and exaggerate its effect (Figure 5-2). 
 
Figure 5-2: Immunoblots showing a time course using 2 different 
concentration of NaB (5 mM and 20 mM) and stimulated or not with HkEc. 
Cells were stimulated with 20 mM NaB without any bacterial challenge (A). 
At 5 minutes, there was an increase in the phosphorylation of ERK1/2 upon 
addition of NaB that decreased over time, showing that NaB itself disturbs 
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ERK1/2 signalling. Upon HkEc stimulation using a concentration of 20 mM 
of NaB, a steady-state of phosphorylation is observed in ERK1/2. At 20 
mM, NaB itself does not cause activation of NFkB and does not disturb the 
NFkB phosphorylation pattern after HkEc stimulation (B). The basal level 
of phospho-ERK1/2 is higher with 5 mM and 20 mM of NaB when 
compared with untreated THP-1 cells (C). After HkEc stimulation, the same 
steady-state of ERK1/2 phosphorylation is observed when using either 5 
mM or 20 mM NaB (B and C). Vinculin was used as a loading control. 
Results shown are of a single experiment. The results of a single 
experiment are limited to establish a proper cause-effect of the 
experimental conditions. 
  
 Figure 5-2 showed that NaB itself is capable of inducing phospho-
ERK1/2 and upon HkEc stimulation the presence of NaB seems to stabilize 
the pERK signal. In contrast, the pattern of NFkB activation (pNFkB) was 
not influenced by NaB. It appears that ERK1/2 may be an important target 
of NaB exposition.  
 
5.3 Message and protein levels of TNF are elevated on NaB samples  
 Although subtle, the disturbance in ERK1/2 signalling caused by 
NaB seems to have an effect on TNF regulation. So far, it has been shown 
that for a full induction, TNF requires ERK activation and NaB seems to 
disrupt the phosphorylation state of ERK, keeping it hyperactive (Figures 
4-14 and 5-2). NaB in combination with HkEc increases the TNF mRNA 
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levels and results in higher TNF secretion than HkEc alone (Figures 5-3 
and 5-4). 
 
Figure 5-3: TNF gene expression measured by qRT-PCR. TNF mRNA 
expression is higher in HkEc + NaB than in HkEc alone. Increasing the 
NaB concentration from 5 mM to 20 mM intensify TNF expression at 1 h 
and 2 h (A and B, respectively). Inhibition of ERK1/2 signal reduces TNF 
expression (C). TNF gene expression occurs mainly during the first 4 hours 
and is almost completely lost after 6 hours (see Figure 3-16F). The 
cumulative effect on TNF gene expression is significantly higher upon NaB 
exposure (D and E). Results shown are mean ± SEM of 2 (A-C) and 4 (D 
and E) independent experiments, *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001; (one-way ANOVA with Tukey’s test (A and B); two-tailed, 
unpaired t-test (C and E); area under the curve (D)). 
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Figure 5-4: TNF (A) and IL8 (B) cytokine secretion levels in THP-1 cells 
stimulated with HkEc ± NaB for 4 h and measured by ELISA. TNF was 
increased because of NaB treatment, while IL8 levels were similar and 
used as a control. Results shown are mean ± SEM for 5 independent 
experiments., *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001; (two-tailed, 
unpaired t-test). 
 
5.4 NaB does not interfere with mRNA stability 
In view of a high TNF mRNA level upon NaB exposure, an experiment 
was designed to test if the mRNA stability would be affected by NaB 
exposure. Actinomycin D, a chemotherapy medication used to treat a 
variety of cancers, was used to stop transcription and test if NaB exposure 
would interfere with TNF mRNA decay. Actinomycin D does this by binding 
DNA at the transcription initiation complex and preventing elongation of 
RNA chain by RNA polymerase212. 
THP-1 cells were stimulated with HkEc for 4 hours to induce TNF 
transcription. At 4 hours, samples were treated with either actinomycin D 
or NaB plus actinomycin D and the mRNA levels were investigated over 
time (Figure 5-5). 
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Figure 5-5: TNF gene expression measured by qRT-PCR. THP-1 cells 
were stimulated with HkEc for 4 h (Time 0) and either actinomycin D or 
NaB plus actinomycin D added to evaluate the mRNA decay. Addition of 
NaB did not change the speed of TNF mRNA decay (not significant). 
Results shown are mean ± SEM of 1 independent experiment, *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001; (two-tailed, unpaired t-test). 
 
5.5 Discussion 
Our previous experiments demonstrated that TNF is hyper-secreted 
upon NaB exposure and it is induced very early after HkEc stimulation. The 
TNF mRNA levels reach a peak one hour after bacterial challenge and in 
6 hours, almost all the message is gone. It was also shown that the MEK1 
and MEK2 inhibitor PD98059 blocks ERK1/2 phosphorylation and it causes 
an important reduction in TNF levels when added prior to bacterial 
stimulation, and has no effect when added 4 hours after bacterial 
challenge, suggesting that the initial induction of TNF occurs mainly 
downstream of TLR activation. 
 Focusing on this early stage of the immune response, we observed 
that secretion of TNF is elevated upon NaB exposure after 4 h HkEc 
stimulation. This elevated secretion was a consequence of an increased 
message cumulated during the first 4 hours of stimulation. These facts led 
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us to have in-depth look at the signalling cascade downstream of TLR 
activation. 
 We found that NaB, at 20 mM without any bacterial challenge, 
disturbs ERK1/2 phosphorylation and becomes hyper-phosphorylated 5 
minutes after NaB addition, with the strength of this signal decreasing over 
time.  
 THP-1 cells have an already high basal level of phosphor-ERK1/2, 
which might be linked to their malignant nature, and upon HkEc stimulation 
this phosphorylation state fluctuates over time. However, upon NaB 
exposure, phosphor-ERK1/2 remains always highly phosphorylated.  
 Lack of activation of ERK1/2 results in defective TNF secretion, 
which results in an inadequate transcriptional and post-transcriptional TNF 
induction213,214,215,216. Tumour Progression Locus 2 (TPL2) is a member of 
the serine/threonine protein kinase family and is required for LPS-induced, 
TLR4-mediated activation of the MAPK/ERK pathway in macrophages; 
being critical for TNF production. Peritoneal macrophages from TPL2 
knockout mice showed no activation of ERK1/2 and defective TNF 
secretion. TPL2 is important for transport TNF mRNA from the nucleus to 
the cytoplasm213. Blocking of ERK1/2 was also found to interfere with TNF 
biosynthesis in human monocytes and macrophages, at both the 
transcriptional and post-transcriptional levels215.  
Full TNF secretion was dependent on ERK1/2 signalling. NaB 
exposure resulted in elevated TNF secretion and an increase in TNF 
mRNA levels, which was potentiated by a higher concentration of NaB. 
Taken together, these results suggest that ERK1/2 signalling plays a 
crucial role in TNF response. The disturb once induced by NaB exposure 
in the early ERK1/2 phosphorylation and maintenance of hyper-
phosphorylated state during HkEc stimulation might be the cause of the 
disordered TNF synthesis induced by NaB exposure. However, more 
studies are required for elucidation of this question. 
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Chapter 6 IL6 deficiency contributes to TNF 
deregulation upon NaB exposure (Signal 3) 
6.1 Introduction 
Cytokines are signalling molecules that are very important 
immunomodulatory agents. The immune system depends on cytokine 
signalling to recruit new cells to a site of infection and for modulating the 
immune response. IL6 is mainly considered a pro-inflammatory cytokine, 
but studies have shown that IL6 also has anti-inflammatory 
activity179,180,217.  
IL6 is one of the major inducers of acute phase proteins and participates 
in many situations when there is a homeostatic perturbation. For instance, 
IL6 knockout mice release higher levels of TNF than WT animals in 
endotoxemia models180. The IL6 family include: IL6, IL11 and IL31 that 
share a common receptor and signal transducer subunit, the membrane 
glycoprotein gp130. The signal initiates when IL6 binds to the membrane 
IL6 receptor (IL6r), and subsequently, IL6/IL6R complex associate with 
gp130, leading to the gp130-homodimer formation and signal initiation179. 
This complex transduces IL6 signals resulting in the activation of the 
JAK/STAT3 signalling pathway. 
 In chapter 3, it was shown that NaB exposure reduces the secretion 
of IL6 (Figure 3-18A) and increases TNF (Figure 3-19A) after HkEc 
stimulation. TNF secretion peaked at 6 hours and gradually decreases 
after HkEc stimulation, but it is kept elevated upon NaB treatment (Figure 
3-30). Although hyper-secretion of TNF is observed at the early stages of 
the immune response in the presence of NaB (Figure 5-4), it is unclear why 
the levels of TNF do not decrease at the same rate as that seen with HkEc 
alone. The second mechanism of TNF regulation must be disturbed by the 
inclusion of NaB and may relate to the loss of IL6 secretion and a feedback 
mechanism via IL6R/gp130 (Figure 6-1). 
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Figure 6-1: IL6 signalling cascade. IL6 initially binds to the non-signalling 
IL6 receptor, this complex binds to two molecules of gp130. Engagement 
of the IL6r to gp130 promotes a rearrangement of gp130 that leads to 
autophosphorylation of JAK and promotes the recruitment and 
phosphorylation of STAT3. STAT3 translocates to the nucleus and 
initiates/inhibits transcription of target genes. Image adapted from Yu et. 
al. (2007)218.  
 
6.1.1 STAT3 is phosphorylated by IL6 stimulation and by cytokines 
released upon HkEc challenge 
 STAT3 is the main transcription factor downstream of IL6/IL6r 
signalling. To investigate the role of IL6 in TNF regulation, IL6/STAT3 
signalling was studied using agonists and inhibitors of STAT3. Firstly, THP-
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1 cells stimulated with IL6 demonstrate STAT3 phosphorylation which 
peaks between 30 and 60 mins (Figure 6-2).  
 
 
Figure 6-2: Phosphorylation of STAT3 was evaluated upon stimulation 
with 10 ng/mL of recombinant IL6.  Phosphorylation was detected at 5 
minutes and peaked at 30 minutes of IL6 stimulation. Results shown are 
representative of 2 independent experiments. 
 
 Secondly, STAT3 is phosphorylated upon HkEc stimulation (Figure 
6-3). Since STAT3 is mainly activated downstream of cytokines-cytokine 
receptors interactions, brefeldin A was used to inhibit cytokines secretion 
and the phosphorylation of STAT3 was investigated in the early and late 
immune response (Figure 6-4). 
 
 
Figure 6-3: Phosphorylation of STAT3 is observed at 2 h HkEc stimulation, 
regardless the NaB exposure. Results shown are representative of 4 
independent experiments. 
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Figure 6-4: Blockage of cytokine secretion by brefeldin A inhibits STAT3 
phosphorylation. Brefeldin A does not affect the signal directly downstream 
of TLR after HkEc stimulation, as observed by normal P38 and NFkB 
phosphorylation, but STAT3 activation is completely abolished in the short 
(A) and long-term (B). This suggests that STAT3 is indirectly activated 
upon HkEc stimulation, probably through the release of cytokines. Results 
shown are representative of 1 (A) and 3 (B) independent experiments. 
 
 In view of the fact that IL6 is first observed in the supernatant of 
HkEc-stimulated THP-1 cells at 6 hours (Figure 3-16) and the peak in 
STAT3-phosphorylation happens after 12 hours (Figure 6-4), the role IL6 
plays in this response was investigated (Figure 6-5). 
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Figure 6-5: Phosphorylation of STAT3 was evaluated upon HkEc 
stimulation ± NaB over a 24 h period. Phosphorylation levels were found 
to be diminished with the inclusion of NaB at 6, 12 and 24 hours (A). This 
was confirmed when the cumulative levels of p-STAT3 were calculated (B 
and C). Results shown are representative of 4 independent experiments 
and shown as mean ± SEM, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001; 
(area under the curve; two-tailed, unpaired t-test). 
 
6.1.2 STAT3 activation negatively regulates TNF induction and 
secretion 
To investigate the participation of STAT3 signalling on TNF 
regulation, AG490, a JAK2 inhibitor that blocks the JAK/STAT3 signal, was 
used. The effect of IL6 on TNF release was also studied through the use 
of recombinant IL6 and a neutralizing anti-IL6 antibody. 
Inhibition of STAT3 by AG490, led to an increase in gene expression 
and release of TNF and reduced secretion of IL6, while IP10 remained 
unchanged (Figure 6-6).  
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Figure 6-6: mRNA (TNF, A) and cytokine levels (B-D) after HkEc in 
combination with either NaB or AG490. STAT3 inhibition increased TNF 
gene expression (A) and cytokine secretion (B) to a similar level as 
observed with NaB. Furthermore, it reduced the levels of IL6 (C) and had 
no effect on IP10 secretion (D). Results shown are mean ± SEM, n= 3 (A) 
and n=5 (B-D) independent experiments and analysed using one-way 
ANOVA with Tukey’s test (*p<0.05, **p<0.01, ***p<0.001, and 
****p<0.0001). 
 
 Since the use of inhibitors may interfere with other cellular functions, 
the effect of IL6 on STAT3 activation and regulation of TNF was tested 
using a neutralization assay with an anti-IL6 antibody, which binds and 
sequesters the secreted IL6 by antigen/antibody reaction. The efficiency of 
the anti-IL6 antibody to bind to the cytokine was evaluated by measuring 
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the IL6 levels after HkEc stimulation (Figure 6-7A). Similar to the STAT3 
inhibitor AG490, neutralization of IL6 by addition of an anti-IL6 antibody 
increased the release of TNF (Figure 6-7B). 
 
Figure 6-7: Neutralization of IL6 increases the levels of TNF. 
Neutralization of IL6 by an anti-IL6 antibody resulted in undetected levels 
of IL6 in the supernatant (A) and hypersecretion of TNF (B).  Results shown 
are representative of 1 (A) and 2 (B) independent experiments and shown 
as mean ± SEM, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001; (two-tailed, 
unpaired t-test). 
Finally, we investigated the effects of directly activating STAT3 
through the inclusion of rIL6 on TNF secretion. Addition of rIL6 showed a 
reduction in TNF gene expression resulting in a level similar to HkEc alone, 
therefore normalizing the effect of NaB (Figure 6-8A). The half-life of 
recombinant IL6 in cell culture is very short. Five thousand picograms 
added to cell culture dropped to less than a half during the first 4 hours 
(Figure 6-8B). In order to evaluate the effects of IL6 in a way more similar 
to what happens in a normal condition, an experiment was designed with 
IL6 being added at the same time as HkEc stimulation or after 12 hours 
(IL6 ±) of bacterial challenge in the presence or absence of NaB (Figure 6-
8C). The total time of HkEc stimulation was 24 h in all cases. Addition of 
IL6 after 12 hours of HkEc stimulation was chosen because it simulates 
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what was seen in IL6 dynamics (Figure 3-16G), which showed a boost in 
its secretion between the period from 12 h to 24 h.  
 
Figure 6-8: Effects of recombinant IL6 in TNF response. Co-stimulation of 
10 ng/mL of IL6 with HkEc brought the elevated levels of TNF mRNA 
induced by NaB back to normal (A). IL6 showed a short half-life in THP-1 
culture, more than half of the initial dose of 5000 pg/mL added to the cell 
culture could not be detected anymore at 4 hours, dropping to almost zero 
at 24 hours. Addition of IL6 at the same time of HkEc stimulation (IL6 +), 
does not change the levels of TNF after 24 hours, probably due to its short 
life in cell culture. However, when IL6 was added later at 12 hours (IL6 ±), 
TNF levels were brought to normal levels observed without NaB exposure 
(C). Results shown are mean ± SEM, n= 3 (A), n=1 (B) and n=3 (C) 
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independent experiments and analysed using one-way ANOVA with 
Tukey’s test (*p<0.05, **p<0.01, ***p<0.001, and ****p<0.0001). 
 
6.2 Discussion 
In Chapter 5, it was shown that there is a hyper-active TNF response 
to HkEc stimulation and NaB exposure. Although it can explain the initial 
high levels of TNF, TNF remains elevated for a longer period in NaB treated 
samples and do not show a similar reduction rate than the one observed 
in HkEc only. It led us to investigate a second mechanism that would add 
to the one previously described. This mechanism would be related to IL6 
deficiency and impaired STAT3 signalling. 
In this chapter, it was shown that STAT3 signalling downstream of IL6r 
binding negatively regulates TNF secretion. Firstly, we demonstrated 
STAT3 phosphorylation upon IL6 stimulation. Secondly, STAT3 can be 
activated not only by IL6 but for other cytokines secreted by the cell. STAT3 
phosphorylation is observed at 2 h (at this time, no IL6 has been produced 
by THP-1 cells) after HkEc stimulation and this signal is unaffected by NaB. 
Brefeldin A, a potent inhibitor of cytokine secretion, completely abolishes 
STAT3 phosphorylation at an early and late stage, while preserving a 
normal signal downstream of TLR activation. We have provided convincing 
evidence of activation of STAT3 by cytokines occurs by 
autocrine/paracrine stimulation and not by any other signal.  
Yoon et. al. proposed a mechanism of activation of STAT3 by ROS 
and autophagy, which would induce IL6 secretion and could be inhibited 
by knockdown of P22phox and antioxidants219. Our results support exactly 
the contrary, ROS induce IL6 secretion and IL6 (and other cytokines) thus 
activate STAT3. Blockage of cytokine secretion completely inhibits STAT3 
activation. 
The STAT3 inhibitor AG490 increased the message and the secretion 
of TNF in HkEc stimulated cells. Neutralization of IL6 by an IL6 antibody 
had a similar effect to AG490 in reducing TNF secretion. On the other hand, 
IL6 negatively regulated TNF at both, the message and protein level.  
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Thirdly, NaB-induced IL6 deficiency attenuates the activation of STAT3 
at later stages (6-24 h) of the immune response. Several studies support 
the role of STAT3 in controlling inflammation induced by TLR 
stimulation216,220,221,222,223. In human monocytes, STAT3 activation reduces 
TNF production induced by LPS through IL10/STAT3 signalling216,221. 
Cardiomyocytes from mice with restricted STAT3 knockout showed higher 
levels of TNF than wild-type controls upon LPS stimulation222. Here we 
showed that IL6 rather than IL10 (which was secreted only in very small 
concentrations - see Figure 3-3) seemed to exert some type of control in 
TNF regulation through STAT3 activation. 
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Chapter 7 Quantitative proteomic profiling of 
THP-1 cells stimulated with LPS and NaB 
7.1 Introduction 
THP-1 is a human monocytic cell line that can be differentiated in 
macrophages. The classical monocyte-macrophage differentiation inducer 
is PMA, but other stimulants, such as LPS and HkEc, can also induce 
differentiation as shown in Figure 3-1. Activation of THP-1 cells with LPS 
or HkEc stimulation stops cell proliferation (Figure 3-2) and differentiate 
them into a pro-inflammatory phenotype (Figure 3-16 and 3-20). This 
activation leads the cell to undergo maturation into macrophage-like cells, 
which upregulate membrane receptors such as ICAM-1 and CD80/CD86 
and synthesizes pro-inflammatory cytokines224. 
To have a better understanding of the overall changes caused by 
LPS stimulation and the effects of NaB, two quantitative proteomic profiles 
of THP-1 cells were carried out, one to evaluate the dynamic changes in a 
time course with LPS stimulation, and another with samples stimulated for 
0 (untreated), 12 and 24 h in the presence or absence of NaB using LC-
MS/MS. This is an ongoing study in collaboration with Professor Lilley and 
Dr Mulvey (University of Cambridge). Data analysis is not completed yet 
and extra experiments will be added to support the findings. 
  
7.2 LPS stimulation decreases the levels of proteins related to the 
cell cycle and increases proteins associated with innate 
immunity 
THP-1 cells were stimulated with LPS from Salmonella abortus equi 
S-form, which is a smooth form of LPS. This smooth LPS requires TLR4 
internalization and is CD14-dependent (see section 1.3.2.2), leading to a 
type I interferon response through TRIF signalling pathway. 
THP-1 cells were stimulated with 200 ng/mL of LPS for 0 (untreated), 
2, 4, 6, 12, 24 hours. This investigation led to the identification of 4292 
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proteins with 556 proteins (≈13%) regulated by LPS. The biggest fold 
changes happened between 0 and 24 hours. Statistical analysis was based 
on p-value calculated between 0 and 24 hours and adjusted for a false 
discovery rate using the method of Benjamini–Hochberg158, with a q 
value=0.05 (Figure 7-1).  
 
Figure 7-1: Heatmap of 556 differentially expressed genes influenced by 
LPS stimulation (adjusted p<0.05). Most of the changes happened 
between 12 and 24 hours with 322 proteins downregulated and 234 
upregulated proteins.  
The heatmap showed that the biggest changes occurred between 
untreated and 24 h stimulation, with 2 and 4 h showing a similar profile to 
untreated, 6 h presented a transitional stage, and 12 h was almost similar 
to 24 h. Due to these results, all subsequent analysis were conducted 
between untreated and 24 h stimulated groups. 
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The proteins regulated by LPS stimulation were split into 
upregulated or downregulation and submitted to cluster analysis of 
biological processes on STRING website (Figures 7-2 and 7-3)225.  
 
Figure 7-2: Cluster analysis of proteins down-regulated by LPS 
stimulation. The top five clusters of biological processes with the lowest p-
value were associated with the cell cycle (mitotic cell cycle process, mitotic 
cell cycle, mitotic nuclear division, cell division, cell cycle process). 
Coloured spheres are related to one of the five clusters and many of them 
were involved in three or more clusters. Image generated on STRING  
website. 
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Figure 7-3: Cluster analysis of proteins upregulated by LPS stimulation. 
There were two main clusters identified in the upregulated group: response 
to virus with 33 proteins and a p-value 4.22E-26 (red spheres) and innate 
immune response (49 proteins, p-value 2.8E-21, blue spheres). Image 
generated on STRING  website. 
 
Taking the results of Figures 7-2 and 7-3 together, LPS stimulation 
mainly caused a reduction in the cell cycle, which is expected during 
monocyte/macrophage differentiation and triggered the immune response, 
especially by activating the TRIF pathway leading to a type I interferon 
response, a usual response observed in viral infection.  
To validate the findings of the proteomics data, western blots were 
carried out for the proteins optineurin (OPTN gene) and P62 (SQSTM1 
gene), which were chosen because of their strong up-regulation induced 
by LPS stimulation (Figure 7-4). 
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Figure 7-4: Validation of proteomics data by western blot. The bar graphs 
are related to protein quantification by proteomics samples. Both proteins, 
P62 (A) and optineurin (B), showed a similar pattern with an increasing 
expression over time. Results shown in the immunoblots are of an 
individual experiment. The results of a single experiment are limited to 
establish a proper cause-effect of the experimental conditions. 
 
 Optineurin and P62 expression increased after LPS stimulation in 
the proteomic analysis and these results matched with the expression of 
the same proteins in immunoblots.  
Since the majority of the changes were observed between untreated 
samples and LPS stimulation for 12 and 24 hours, these time points were 
chosen for studying the effects of NaB, but to reduce the size of the thesis, 
the 12 hours samples were not included in further analysis. 
 
7.3 NaB attenuates the overall response to LPS and affects the 
amino acid metabolism 
In a repeated experiment, untreated and 24 h LPS stimulated ± NaB 
were analysed in triplicate. LPS stimulation resulted in an alteration in 762 
out of 6865 proteins with 473 proteins downregulated and 289 proteins 
regulated with a cut off adjusted p-value <0.05. 
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Figure 7-5: Cluster analysis of proteins down-regulated by LPS 
stimulation. The top five clusters of biological processes with the lowest p-
value were associated with the cell cycle (mitotic cell cycle process, mitotic 
cell cycle, mitotic nuclear division, cell division, cell cycle process). 
Coloured spheres are related to one of the five clusters and many of them 
were involved in three or more clusters. Image generated on STRING  
website. 
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Figure 7-6: Cluster analysis of proteins up-regulated by LPS stimulation. 
Up-regulated proteins were less abundant and clustered in a response to 
virus and innate immunity. Image generated on STRING  website. 
 
 The response to LPS stimulation in this repeated experiment was 
very similar to that previously observed and explained in Figures 7-2 and 
7-3. It is important to note that TNF was not detected in any of the 
proteomics samples. It is because TNF is not stored within the cell as 
shown in Figures 3-24 and 3-25. Without any agent to trap the TNF inside 
the cell (e.g. Brefeldin A), only a small amount of TNF is found within the 
cell, which seems to be below the detection limit of the proteomic study.  
In order to restrict the analysis and focus on the most significant 
changes, the p-value was reset to <0.01 in the volcano plot (Figure 7-7) 
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Figure 7-7: Volcano plot showing the changes in protein expression upon 
LPS stimulation for 24 h. There were 58 proteins upregulated and only 4 
were found to be reduced after LPS stimulation. Proteins were labelled 
based on an adjusted p-value <0.001 (grey dots, not significant; red dots, 
statistically significant). 
 
To evaluate the functional implication of these proteins, a cluster 
analysis was carried out and showed the main proteins were related to 
virus defence and innate immunity (Figure 7-8). 
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Figure 7-8: Cluster analysis of proteins regulated by LPS stimulation. Two 
clusters dominated most of the proteins with high interactions, defence to 
virus with 17 proteins and a p-value 1.87E-20 (yellow spheres) and innate 
immune response (25 proteins, p-value 5.37E-18, blue spheres). All were 
upregulated. On the other hand, 2 out of 4 proteins down-regulated by LPS 
were involved in regulation of lipid catabolic process (APOA1 and APOC1, 
green spheres. Image generated on STRING  website. 
 Similarly to what was observed in the previous analysis (Figures 7-
3 and 7-6), using a more restricted p-value (>0.001), the predominant 
responses to LPS was related innate immunity and response to virus. 
 NaB in combination with LPS caused fewer changes in protein 
expression compared to LPS alone, with only 27 proteins up-regulated and 
none down-regulated (Figure 7-9). All of the up-regulated proteins resulting 
176 
 
from the inclusion of NaB were also elevated in the LPS alone dataset.  
Cluster analysis showed proteins related to virus defence and innate 
immunity similar to LPS alone (Figure 7-10). 
 
Figure 7-9: Volcano plot showing the changes in protein expression in NaB 
treated samples upon LPS stimulation for 24 h. There were 27 proteins 
regulated by LPS stimulation with all of them overexpressed. The cut off 
was set based on an adjusted p-value <0.001 (grey dots, not significant; 
red dots, statistically significant). 
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Figure 7-10: Cluster analysis of proteins regulated by LPS stimulation 
upon NaB exposure. Two clusters dominated most of the proteins with high 
interactions, defence to virus with 13 proteins and a p-value 3.04E-19 
(yellow spheres) and innate immune response (16 proteins, p-value 2.58E-
15, blue spheres), with all proteins upregulated. Image generated on 
STRING website. 
 
 LPS stimulation in combination with NaB exposure caused a similar 
but attenuated response than that observed with LPS alone. 
 To analyse the effect of NaB itself on THP-1 cells, untreated THP-1 
cells were compared with cells exposed to NaB only (Figure 7-11). Only 
one cluster with a p-value <0.05 was identified in the NaB exposed dataset 
and was related to biosynthesis of amino acids (Figure 7-12). 
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Figure 7-11: Volcano plot showing the changes in protein expression due 
to NaB exposure. Cells were incubated with or without 5 mM NaB for 24 h. 
There were 24 proteins regulated by NaB exposure, 16 downregulated and 
8 upregulated. The cut off was set based on an adjusted p-value <0.05 
(grey dots, not significant; red dots, statistically significant). 
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Figure 7-12: Cluster analysis of proteins regulated by NaB exposure. A 
single cluster related to biosynthesis of amino acids (red spheres) was 
found with a p-value <0.05. PSAT1 and PHGDH were up, while GLUL 
downregulated. Image generated on STRING  website. 
 
 NaB exposure led to a predominant down-regulation in proteins 
levels detected by mass spectrometry. When these down-regulated 
proteins were investigated further, only one cluster was found, which was 
related to amino acid biosynthesis. These proteins will be better 
investigated later in this chapter. 
 Next, the effect of NaB was evaluated in combination with LPS 
stimulation (Figures 7-13 and 7-14).  
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Figure 7-13: Volcano plot showing the changes in protein expression due 
to NaB exposure upon LPS stimulation. Cells were incubated with 5 mM 
NaB for 24 h. There were 24 proteins regulated by NaB exposure, 16 
downregulated and 8 upregulated. The cut off was set based on an 
adjusted p-value <0.05 (grey dots, not significant; red dots, statistically 
significant). 
 
 The proteomics data showed that IL1β was upregulated on 
stimulation with LPS (Figure 7-9) and NaB exposure impaired its synthesis 
(Figure 7-13). This results in a decreased secretion of IL1β as shown in 
Figure 3-20A, which links these findings in the proteomics to a functional 
consequence of NaB exposure. Other proteins that show a similar pattern 
are part of the matrix metallopeptidase (MMP) family, MMP9 and MMP14, 
MMP9 is upregulated after LPS stimulation and comparison with NaB 
treated samples showed a reduction in these two metalloproteases, which 
are known to play a role in inflammation and innate immunity. 
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Figure 7-14: Cluster analysis of proteins regulated by NaB exposure upon 
24 h LPS stimulation. Metabolic pathways dominated the clusters. The 
glycine, serine and threonine metabolism showed 3 proteins (green 
spheres, p-value 0.000735) and metabolic pathways (8 proteins, p-value 
0.000735, yellow spheres). Image generated on STRING  website. 
 
 PSAT1 deficiency has been associated with human diseases such 
as phosphoserine aminotransferase deficiency226 and Neu-Laxova 
Syndrome 2227. PSAT1 is a protein involved in the synthesis of L-serine 
from 3-phospho-D-glycerate. L-serine synthesis has three steps: step 1 
involves the D-3-phosphoglycerate dehydrogenase (PHGDH); step 2, 
PSAT1 and step 3, phosphoserine phosphatase (PSPH) (Figure 7-15A). 
All three proteins were upregulated upon NaB exposure regardless LPS 
stimulation (Figure 7-15B-D).  
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Figure 7-15: Proteins involved in the serine biosynthetic pathway (A) 
PHGDH, PSAT1, and PSPH are regulated by NaB exposure.  PHDG, 
PSAT1, and PSPH were overexpressed in NaB samples, these proteins 
are responsible for step 1-3 in L-serine synthesis subpathway, respectively 
(B-D). Image adapted from Luo, J (2011)228.  
 
PSAT1 was found reduced in all NaB treated samples since they 
were pre-incubated for 24 h prior stimulation. To evaluate the expression 
of PSAT1, THP-1 cells were exposed to NaB and analysed by western blot 
(Figure 7-16). 
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Figure 7-16: Expression of PSAT1 was investigated by western blot upon 
NaB treatment. PSAT1 expression increases after NaB exposure (A). 
Protein quantification showed a continuous increase in PSAT1 expression 
over 24 h. Results shown are representative of 2 independent experiments. 
 
 Studies in human volunteers and animal models have demonstrated 
that administration of NaB leads to NaB metabolism to hippuric 
acid104,105,106, which here can be translated by elevation of all three main 
proteins involved in the serine biosynthetic pathway: PHGDH, PSAT1, and 
PSPH. It suggests that NaB exposure alters the cell metabolism requiring 
more efforts to its breakdown. 
 Changes in cellular metabolic pathway showed the highest number 
of proteins regulated by NaB in LPS-stimulated cells (Figure 7-14). It was 
also shown that stimulation with LPS leads the cell to produce proteins 
related to innate immunity, with just 4 proteins downregulated during this 
process and two of them, the APOA1 and APOC1, involved in a lipid 
catabolic process. 
 
7.4 Discussion 
To my knowledge, this is the first ever study using quantitative 
proteomics to study the global response of cells to NaB. Our preliminary 
analysis has provided evidence to support the notion that NaB can alter 
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the metabolic processes of immune cells and also impact on the overall 
immune response to LPS stimulation. In addition, I have also been able to 
characterise the change in the proteome of THP-1 cells upon sLPS 
exposure, which has provided a crucial information on how these cells 
adapt their proteins in order to respond to the antigenic challenge. The 
quantitative proteomics reflected a number of known alterations in 
monocyte to macrophage differentiation such as a down-regulation of 
many proteins associated with the cell cycle and the up-regulation in 
classical differentiation markers229. These findings provide some 
confidence that the use of mass spectrometry and TMT multiplex labelling 
can provide quantitative results, which are reliable and reproducible.  
NaB exposure without an immune challenge does not cause THP-1 
cells differentiation or activation. Only a few random proteins were affected 
by NaB exposure and were related to its metabolism. The response to LPS 
was dominated by the up-regulation of proteins related to the innate 
immunity reinforcing the immune competence of THP-1 cells230. 
Another important finding was the up-regulation of proteins related 
to the anti-viral response. The predominance for the elevation of the anti-
viral proteins was attributed to the use of the smooth form of LPS used in 
these experiments.  Smooth LPS expresses the O-chains, is CD14-
dependent and requires internalization for efficient immune 
activation125,143, which activates the MYD88-independent (TRIF) pathway 
(see section 1.3.2.2). Activation of the TRAM/TRIF pathway downstream 
TLR4 activation induces a type I interferon response, in a similar manner 
to other intracellular nucleic acids sensing TLRs, such as TLR3, 7, 8, 9, 
and 13. The classical cytokine profile induced by the type I interferon 
response involves the potent secretion of interferon- and IP10, which 
are induced by IRFs. The overall response to LPS in combination with NaB 
is not very different from the observed with LPS alone but seems to be 
attenuated4,81,95. 
NaB exposure seems to intensify the metabolism pathway which is 
responsible for the generation of hippuric acid as observed by an increase 
in the three key proteins involved in L-serine synthesis subpathway, the 
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PHGDH, PSAT1, and PSPH. These proteins are elevated by the presence 
of NaB and their levels increase further upon LPS stimulation. It is difficult 
to say if this increase is due to an increase in NaB uptake or if it results 
from a higher metabolic demand resulting from the activation/differentiation 
induced by LPS.  
In any case, it adds an unnecessary metabolic demand to an 
already over requisitioned cell. It might incur an extra energy expenditure 
and depletion of important metabolites, amino acids and enzymes which 
could impact on the cells ability to mount an immune response. Insufficient 
capacity to deal with the metabolic demand of NaB and thus, accumulation 
of intermediate products and reduced availability of metabolic enzymes is 
behind the main mechanism responsible for NaB toxicity13,105,106,107. 
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Chapter 8 NaB exposure disturbs the linear 
relationship between IL6 and TNF in PBM-DM 
8.1 Introduction 
All the previous work with NaB was carried out in undifferentiated 
THP-1 cells, which tend to be less responsive than differentiated 
macrophage-like cells and primary PBM-DM. Another difference between 
working with cell lines and primary cells is that they are likely to show a 
more similar response because there is no individual variation.  
In order to investigate if NaB would cause a similar effect in primary 
cells, a pilot study was carried out with healthy individuals and the findings 
analysed in combination with previous data obtained from patients with 
CGD, OFG, and healthy controls. 
 
8.2 Primary macrophages tolerate high concentrations of NaB  
NaB toxicity was tested in primary MDM (prepared as described in 
section 2.1.2) using concentrations from 0-32 mM of NaB and incubated 
for 24 h (Figure 8-1).  
 
Figure 8-1: The effects of NaB on MDM viability. MDMs were treated with 
a range of NaB concentrations (0-32 mM) and incubated for 24 h. NaB is 
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well-tolerated at concentrations ≤ 16 mM, with an average cell loss around 
3%. Results shown are mean ± SEM of an individual experiment, n=8. 
 
 PBM-DM appeared to tolerate higher concentrations of NaB than 
THP-1 cells (see section 3.3), showing only 3% of cell loss at a 
concentration of 16 mM. Although we tested other concentrations of NaB 
in MDM, 5 mM was established as the standard dose. 
 
8.3 NaB disturbs the positive correlation between TNF and IL6 
 PBM-DMs were stimulated with HkEc (MoI 20:1) in the presence or 
absence of NaB (no NaB pre-incubation was done in PBM-DM) and the 
levels of IL6 and TNF measured by ELISA (Figure 8-2).  
 
Figure 8-2: The effects of 5 mM NaB on cytokine secretion upon HkEc 
stimulation. Response to NaB showed individual variance, without 
reaching significance. Results shown are mean ± SEM of an individual 
experiment (n=6); ns, non-significant; (two-tailed, paired t-test). 
 
 The levels of IL6 and TNF of MDM of patients with OFG and healthy 
controls (HC) were evaluated upon 24 h HkEc stimulation (Figure 8-3). 
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Figure 8-3: The levels of IL6 and TNF in PBM-DM stimulated with HkEc 
(MoI 20:1) in 7 HC and 12 OFG patients were measured by multiplex 
immunoassay. OFG patients showed higher levels of TNF. The positive 
linear correlation between IL6 and TNF was disturbed in OFG patients. 
Results shown in A and B are mean ± SEM, two-tailed, unpaired t-test). C 
and D, simple linear regression analysis, *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001. Data from two HC samples varied only in a maximum of 40 
pg/mL and they appear overlapping in 8-3C.Data kindly provided by Dr 
Helen Petersen.  
 
 NaB exposure in PBM-DM rather than showing a reduction in IL6, it 
seems to disturb the correlation between IL6 and TNF, which is already 
disturbed in OFG patients (Figure 8-4). 
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Figure 8-4: Correlation analysis between TNF and IL6 under two different 
concentrations of NaB in PBM-DM stimulated with HkEc. The positive 
correlation found TNF and IL6 (A) is disturbed by co-incubation of 1 mM of 
NaB (B) and lost at a concentration of 5 mM (C). Results shown are simple 
linear regression analysis. 
 
8.4 Discussion 
Monocyte to macrophage differentiation prepares the cell to actively 
participate in the inflammatory and the immune response231229. This 
process results in the up-regulation of a number of cellular processes, such 
as antigen presentation, that makes the macrophage much more efficient 
to deal with harmful stimuli than monocytes164,229.  
Interestingly I was able to demonstrate that PBM-DM were more 
resistant to NaB toxicity, tolerating higher doses than THP-1 cells. This may 
be due to change in the oxidative stress response within these cells or an 
increase in the metabolic processes needed to remove NaB from the cells. 
I used a dose of 5 mM of NaB, in accordance with the studies on THP-1 
cells, which in hindsight may have been too low to study the effects of ROS 
depletion in PBM-DM. The results with 5 mM were highly variable in the 
PBM-DM and did not replicate the THP-1 data. The main effects of NaB, 
which are the modulation of IL6 and IL1β, are directly linked to its ability to 
neutralize ROS, if 5 mM was insufficient to achieve this then I would not 
observe the same phenotype as when THP-1 cells were used. 
Interestingly, one of the major up-regulated processes are seen in 
monocyte to macrophage maturation are the components of the NADPH 
oxidase. TLR4 stimulation results in the activation of the NADPH oxidase 
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and the generation of ROS, which may require higher levels of NaB in order 
to suppress the ROS dependent signalling in PBM-DM. 
In this pilot study, the concentration of NaB needs to be optimized 
according to the mature macrophage condition. Another methodologic 
change that requires optimization is the incubation time with NaB. In all 
experiments with PBM-DM, NaB was administered concomitant with HkEc 
stimulation. THP-1 cells showed an immediate response to NaB, which 
was potentialized by pre-incubation for 12-24 h. 
Although without a clear effect on IL6 or TNF secretion, NaB 
exposure did disrupt the linear correlation between these two cytokines, in 
a similar manner as to what I observed in THP-1 cells. Disruption in 
macrophage cytokine release is known to contribute to the pathogenesis 
of CD178. PBM-DM of OFG patients stimulated with HkEc secrete higher 
levels of TNF than healthy controls and the linear correlation between IL6 
and TNF is compromised. NaB exposure causes a similar disruption in 
cytokine secretion, which can potentiate the already disturbed 
inflammatory response observed in patients with OFG47,56,58. 
This is only a preliminary data that still requires optimization. The lack 
of statistical significance can be explained by the higher variation observed 
in individuals and the reduced sample size. Using a power of 0.8, statistical 
difference is expected to be observed with 10 samples for IL6 secretion. 
Besides that, NaB still showed an effect on cytokine secretion that 
resembles the alteration observed in OFG patients and further 
investigation is warranted. 
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Chapter 9 Conclusion 
The present study demonstrates that NaB does influence human 
monocytes, which includes small metabolic changes without the need for 
an immune stimulation, and a much bigger effect on the immune response 
causing an important attenuation of cytokine secretion upon bacterial 
challenge and TLR activation. 
At high doses, NaB is toxic to THP-1 cells in a time- and dose-
dependent manner, but at 5 mM, NaB is well-tolerated by these cells. The 
biological effects of NaB on cytokine secretion and ROS neutralization are 
also dose-dependent.  
IL6 and IL1β are the major cytokines that are down-regulated at both 
the message and secretion levels in THP-1 cells. This is in agreement with 
the majority of the literature which used a range of cell types and stimuli. It 
is, therefore, possible to conclude that NaB has a similar effect on almost 
all cells and this is probably due to its ability to neutralize ROS within the 
cytosol. The concentration of NaB needed to achieve this neutralization will 
probably be cell-type specific and also be influenced by secondary events 
such as infection and environmental effects (UV radiation exposure, 
medication etc). ROS are normally generated by the cells during 
mitochondrial respiration and are controlled by antioxidant enzymes 
produced by the cells. Upon TLR or rTNF stimulation, there is an increase 
in ROS generation. These extra ROS molecules can act as signalling 
molecules and influence the immune response. My data has identified IL6 
and IL1β as highly dependent on the ROS signal and other cytokines such 
as IP10 and IL8 being independent of this pathway. NaB ability to react 
and neutralize ROS, impairs the secondary signal, and thus IL6 and IL1β 
are not properly induced. This mechanism of action and effects on cytokine 
secretion is reproduced by other antioxidants and dependent on their ability 
to control ROS.  
TNF is hyper-secreted by THP-1 cells at NaB concentrations above 
5 mM and appears to be related to ERK1/2 and STAT3 signalling. These 
two signals are not directly connected, but combine their effects resulting 
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in the elevation of TNF. NaB itself disturbs the ERK1/2 signal, and upon 
HkEc stimulation, it seems to maintain a steady state of 
hyperphosphorylation, disturbing the function of this signalling pathway on 
TNF regulation. The importance of the ERK1/2 pathway is evident through 
the inclusion of the MEK1 and MEK2 inhibitor PD98059, which results in 
the loss of TNF induction. ERK1/2 signalling is only required for the initial 
induction of TNF and this is hyperactivated in the presence of NaB. The 
prolonged secretion of TNF, that is also evident from the inclusion of NaB 
during an immune response, results from an alteration in the IL6/IL6R 
STAT3 pathway. This secondary mechanism involved in TNF deregulation 
is an indirect effect of NaB since this signal comes from IL6. IL6 is released 
at a later stage of the immune response and activates STAT3 through an 
autocrine/paracrine mechanism which requires the expression of the IL6R. 
STAT3 activation results in the down-regulation of TNF. Due to the 
inhibitory effects of NaB on IL6 secretion, this signal is impaired and thus 
this regulatory control of TNF via STAT3 is attenuated. STAT3 activation 
by IL6 or STAT3 inhibition by the JAK/STAT3 inhibitor AG490 and by 
neutralization of IL6 signalling using an anti-IL6 antibody showed a 
downregulation or upregulation of TNF levels respectively. 
A quantitative proteomics analysis on THP-1 cells stimulated by 
LPS identified a major alteration in the proteome, which involved a number 
of highly relevant cellular processes such as the down-regulation of the cell 
cycle, while proteins related to innate immunity, especially those 
associated with an anti-viral response were upregulated. The inclusion of 
NaB during an LPS stimulation results in a similar response as that seen 
with LPS alone, but the change in the proteome is milder, suggesting that 
the overall immune response is attenuated. Another consequence of NaB 
exposure is the activation of enzymes associated with its metabolism. The 
proteins PHGDH, PSAT1, and PSPH that are associated with the L-serine 
synthesis subpathway, and more importantly they are also involved with 
the metabolism of NaB to hippuric acid, are all overexpressed upon NaB 
exposure. This metabolism requires energy expenditure, which suggests 
an additional burden on the cells exposed to NaB. 
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Although still requiring optimization, a pilot study in PBM-DM 
suggests that NaB exposure disturbs the linear correlation between IL6 
and TNF secretion in THP-1 cells, this correlation was also found to be 
disturbed in patients with OFG and might be associated with the negative 
effects of NaB-containing foods on patients with OFG. 
ROS generation and IL6 secretion are a combination found 
underlying many chronic inflammatory diseases, our results suggest that 
NaB (or any other substance capable of neutralizing ROS) can be an 
effective therapy to control the chronic inflammation associated with 
diabetes, atherosclerosis, rheumatoid arthritis, neurodegenerative 
disorders, and so on.  
 
 
9.1 Future directions 
The work presented in this thesis has identified important mechanisms 
involved with NaB effects on the innate immune response that can be 
expanded with further investigations, such as: 
 Optimization of NaB exposure to MDM and investigation of its effect 
on immune response upon bacterial/TLR stimulation 
 We have obtained ethical approval to carry out a clinical 
investigation in OFG patients, which intends to test patients’ sensitivity to 
benzoates using patch tests, collect peripheral blood and study biopsy 
samples to evaluate gene expression profiles. Testing the effects of NaB 
on the immune response in white blood cells from individuals with OFG 
and compare them to healthy controls. 
 The results presented here demonstrated an important role of ROS 
in the modulation of the immune response. It suggests that the control of 
ROS generation can be a promising mechanism to treat diseases 
associated with chronic inflammation, specifically NDD. This would be a 
worthwhile avenue to continue in the longer term. 
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ABSTRACT The human microbiome is affected by multiple factors, including the
environment and host genetics. In this study, we analyzed the salivary microbiomes
of an extended family of Ashkenazi Jewish individuals living in several cities and in-
vestigated associations with both shared household and host genetic similarities. We
found that environmental effects dominated over genetic effects. While there was
weak evidence of geographical structuring at the level of cities, we observed a large
and signiﬁcant effect of shared household on microbiome composition, supporting
the role of the immediate shared environment in dictating the presence or absence
of taxa. This effect was also seen when including adults who had grown up in the
same household but moved out prior to the time of sampling, suggesting that the
establishment of the salivary microbiome earlier in life may affect its long-term com-
position. We found weak associations between host genetic relatedness and micro-
biome dissimilarity when using family pedigrees as proxies for genetic similarity.
However, this association disappeared when using more-accurate measures of kin-
ship based on genome-wide genetic markers, indicating that the environment rather
than host genetics is the dominant factor affecting the composition of the salivary
microbiome in closely related individuals. Our results support the concept that there
is a consistent core microbiome conserved across global scales but that small-scale
effects due to a shared living environment signiﬁcantly affect microbial community
composition.
IMPORTANCE Previous research shows that the salivary microbiomes of relatives
are more similar than those of nonrelatives, but it remains difﬁcult to distinguish the
effects of relatedness and shared household environment. Furthermore, pedigree
measures may not accurately measure host genetic similarity. In this study, we in-
clude genetic relatedness based on genome-wide single nucleotide polymorphisms
(SNPs) (rather than pedigree measures) and shared environment in the same analy-
sis. We quantify the relative importance of these factors by studying the salivary mi-
crobiomes in members of a large extended Ashkenazi Jewish family living in differ-
ent locations. We ﬁnd that host genetics plays no signiﬁcant role and that the
dominant factor is the shared environment at the household level. We also ﬁnd that
this effect appears to persist in individuals who have moved out of the parental
household, suggesting that aspects of salivary microbiome composition established
during upbringing can persist over a time scale of years.
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The human microbiome is the name given to the collected communities of bacteriathat live on and in the human body. The oral microbiome is one of the most diverse
(1) of any human-associated microbial community (2). The oral microbiome is a
causative factor in conditions such as dental caries (3), periodontal disease (4), and
halitosis (5) and has also been implicated as a reservoir for infection at other body sites
(2) and in the pathogenesis of nonoral diseases, such as inﬂammatory bowel disease (6).
Strictly speaking there is no single “oral microbiome,” as its composition is highly
heterogeneous at different sites in the mouth (7, 8), but the term is commonly used to
encompass all of these sites. Site-speciﬁc microbiomes can be observed in the peri-
odontal sulcus, dental plaque, tongue, buccal mucosa, and saliva (9). The salivary
microbiome exhibits long-term stability and can be considered an important reservoir
that contains microorganisms from all distinct ecological niches of the oral cavity.
Characterizing and understanding the factors deﬁning the composition of the salivary
microbiome are thus crucial to understanding the oral microbiome (10, 11).
Some factors that are thought to inﬂuence the human microbiome include envi-
ronment, diet, disease status, and host genetics (12). The relative importance of these
factors for the oral microbiome is still under debate, with the majority of previous
studies focusing on the gut microbiome (7–9), although it seems reasonable to assume
some potential interaction between the salivary microbiome and microbial communi-
ties in other parts of the human body, including the intestinal tract (10).
There is evidence that genetically related individuals tend to share more gut
microbes than unrelated individuals do, whether or not they are living in the same
house at the time of sampling (13, 14). However, the levels of covariation are similar in
monozygotic and dizygotic twins, suggesting that a shared early environment may be
a more important factor than genetics (13, 15). The effect of cohabitation with direct
and frequent contact is greatest when considering the skin microbiome, with a
less-evident effect on the gut and salivary microbiomes (11).
There is also evidence that genetic variation is linked to microbiome composition
across other body sites, including the mouth (12), with a recent genome-wide associ-
ation study (GWAS) identifying several human loci associated (P  5  108) with
microbial taxonomies in the gut microbiome (16). However, no study thus far has
incorporated both genetic relatedness (as a continuous variable) and shared environ-
ment into the same analysis of the salivary microbiome.
Despite high diversity between individuals, the salivary microbiome appears to have
little geographical structure at the genus level at the global scale (17). Nevertheless, at
smaller geographical scales, it appears that the environment plays a role in the oral
microbiome. Song et al. studied 60 household units and found that the bacterial
composition of dorsal tongue bacterial samples was more similar between cohabiting
family members than for individuals from different households, with partners and
mother-child pairs having signiﬁcantly more similar communities (18). However, this
did not include information on genetic relatedness in addition to family relationships.
It appears that household-level differences in the salivary microbiome may also apply
to genetically unrelated individuals and nonpartners, with a similar pattern observed in
analysis of 24 household pairs of genetically unrelated individuals, only half of whom
were considered romantic couples at the time of sampling (19).
The establishment of the oral microbiome appears to proceed rapidly in the ﬁrst few
years of life, with a notable increase in diversity from 0 to 3 years (18), especially after
the eruption of teeth (20). The plaque microbiome also appears stable within adult
individuals over a period of at least 3 months, with a unique “ﬁngerprint” of oligotypes
discernible even within a single bacterial genus (21). Another study indicates that the
salivary microbiome is relatively stable over a year, despite measurable effects of
interventions like ﬂossing (22). Taken together, these ﬁndings suggest the intriguing
hypothesis that once a particular oral microbiome is established earlier in life, it can
potentially persist for months and perhaps even years, particularly if external factors
such as diet remain ﬁxed. If this were true, shared upbringing effects would continue
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to be detected in the salivary microbiome even after individuals are no longer living in
the same household (15).
A recently described large Ashkenazi Jewish family (23) offers an opportunity to
investigate the effect of both environment and genetics in closely related individuals.
The availability of host genetic data for this cohort means that we can calculate
similarity between individuals based on single nucleotide polymorphisms (SNPs), rather
than using measures of relatedness from pedigrees that do not precisely correspond to
shared genetic content (24). We hypothesized that using this more accurate measure
of host genetic similarity could lead to different conclusions about the proportion of
shared microbiome composition attributable to genetics compared to previous studies.
While, like other studies, we lack information on potential confounders such as diet and
lifestyle (17), due to shared cultural practices between members of the ultraorthodox
Ashkenazi Jewish community (25), we believe that confounding factors are likely to be
more controlled for in this cohort than in others. For this reason, this cohort represents
a unique opportunity to compare the salivary microbiome within a large number of
individuals living in separate locations but nevertheless sharing a similar diet, lifestyle,
and genetic background and to investigate the long-term effect of shared upbringing
on salivary microbiome composition.
RESULTS
Description of cohort. The families analyzed in this study have been already
described in detail by Levine et al. (23). All individuals sampled were from the
ultraorthodox Ashkenazi Jewish community. Family A comprised more than 800 indi-
viduals living in at least eight cities in four countries. Family B comprised more than 200
individuals living in at least four cities in three countries. The unrelated controls were
sampled from the same community as the two families. In total, data were generated
from samples from 133 individuals in family A, 18 individuals in family B, and 27
controls.
Using minimum entropy decomposition (see Materials and Methods), we found 271
phylotypes in the total microbiome data set, all of which were present when consid-
ering just family A. Of these 271 phylotypes, 49 were present in 95% of individuals
within family A, with the Firmicutes the most abundant phyla (Fig. 1a) as observed in
previous oral microbiome studies (15, 26). The most abundant genera were Strepto-
coccus (30.4%), Rothia (18.5%), Neisseria (17.1%), and Prevotella (17.1%). The composi-
FIG 1 The family within this study contains a representative sample of variation in salivary microbiome composition compared to controls. (a) Relative
abundance of the six bacterial phyla found in saliva samples from family A sorted by decreasing Firmicutes content. The color scheme used here was adapted
from that in Stahringer et al. (15). The 271 MED phylotypes were assigned to taxa using RDP based on the HOMD database. (b) Nonmetric multidimensional
scaling based on Bray-Curtis dissimilarity between samples shows high overlap between family A, family B, and unrelated Ashkenazi Jewish controls. NMDS1,
nonmetric multidimensional scaling axis 1.
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tion of samples was similar between the two families (families A and B) and the
unrelated controls (Fig. 1b). These groupings had a small but signiﬁcant effect in an
analysis of variance (R2  0.015; P  0.01), but this is typical of comparisons between
such large groups that may differ in an unknown number of confounded variables (e.g.,
diet, genetics, lifestyle). We concluded that family A was at the very least a represen-
tative sample capturing the majority of the variation present in the wider Ashkenazi
Jewish population, if not also individuals who are not Ashkenazi Jewish (for comparison
with Human Microbiome Project data, see Fig. S3 in the supplemental material).
This cohort was originally collected for a study of the genetics of Crohn’s disease
(23), and 28 individuals within our sample had a diagnosis of the disease at the time of
saliva sample acquisition. We found no signiﬁcant effect of Crohn’s disease on salivary
microbiome composition with an exploratory analysis of variance (R2  0.009; P 
0.101; n  148) accounting for other variables. It was therefore not included as a
covariate in further analysis.
Host genetic similarity is weakly correlated with salivary microbiome similar-
ity. We performed an exploratory analysis on individuals in family A with both genetic
and microbiome data available (n  111) (Fig. S4) and found that genetic kinship was
weakly but signiﬁcantly associated with salivary microbiome dissimilarity computed
using Bray-Curtis dissimilarity (Fig. S5a; r  0.065 by Mantel test; P  0.001). This
analysis does not take into account confounding by the shared environment and
therefore sets a probable upper bound on the variation that can be attributed to host
genetics. An exploratory analysis of microbiome variation across a subfamily within
family A (n  44) showed that individuals from the same household had a more similar
microbiome composition as measured by Bray-Curtis dissimilarity (mean  standard
deviation [SD], 0.623  0.088) compared with individuals from different households
(0.652  0.084), and this difference was signiﬁcant (P  0.001 by two-sided t test). An
exploratory visual representation of this variation showed further clustering by house-
hold, although there was large overlap between households in two dimensions (Fig. 2).
However, such an analysis is insufﬁcient; household is obviously correlated with vari-
ation in host genetics (Fig. S6) because parents tend to live with their children. This
emphasizes the need for a quantitative approach looking at the effect of both house-
hold and genetics simultaneously as well as other potential confounders.
The approach we chose to use was adonis, which performs a permutational analysis
of variance in community composition using a sequential sum-of-squares approach
(27). We used Bray-Curtis dissimilarities to quantify differences in salivary microbiome
composition between individuals. The following sections present our analyses attempt-
ing to quantify the effects of shared environment and genetics. The analysis groups
were effectively nested as follows: individuals cohabiting with at least one other
FIG 2 Salivary microbiome composition appears associated with household in an exploratory analysis. Salivary microbiome samples cluster somewhat by
household (shown by different colors) despite large overlap between them, shown by a nonmetric multidimensional scaling based on Bray-Curtis dissimilarity
between samples from individuals in a particular subfamily (n  44) within family A (a). This ﬁgure includes individuals who are currently living together (ﬁlled
circles), those who had moved out of their childhood home (empty circles), and those for whom data were missing (faint circles). This clustering could be due
to shared environment or also due to shared genetics, as is obvious from the pedigree (b).
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individual (n  26; Table 1), individuals who had cohabited with at least one other
individual, either at the time of sampling or beforehand (n  61; Table 2), individuals
living in four different cities who were not necessarily cohabiting with another indi-
vidual (n  82; Table S1), and individuals with host genetic information available (n 
111; Table 3).
Shared household is the dominant factor affecting salivary microbiome com-
position. We performed a permutational analysis of variance on the salivary micro-
biome dissimilarities for 26 individuals within family A, each of whom lived in a
household with at least one other individual in the cohort. At the time of sampling,
these cohabiting individuals lived in a total of 16 households in four cities (cities I, II, III,
and IV). To account for host genetics, we included axes from a metric multidimensional
scaling (MDS) of pairwise genetic distances between individuals as explanatory vari-
ables (see Materials and Methods and Fig. S6). The magnitude of the effect of a
signiﬁcant variable is given by the amount of variance explained (R2 in tables).
TABLE 1 Permutational analysis of variance (adonis) results for 26 cohabiting individuals
who lived in the same household with at least one other individuala
Variableb
City only Household only
City and
householdc
R2 P R2 P R2 P
Sequencing plate 0.048 0.190 0.048 0.075 0.048 0.458
Gender 0.032 0.724 0.032 0.4 0.032 0.467
Age 0.069 0.017 0.069 0.004 0.069 0.013
MDS1 0.031 0.757 0.031 0.537 0.031 0.727
MDS2 0.050 0.142 0.050 0.052 0.050 0.099
MDS3 0.030 0.807 0.030 0.585 0.030 0.862
MDS4 0.049 0.162 0.049 0.054 0.049 0.097
MDS5 0.029 0.824 0.029 0.614 0.029 0.791
City 0.080 0.400 0.080 0.178
Household 0.300 0.001 0.220 0.001
Residuals 0.582 0.362 0.362
Total 1.000 1.000 1.000
aSharing a household was always signiﬁcant and explained the most variance of any variable (18%) even
in a model that nests permutations within cities.
bThe order of variables in the model is given by their order in the table. MDS1 to MDS5 are the ﬁve axes of
metric multidimensional scaling (MDS).
cPermutations stratiﬁed by city in this analysis.
TABLE 2 Permutational analysis of variance (adonis) results for 61 individuals who had at
least cohabited at some pointa
Variableb
City only Household only
City and
householdc
R2 P R2 P R2 P
Sequencing plate 0.029 0.018 0.029 0.012 0.029 0.013
Gender 0.018 0.258 0.018 0.219 0.018 0.257
Age 0.038 0.002 0.038 0.001 0.038 0.002
MDS1 0.014 0.668 0.014 0.607 0.014 0.740
MDS2 0.017 0.362 0.017 0.305 0.017 0.440
MDS3 0.020 0.173 0.020 0.141 0.020 0.263
MDS4 0.020 0.150 0.020 0.118 0.020 0.147
MDS5 0.012 0.783 0.012 0.744 0.012 0.943
City 0.056 0.149 0.056 0.934
Household 0.239 0.021 0.183 0.044
Residuals 0.777 0.594 0.594
Total 1.000 1.000 1.000
aSharing a household was always signiﬁcant and explains the most variance of any variable (18%) even in
a model that nests permutations within cities.
bThe order of variables in the model is given by their order in the table.
cPermutations stratiﬁed by city in this analysis.
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There was no signiﬁcant effect of any of the MDS axes, suggesting that host genetics
in closely related individuals does not signiﬁcantly affect microbiome composition. We
investigated the effect of environment using two levels of geography: city and house-
hold (Table 1). A city-only model showed no signiﬁcant effect of environment (R2 
0.08; P  0.4), whereas a household-only model showed a signiﬁcant effect (R2  0.30;
P  0.001). This was reproduced in a model containing both geographical variables,
with permutations stratiﬁed by city, where household was still a signiﬁcant effect (R2 
0.22; P  0.001), suggesting that differences at the level of household are more
important than at larger geographical scales. We conﬁrmed that city-level effects were
small by extending our sample to 82 individuals across the four cities who were not
necessarily cohabiting with others (48 individuals for city I, 13 for city II, 12 for city III,
and 9 for city IV) and found that city still had a small effect, although it was signiﬁcant
(R2  0.053; P  0.01). In this analysis, we also found no signiﬁcant effect of genetics,
but age was signiﬁcant (R2  0.028; P  0.0101) (Table S1).
Spouses share taxa at the subgenus level. Restricting the analysis to only married
couples within family A (n 16; eight couples), shared household explained even more
of the variance (R2  0.591; P  0.001). Subtle variations in the relative abundance of
phylotypes within the same genus between households were observable, even within
the same city location. For example, Leptotrichia phylotypes qualitatively varied con-
sistently between spouse pairs, and these patterns were also seen in children living at
home (Fig. 3). Minimum entropy decomposition (MED) phylotype X2772 was present in
both spouses in household A1.7 and was also present in the two youngest children
within that household (10 years old). Similarly, within household A2.4, the Leptotrichia
phylotypes of the two children who were 10 years old were more similar than the
Leptotrichia phylotype of an older child. Quantitatively, repeating the permutational
analysis of variance based only on the composition of phylotypes within Leptotrichia
showed that spousal pair explained 68.4% of variance, although this was not signiﬁcant
(R2 0.684; P 0.068), and spouses had signiﬁcantly more similar subgenus phylotype
composition than nonspouses did (Fig. S7b). Similar patterns with spouses were also
visible in other abundant genera (Fig. S7a), with spouses on average having a signiﬁ-
cantly more similar subgenus phylotype composition than nonspouses did (mean 
standard error [SE] difference in Bray-Curtis dissimilarity for each genus, 0.048 
0.013; Fig. S7b).
Household effects persist in individuals who are no longer cohabiting. There
were an additional 35 individuals who had grown up in a household with at least one
TABLE 3 Comparison of pedigree-based and genome-wide measures of kinship to take
host genetics into account in a permutational analysis of variance (adonis) on salivary
microbiome dissimilarities of 111 individualsa
Variableb
Pedigree (kinship2)
Genome-wide SNPs
(LDAK)
R2 P R2 P
Sequencing plate 0.028 0.001 0.028 0.001
Gender 0.011 0.094 0.011 0.096
Age 0.023 0.001 0.023 0.001
MDS1 0.010 0.174 0.011 0.119
MDS2 0.007 0.706 0.010 0.231
MDS3 0.012 0.063 0.011 0.131
MDS4 0.016 0.009 0.011 0.111
MDS5 0.009 0.325 0.007 0.617
Parental household 0.215 0.001 0.217 0.001
Residuals 0.670 0.671
Total 1 1
aUsing pedigree information to produce kinship results in a signiﬁcant association with human genetics via
the fourth MDS axis, which is not present using kinships calculated with LDAK based on genome-wide
SNPs.
bThe order of variables in the model is given by their order in the table.
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other individual present but who no longer lived together at the time of sampling. To
see whether the effects of household persisted, we repeated analysis of variance with
these individuals included along with the cohabiting individuals (n  61; Table 2). The
effect of household remained signiﬁcant (R2 0.183; P 0.044), and no axes of human
genetic variation were signiﬁcant (P  0.05). Age had a signiﬁcant effect (R2  0.038;
P  0.01).
FIG 3 Variation within a genus shows household-level differences in relative abundances of
phylotypes, shown here with the relative abundance of phylotypes within Leptotrichia. The relative
abundance of phylotypes within seven pairs of spouses shows clear associations with household,
with spouses signiﬁcantly more similar in phylotype composition within Leptotrichia (P  0.039 by
two-sided t test). These patterns are to some extent recapitulated in their children. Looking at
children still living at home, MED phylotype X2772 is not observed in any individual from household
A2.4 but is found in both spouses and two children living in household A1.7. Solid red circles
indicate children 10 years at the time of sampling, who appear more similar to each other than
other pairs of children. For variation within the top 12 most abundant genera between spouses, see
Fig. S7 in the supplemental material.
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Other variables such as age and sequencing plate had smaller effects than house-
hold in all our analyses of variance. However, we chose the order of variables as
presented in our tables (Tables 1, 2, and 3) to test for the effect of household after
controlling for other variables. Because of the sequential sum-of-squares approach used
by adonis, this ordering of variables can have an effect with an unbalanced design. To
check that this was not biasing our results and therefore our conclusions about the
important factors for salivary microbiome composition, we also investigated the effect
of randomly permuting the order of variables in our model formula (see supplemental
material). The results of this analysis conﬁrmed that household was always signiﬁcant
(false-discovery rate [q]  0.05, with Benjamini-Hochberg multiple testing correction),
as was age.
Relying on pedigree kinships produces a genetic signal. To test whether our
conclusions required using kinships estimated from genome-wide SNP data for indi-
viduals or whether pedigree information was sufﬁcient, we also repeated our analyses
using pedigree kinships (see Materials and Methods). Using pedigree kinships resulted
in a small but signiﬁcant amount of variation in microbiome composition being
attributable to host genetics via MDS axis 4 (R2  0.016; P  0.01; Table 3).
DISCUSSION
We have conducted, to our knowledge, the ﬁrst simultaneous investigation of the
role of environment and host genetics in shaping the human salivary microbiome in a
cohort of closely related individuals within a large Ashkenazi Jewish family. We found
a weak correlation between host kinship and salivary microbiome dissimilarity before
taking shared household into account and an apparent small but signiﬁcant effect of
genetics when using kinships based on the family pedigree as proxies for genetic
similarity. However, when using kinship estimates based on genome-wide SNPs be-
tween individuals and simultaneously controlling for shared household with a permu-
tational analysis of variance, we ﬁnd no support for any clear effect of human genetics,
suggesting that shared environment has a much larger effect than genetics and is the
dominant factor affecting the salivary microbiome. Typically shared household had an
order of magnitude greater effect compared with other signiﬁcant variables. For
example, in our analysis where city was also used as an environmental variable, the
variance explained was as follows: household (18.3%), age (3.8%), and sequencing plate
(2.9%) (Table 2).
We also observed that younger children living in the same household shared subtle
variations in phylotype abundance within genera with their parents (Fig. 3). However,
despite a persistence of household effects, it would be wrong to conclude that the
salivary microbiome is completely ﬁxed once established, as it clearly has aspects that
can change over time. For example, shared household explained more variation for
spousal pairs (likely due to frequent contact between them) and that phylotypes
observed in younger children and their parents were not seen in older children (likely
due to less frequent contact between them). Taken together, these observations
support the view that human genetics does not play a major role in shaping the salivary
microbiome, at least not in individuals of the same ethnicity, compared to the envi-
ronment and contact with other individuals.
Our results conﬁrm the seemingly paradoxical situation that the salivary microbiome
is largely consistent across global geographical scales but can show large variation
between households in the same city. Previous studies have also found evidence of
small variations in salivary microbiome composition comparing samples across a global
scale (17). As noted previously, this variation could be inﬂuenced by differences in
environmental or cultural factors, in which case controlling for these differences would
decrease the amount of geographical variation. All individuals in our study follow a
traditional Ashkenazi Jewish lifestyle and subsequently are thought to share a similar
diet and lifestyle regardless of geographical location (25), which may reduce the
variation attributable to city-level differences.
The establishment of the oral microbiome early in life may lead to the persistence
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of a similar composition over several years. The microbial composition of sites within
the mouth has been previously observed to be persistent within individuals over
periods of months (21) to a year (22), and we see similar strain-level variation between
spouses and their young children as observed between individuals by Utter et al. (21)
(Fig. 3). Our results indicate the persistence of household effects in individuals no
longer cohabiting, suggesting that the salivary microbiome composition established
early in life via shared upbringing is able to persist for at least several years. It has been
observed that monozygotic twins do not have signiﬁcantly more similar gut micro-
biomes than dizygotic twins (13). Stahringer et al. observed the same effect in the
salivary microbiome and also found that the salivary microbiomes of twins became less
similar as they grew older and ceased cohabiting, concluding that “nurture trumps
nature” in the salivary microbiome (15). Our ﬁndings from a large number of related
individuals rather than twins support this view, including the persistence of shared
upbringing effects. Shared upbringing appears to be the dominant factor affecting
microbiome composition in both the gut and the mouth, rather than genetic similarity.
This may have implications for understanding the familial aggregation of diseases such
as inﬂammatory bowel disease, which has been suggested to have an environmental
component (28).
The salivary microbiome appears to be far more resilient to perturbation than the
gut microbiome is, with a rapid return to baseline composition after a short course of
antibiotics (29). While this could be because of the pharmacokinetics of the antibiotics
involved, Zaura et al. speculate that this difference may be due to the salivary microbial
ecosystem’s higher intrinsic resilience to stress, as the mouth is subject to more
frequent perturbation (30). Our work supporting the dominant role of the environment
in affecting salivary microbiome composition suggests that another important factor in
long-term persistence may be the regular reseeding of the ecosystem with bacteria
from the external environment.
The fact that we reached our conclusion about the lack of effect of genetics only
after including kinship based on genome-wide SNP markers casts doubt on the
reliability of pedigrees for calculating relatedness. There are several possible reasons for
a discrepancy between kinship estimates from pedigrees and allele sharing (24). One
possibility is errors in the pedigree, most likely due to extrapair paternities, although
this explanation can be ruled out in this data set. More importantly, inherent stochas-
ticity in the Mendelian process of inheritance means that although parents always pass
on 50% of their genes to their offspring, SNPs are inherited together in blocks (i.e.,
haplotypes), meaning that the relatedness between two offspring in a family can be
substantially different from 50%. Finally, and most importantly for this closely related
population, shallow pedigrees cannot fully capture complex inbreeding patterns. Thus,
while pedigrees are a good model for host relatedness in microbiome studies of large
randomly mating populations, they should be used with caution in closely related large
families like this one.
Limitations. Because all individuals in our main cohort were members of the same
extended Ashkenazi Jewish family, the genetic variation in our data set is therefore
much lower than between individuals from a wider population. It is conceivable that
host genetics between more distantly related individuals may play a signiﬁcant role in
affecting salivary microbiome composition. However, we note that a recent study of the
nasopharyngeal microbiome among Hutterite individuals (a founder population in
North America) detected associations between host variation and microbial composi-
tion with a similar cohort size (31), demonstrating that limited genetic variation can be
associated with the composition of other microbiomes; it may simply be that the
salivary microbiome is relatively unaffected by such variation.
Furthermore, our study looked at only overall genetic similarity, assessed using
community comparison metrics based on taxon abundances. They therefore do not
preclude the existence of ﬁne-scale links between particular microbial taxa and indi-
vidual genetic loci, particularly in immune-sensing genes such as those identiﬁed in the
Environment Shapes the Human Oral Microbiome ®
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gut microbiome by Bonder et al. using a much larger cohort (32), although our study
was not designed or have the statistical power to detect such associations.
Additionally, we lack detailed information on diet and lifestyle factors of indi-
viduals in this study. However, the shared cultural practices within this ultraortho-
dox Ashkenazi Jewish family mean that it is not unreasonable to assume that they
share similar lifestyles and diet despite living in different locations around the world
(25).
The apparent persistence of shared upbringing could be confounded by the fact
that individuals may continue living near the household where they grew up. If this
were the case, then our observation could instead be due to the persistence of a shared
environment beyond the household at a level intermediate between household and
city, rather than the persistence of a stable salivary microbiome following environmen-
tal change. Finally, our samples represent only a single cross-sectional snapshot in time.
More long-term longitudinal studies like the work of Stahringer et al. on twins (15) are
necessary to investigate the persistence of the salivary microbiome after its establish-
ment early in life in a variety of relatedness settings.
Conclusion. In summary, our results incorporating a measure of genetic relatedness
using SNPs demonstrate that the overall composition of the human salivary micro-
biome in a large Ashkenazi Jewish family is largely inﬂuenced by shared environment
rather than host genetics. An apparent signiﬁcant effect of host genetics using
pedigree-based estimates disappears when using genetic markers instead, which
shows that in future microbiome research, the use of pedigree relatedness as a proxy
for host genetic similarity should be done with caution. Geographical structuring occurs
to a greater extent at the household level within cities than between cities on different
continents. Living in the same household is associated with a more similar salivary
microbiome, and this effect persists after individuals have left the household. This is
consistent with the long-term persistence of the salivary microbiome composition
established earlier in life due to shared upbringing.
MATERIALS AND METHODS
Ethics. Ethical and research governance approval was provided by the National Research Ethics
Service London Surrey Borders Committee and the UCL Research Ethics Committee. Written informed
consent was provided by all participants.
Cohort. Our cohort contained data from 133 individuals within the same extended family (family A)
living in four disparate cities (I, II, III, and IV) across three continents (see reference 23 for more
information). We also had samples available from 18 individuals from a separate smaller family (family B)
and 27 unrelated Ashkenazi Jewish controls. All individuals studied were of genetically conﬁrmed
Ashkenazi Jewish ancestry (23, 25). When information was not directly available, shared household was
inferred according to age; individuals within this community marry and subsequently leave the family
home at a median age of 21 years (95% conﬁdence interval, 19 to 26 years) (25). Therefore, we assumed
that individuals aged 18 or younger at the time of sampling were living with their parents and individuals
aged 25 or older were not.
For analysis of the effects of household, we included only households with two or more individuals
so as to remove the possibility that we were measuring only interindividual differences, which can be
large in the salivary microbiome (17, 21). Twenty-six individuals were living with at least one other
individual at the time of sampling in a total of nine households. An additional 35 individuals who had
grown up in a shared household with at least one other individual in the cohort but who were no longer
living together were subsequently included in the analysis.
Sampling. Saliva samples were collected in sterile tubes containing saliva preservative buffer by the
method of Quinque et al. (33). For the full protocol, see the supplemental material. Five hundred
milliliters of saliva/preservative buffer was used with PurElute bacterial genomic kit (Edge Biosystems,
Gaithersburg, MD) for DNA extraction. After bacterial DNA extraction, three spike DNAs were added to
all samples at a ﬁnal concentration of 4 pg/ml, 0.4 pg/ml, and 0.08 pg/ml, respectively.
PCR ampliﬁcation, puriﬁcation, and sequencing. The Mastermix 16S basic PCR kit containing
MolTaq 16S DNA polymerase (Molzym GmbH & Co. KG, Bremen, Germany) was used to generate PCR
amplicons. PCR amplicons were puriﬁed in two rounds using the Agencourt AMPure system (Beckman
Coulter, Inc., Beverly, MA) in a Hamilton StarLet (Hamilton Company, Boston, MA) automated liquid
handler. DNA quantitation and quality control were performed using the Agilent 2100 Bioanalyzer
system (Agilent Technologies, Santa Clara, CA).
We used 785F (F stands for forward) and 1175R (R stands for reverse) 16S rRNA primers (see Text S1
in the supplemental material) that ampliﬁed the V5-V7 region of the 16S rRNA gene on the Illumina
MiSeq system (Illumina, San Diego, CA).
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Quality control. To assess technical variation across runs, we spiked samples during library prepa-
ration with a ﬁxed amount of synthetic DNA (see supplemental material). Three unique spike sequences
(length of 350 bases) that could be easily identiﬁed for quality control purposes were designed. We
found, as expected, that the number of spike sequences and the number of putative 16S sequences
(length between 350 and 380 bases) were negatively correlated with each other due to the limited total
sequencing depth of the Illumina MiSeq system (Fig. S1a). The variation in reads corresponding to this
spike across samples was independent of run. We also resequenced a subset of samples without
spikes to verify whether spikes affected our analyses and observed the same qualitative differences
(Fig. S1b), implying that the addition of spikes did not have a negative impact on downstream
analysis. Paired-end reads were merged with fastq-mergepairs in VSEARCH v1.11.1 (34), discarding
reads with an expected error of 1. As the expected length of the V5-V7 region was 369 bases, we
discarded sequences with 350 or 380 bases.
Clustering and taxonomic classiﬁcation. Sequences were clustered with minimum entropy de-
composition (MED) (35). MED requires that the variation in read depth across samples does not differ by
several orders of magnitude, so we discarded samples with fewer than 5,000 reads and subsampled to
a maximum number of 20,000 sequences, resulting in 6,353,210 sequences. We ran MED v2.1 with default
parameters (see Text S1 in the supplemental material), identifying 271 phylotypes in the data set
(Table S2). MED offers higher resolution than operational taxonomic unit (OTU) picking methods do, and
it has previously been shown to differentiate the composition of the oral microbiomes of individuals over
time even within the same genus in a study of plaque samples (21). We veriﬁed that using MED
phylotypes gave very similar compositional dissimilarities compared to using de novo OTUs clustered at
98.5% sequence similarity (Fig. S2) but allowed slightly increased statistical power in analysis of variance
(see supplemental material), consistent with the literature (35). MED phylotypes had taxonomy as-
signed using RDP (36) against the Human Oral Microbiome Database (HOMD) (37). Comparison to
Human Microbiome Project (HMP) samples from various sites in the mouth also indicated that
Ashkenazi Jewish individuals do not have a signiﬁcantly different oral microbiome from those of
other populations, with Ashkenazi Jewish saliva samples clustering with nonplaque samples from
individuals in the HMP (Fig. S3). However, the use of different primers makes it difﬁcult to reach a
robust conclusion on this point.
Inclusion of host genetics.We investigated the effect of relatedness between individuals on salivary
microbiome composition using both genetic kinships (based on SNPs) and pedigree kinships (based on
the pedigree). We calculated pedigree kinships with kinship2 (38) and genetic kinships with LDAK v5.94
(39) using genome-wide SNP data from either the Illumina HumanCytoSNPv12 (Illumina, USA) or the
Illumina HumanCoreExome-24, as described previously (23). These genetic kinships kg are normalized to
have a mean of zero and correspond to genetic similarity between individuals. kg correlates with the
pedigree kinship kp, but there can be substantial spread around the expected values due to the random
nature of genetic inheritance (Fig. S5b), making kg a more accurate measure of true genetic similarity
between individuals (24). We converted these kinships to dissimilarities and then Euclidean distances
(supplemental material) which were used in a multidimensional scaling (MDS) ordination (Fig. S6).
Following Blekhman et al. (12), we used MDS with ﬁve axes as covariates in a permutational analysis of
variance of salivary microbiome dissimilarities.
Statistical analysis. We calculated Bray-Curtis dissimilarities between samples based on relative
abundances of phylotypes, excluding samples with fewer than 1,000 reads. Variance explained in
Bray-Curtis dissimilarities was calculated using the adonis function from the vegan v2.4.1 package in R,
which performs a permutational analysis of variance of distance matrices (27). We used 9,999 permu-
tations, with permutations stratiﬁed by geographical sample location where appropriate.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/mBio
.01237-17.
TEXT S1, DOCX ﬁle, 0.04 MB.
FIG S1, TIF ﬁle, 11.8 MB.
FIG S2, TIF ﬁle, 11.3 MB.
FIG S3, TIF ﬁle, 13.1 MB.
FIG S4, TIF ﬁle, 41.5 MB.
FIG S5, TIF ﬁle, 14.9 MB.
FIG S6, TIF ﬁle, 5.9 MB.
FIG S7, TIF ﬁle, 14 MB.
TABLE S1, DOCX ﬁle, 0.05 MB.
TABLE S2, XLSX ﬁle, 0.3 MB.
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